Methods for the Measurement of  Vitamin D Metabolites and Studies on Their Relationships in Health and Disease by Tang, Jonathan
  
 
 
Methods for the Measurement of 
Vitamin D Metabolites and Studies on 
Their Relationships in Health and 
Disease 
A thesis submitted to the University of East Anglia in accordance 
with the requirements for the degree of  
Doctor of Philosophy 
By 
Jonathan Chung Yan Tang 
Department of Medicine, Norwich Medical School, Faculty of Medicine 
and Health Sciences, University of East Anglia 
2019 
 
This copy of the thesis has been supplied on condition that anyone who consults it is understood 
to recognise that its copyright rests with the author and that use of any information derived 
there-from must be in accordance with current UK Copyright Law. In addition, any quotation or 
extract must include full attribution. 
   
I 
 
Abstract 
The prevalence of vitamin D deficiency in the general population has become a major 
public health problem. Vitamin D deficiency might have significant consequences not only to 
bone health but possible to other autoimmune, infectious, cancer and cardiovascular diseases. The 
explosion of interests in vitamin D had sparked a massive increase in the number of laboratory 
requests for the measurement of serum 25 hydroxyvitamin D (25(OH)D). This in turn highlighted 
problems of the methodologies available for measuring vitamin D metabolites. 
The aim of the study was to develop and fully validate quantitative assays for measuring 
serum vitamin D metabolites by Liquid Chromatography Tandem Mass Spectrometry (LC/MS-
MS). The methods were used to perform analysis on samples collected for vitamin D research 
studies to establish relationships between the metabolites and determine reference intervals. 
Using solid phase extraction to remove phospholipids in sample matrix and derivatisation 
to enhance sensitivity, assays were successfully developed for 25(OH)D3/D2, C3-epi-
25(OH)D3/D2, and for the dihydroxyvitamin D 24,25(OH)2D3/D2 and 1,25(OH)2D3/D2. The 
performance characteristic of the assays satisfied industry standards for method validation. 
Results showed a high prevalence of C3-epi-25(OH)D3 (87.7%) in paediatric samples that 
resulted in misclassification of total 25(OH)D status in 10.4% of cases. Serum 25(OH)D showed 
a significant correlation with 24,25(OH)2D (r2=0.754, p<0.001), but not with 1,25(OH)2D 
(r2=0.1034). The reference intervals (2.5-97.5 percentile) for 25(OH)D:24,25(OH)2D ratio was 
established between 7-23. Loess fitting showed an increase in the 25(OH)D:24,25(OH)2D ratio at 
25(OH)D <50 nmol/L; evidence of reduced catabolic activity during low vitamin D status. In 
contrast, when high dose vitamin D3 was supplemented, serum 24,25(OH)2D was found to be 
grossly elevated to counteract against excessive vitamin D and prevent toxicity. Using the 
1,25(OH)2D:24,25(OH)2D/25(OH)D ratio model, this thesis was the first to demonstrate a 
relationship between the three metabolites, and the association with PTH concentration. 
This thesis has provided new insights to the vitamin D metabolism that will further our 
understanding and appreciation of its role in health and pathophysiological conditions. The 
methods developed have provided an analytical platform for many large scale studies in 
musculoskeletal research and other areas of science; the publications and citations are a testament 
to the impact of this research. 
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25(OH)D   25-hydroxyvitamin D 
25(OH)D3   25-hydroxyvitamin D3 
25(OH)D2   25-hydroxyvitamin D2 
25(OH)D3-2H6   25-hydroxyvitamin D3-[26,26,26,27,27,27,-2H6] 
25(OH)D2-13C3   25-hydroxyvitamin D2-[13C3] 
24R,25(OH)2D3  24R,25-dihydroxyvitamin D3 
24S,25(OH)2D2  24S,25-dihydroxyvitamin D3 
24R,25(OH)2D3-2H6   24R,25-dihydroxyvitamin D3-[2H6] 
23,25(OH)2D3   23,25-dihydroxyvitamin D3 
25,26(OH)2D3   25,26-dihydroxyvitamin D3 
3-epi-25(OH)D3-2H3  3-Epi-25-Hydroxyvitamin –D3-[6,19,19-2H3] 
ANOVA    Analysis of variance 
APCI    Atmospheric pressure chemical ionisation 
C3-epi-25(OH)D3  C3-Epimer 25-hydryoxyvitamin D3 
C3-epi-25(OH)D2  C3-Epimer 25-hydryoxyvitamin D2 
CI     Confidence interval 
CID     Collision induced dissociation 
CLIA    Chemiluminescent immunoassay 
CV     Coefficient of variation 
CVbetween    Between-run coefficient of variation 
CVtotal     Total coefficient of variation 
CVwithin    Within-run coefficient of variation 
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CYP24A1   Cytochrome P450, family 24, subfamily A, polypeptide 1 
d6     hexadeuterated 
DEQAS    Vitamin D External Quality Assessment Scheme 
ELISA    Enzyme-linked immunosorbent assay 
EDTA    Ethylenediamine tetraacetic acid 
ESI    Electrospray ionisation 
HPLC    High performance liquid chromatography 
IQC    Internal quality control 
IS     Internal standard 
ISO     International Organization for Standardization 
IU    International unit 
ID    Isotope dilution 
LC     Liquid chromatography 
LC-MS/MS   Liquid chromatography tandem mass spectrometry 
LLE     Liquid liquid extraction 
LoQ     Limit of quantification 
MeOH    Methanol 
MRM    Multiple reaction monitoring 
MS     Mass spectrometry 
m/z     mass-to-charge ratio 
NaCl     Sodium chloride 
NaOH     Sodium hydroxide 
NIST     National Institute of Standards and Technology 
RF    Radio frequency 
RIA     Radioimmunoassay 
Rpm    Revolutions per minute 
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RT    Room temperature 
Standard deviation SD 
SI-units “Système International d’Unités” (International System of 
Units) 
S/N     Signal-to-noise ratio 
SRM     Standard reference material 
SLE    Supported liquid extraction 
UPLC    Ultra high performance liquid chromatography 
UV    Ultraviolet 
°C    Degrees centigrade 
+ve    Positive 
-ve    Negative 
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Chapter 1 Introduction 
1.1 The Physiology of vitamin D 
The vitamin D family is categorised as either cholecalciferols (vitamin D3) or ergocaliferols 
(vitamin D2). Vitamin D is mainly synthesised in the skin by exposure to sunlight, where UVB 
exposure converts 7-dehydrocholesterol to vitamin D3 (Fig. 1.0). Once it enters the circulation, 
vitamin D3 is metabolised to 25-hydroxyvitamin D3 (25(OH)D3) in the liver by 25-hydroxylase 
and then further metabolised in the kidneys to the most biologically active form 1α,25-
dihydroxyvitamin D3 (1,25(OH)2D3) by the enzyme 1-hydroxylase. 1,25(OH)2D3 increases 
intestinal absorption of calcium and phosphate,  regulates synthesis and secretion of parathyroid 
hormone (PTH), and promotes bone mineralisation. An alternative pathway produces 24R,25-
dihydroxyvitamin D3 (24,25(OH)2D3) by 24-hydroxylase. 80-90% of circulating total 25(OH)D 
is derived from skin exposure to UVB and 10-20% ingested in the diet. 25(OH)D3 in the diet is 
mainly from animal sources (oily fish, fish oils, dairy products, meat) and 25(OH)D2 is mainly 
obtained from irradiated plants (green leafy vegetables, mushrooms, fungal contamination of 
foodstuffs). Total 25(OH)D is the combination of all circulating forms of 25(OH)D3 and 
25(OH)D2. 
 
1.2 Clinical significance of vitamin D 
The clinical effects of vitamin D have been a hot topic among the scientific community, with 
regular reports appearing in the news. Low vitamin D status is prevalent in the UK, particularly 
in young and elderly populations and in ethnic minorities1. Severe vitamin D deficiency leads to 
rickets in children, and osteomalacia in adults. Vitamin D deficiency can cause a reduction in 
serum ionised calcium resulting in secondary hyperparathyroidism which can promote an increase 
in bone turnover to release calcium and phosphate from bone and results in decreased 
mineralisation of newly formed osteoid. The long-term effect of this mineralisation defect 
exacerbates the reduction of bone mass, contributing to increased fracture incidence.  
Beyond bone diseases, epidemiological studies have shown that deficient levels of total 25(OH)D 
are associated with higher risk of colon2, prostate3,4 and breast cancer5. Cardiovascular disease6, 
autoimmune diseases7, diabetic nephropathy8 and schizophrenia are also associated with vitamin 
D deficiency. The wide association is due to the high abundance of vitamin D receptors9 in tissues, 
allowing 1,25(OH)2D to directly or indirectly regulate cell growth, induce apoptosis and control 
metabolism. 
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Figure 1.0 Vitamin D metabolic pathway. 
 
1,25(OH)2D is thought to play an important role in pathophysiological conditions, even more so 
than that of 25(OH)D. Whereas it is well established that measurement of circulating total 
25(OH)D is the best indicator of vitamin D status, measurement of the biologically active 
hormone 1,25(OH)2D  can be a valuable diagnostic and therapeutic tool. 
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1.3 Vitamin D metabolites of interest 
1.3.1 25-hydroxyvitamin D 
Measurement of 25(OH)D is accepted as a reliable clinical indicator of vitamin D status in 
humans. The steady circulating serum level and long half-life of approximately 2 to 3 weeks make 
25(OH)D an ideal diagnostic indicator of vitamin D deficiency and monitoring target in 
supplementation therapy. The Royal Osteoporosis Society (ROS)10 in agreement with the Institute 
of Medicine (IOM)11 defined insufficient vitamin D status as a serum 25(OH)D <50 nmol/L but 
advocated that 25(OH)D concentration should exceed 75 nmol/L, in order to maximise the effect 
on calcium, bone and muscle metabolism. Serum 25(OH)D <30 nmol/L is highlighted by IOM as 
deficient, whereas ROS adopted <25 nmol/L as the severely deficient threshold. In the UK, the 
Scientific Advisory Committee on Nutrition (SACN) that advises the government on diet and 
health published in its report Vitamin D and Health 201612 the population recommended reference 
nutrient intake (RNI) of 10 micrograms (400 IU) of vitamin D per day, for everyone in the general 
population aged 4 years and older throughout the year regardless of sunlight exposure. The RNI 
and safe intakes were developed to ensure that the majority of the UK population has sufficient 
25(OH)D to protect musculoskeletal health. 
 
a. b.   
Figure 2.1 Structure of (a) 25-hydryoxyvitamin D3 and (b) 25-hydryoxyvitamin D2 
  
Two forms of 25(OH)D exist (Figure 2.1) being 25(OH)D3, which is mainly derived from skin 
exposure to UVB and to a minor extent from diet and supplements, and 25(OH)D2, which is 
mainly derived from supplements and to a small extent from dietary origin. When measuring 
25(OH)D, it is important the assay methodology has co-specificity for 25(OH)D3 and 25(OH)D2, 
as both metabolites are metabolically active, more so for 25(OH)D3. The serum concentration of 
25(OH)D3 is higher than 25(OH)D2 due to the cutaneous synthesis by UVB radiation and broader 
sources of vitamin D3 available in foods and supplements derived from animal origin. 25(OH)D2 
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is less prevalent though can be present in individuals taking vitamin D2 supplements derived from 
plant products. 
Biochemical assessment of vitamin D status is frequently performed on patients with bone 
diseases and musculoskeletal symptoms such as osteomalacia and widespread chronic pain. For 
asymptomatic individuals, daily 400 IU vitamin D3 supplement is recommended by the Public 
Health England (PHE) for specific population groups that are at risk of vitamin D deficiency; in 
particular to older people aged >65 years, pregnant and breastfeeding women, infants and young 
children aged <5 years, and people who lack sunlight exposure (e.g. housebound)13. For patients 
presenting with severe vitamin D deficiency, a loading regimen up to a total of approximately 
300,000 IU can be prescribed either as weekly or daily split doses, followed by a maintenance 
regimen of 800-2000 IU per day (up to a maximum of 4000 IU daily) starting one month after 
loading regimen10. Although such dosing regimen is unlikely to result in toxicity, clinicians are 
advised that certain groups of patients with increased vitamin D sensitivity may be at risk of 
developing toxicity or adverse side effects; in conditions due to genetic abnormalities in vitamin 
D metabolism, co-morbidities such as CKD, granuloma-forming diseases or 
hyperparathyroidism. Assessment of vitamin D status by measurements of serum 25(OH)D, 
adjusted calcium and PTH (for hyperparathyroidism patients) are recommended to monitor 
treatment and compliance with medication. 
Vitamin D toxicity is rare; severe cases can manifest through chronic hypercalcaemia. Less severe 
cases can be identified by hypercalciuria, if left untreated could increase the risk of forming renal 
stones. There are reports of increased incidents of falls and fractures in the older population 
associated with the use of high doses of vitamin D administered annually or monthly14,15. Current 
evidence suggests the correlation of risks vs benefit effects of vitamin D exhibit a U-shaped curve, 
rather than a J-shaped curve. Although higher doses of vitamin D supplement were more effective 
in reaching 25(OH)D concentration of 50 nmol/L, high supplementation levels can be detrimental 
to the patients. Vitamin D replacement regime must be carefully optimised under medical 
supervision, based on the characteristics of the patient, in combination with measurements of 
25(OH)D and other downstream metabolites of vitamin D. 
 
1.3.2 C3-Epimer 25-hydroxyvitamin D 
25(OH)D3 and 25(OH)D2 can be metabolised through an alternate C3 epimerisation pathway, 
into C3-epi-25(OH)D3 and C3-epi-25(OH)D2 (Fig. 1.2), and further into their respective C3-epi-
1,25(OH)2D forms16. Reports had shown that C3-epi-1,25(OH)2D3 is nearly as potent as 
1,25(OH)2D3 in suppressing PTH secretion, but has reduced calcaemic properties17. The 
biological relevance of C3-epi-25(OH)D remains to be elucidated. Studies have found detection 
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of the epimer in 23% of infant sera less than 1 year old accounting for up to 61% of total 25(OH)D 
concentration when determined using a LC-MS/MS method18.  
The 3-epi-25(OH)D3 metabolite is identical in chemical structure to 25(OH)D3 except for 
molecular asymmetry at the OH position on C3. As both forms have the same mass precursor to 
product ion transitions, insufficient separation of the C3-epimer could lead to overestimation of 
25(OH)D319. Several studies have been published using cyano-propyl (SB-CN)20, chiral21 and 
pentafluorophenyl (PFP)22 columns to resolve C3-epi-25(OH)D chromatographically. However, 
long run times from 6.4 to 40 minutes making such assays difficult to implement in routine clinical 
laboratories. 
a. b.  
Figure 3.2 Structure of (a) C3-Epimer 25-hydryoxyvitamin D3 and (b) C3-Epimer 25-
hydryoxyvitamin D2 
 
Epidemiologic studies on general population had shown serum concentration of C3-epi-25(OH)D 
is closely related with 25(OH)D that is independent of vitamin D binding protein and genetic 
influences23,24. There is considerable variability in serum C3-epi-25(OH)D concentration between 
individuals and substantial difference in the production of the metabolite in response to vitamin 
D supplementation. Case reports had shown that patients who took high doses of over-the-counter 
cholecalciferol and ergocalciferol were found with substantial serum levels of C3-epi-25(OH)D3 
and C3-epi25(OH)D225-27. Such cases highlight the need to evaluate the use of non-prescribed 
forms of vitamin D supplements. 
 
1.3.3 1α,25-dihydroxyvitamin D 
1,25(OH)2D (calcitriol) (Fig. 1.3) is the physiologically active form of vitamin D. It is a product 
of the enzymatic hydroxylation of 25(OH)D by 1α-hydroxylase that takes place primarily in the 
kidneys. The physiological regulation of 1,25(OH)2D is more tightly regulated than 25(OH)D, 
when serum 25(OH)D stores decline, 1,25(OH)2D is maintained by increasing PTH stimulation 
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of 1α-hydroxylation. Measurement of serum 1,25(OH)2D should be considered upon suspicion of 
deficiency or excess of 1,25(OH)2D leading to hypo- or hypercalcaemia, hypoparathyroidism and 
hypomagnesemia. Decreased concentrations are found in patients with renal insufficiency, 
vitamin D dependent rickets (1α-hydroxylase deficiency), X-linked hypophosphataemia and 
hypoparathyroidism. Increased 1,25(OH)2D concentrations are found in vitamin D-deficient 
rickets (end-organ resistance), granulomatous disorders and hereditary hypophosphataemic 
rickets. It is important to stress that serum concentration of 1,25(OH)2D does not reflect the 
nutritional vitamin D status of an individual. 
 
a. b.  
Figure 1.3 Structure of (a) 1α,25-dihydroxyvitamin D3 and (b) 1α,25-dihydroxyvitamin D2 
 
1,25(OH)2D measurements can be used in clinical settings or disease-focused patient studies. The 
use in healthy population-based or vitamin D supplementation studies is rare; serum concentration 
does not correlate with 25(OH)D, except in patients with chronic kidney disease (CKD)28, where 
a greater association is observed between 1,25(OH)2D and 25(OH)D dependent upon the severity 
of the renal impairment. Despite being the most biologically active form of vitamin D metabolite, 
1,25(OH)2D is not used for the assessment of vitamin D status. Serum concentration is tightly 
regulated by the hydroxylation enzymes expressed by the actions of CYP27B1 and CYP24A1, 
and influenced by PTH and FGF23. Mutations of the CYP27B1 and CYP24A1 genes can result 
in excessive production of serum 1,25(OH)2D and develop into a persistent state of 
hypercalcaemia – a condition known as Idiopathic Infantile Hypercalcaemia (IIH). Clinical 
manifestations of IIH depend largely on the age of diagnosis. Infants present with weight loss, 
failure to thrive, vomiting, dehydration, lethargy and hypotonia. Adults with total or partial 
CYP24A1 mutations most frequently present with nephrolithiasis and/or nephrocalcinosis. 
Distinguishable biochemical profile of IIH includes hypercalcaemia, low PTH and elevated 
1,25(OH)2D. Serum 25(OH)D concentration can remain normal as the condition is affecting 
inadequate disposal of 1,25(OH)2D and not excessive substrate. Low serum concentration of 
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24,25(OH)2D and elevated 25(OH)D:24,25(OH)2D vitamin D metabolite ratio (VMR) have 
proved to be useful in identifying patients with CYP24A1 mutations. Further details to be 
presented in 1.3.4. 
Before the introduction of fully automated platforms, measurement of serum 1,25(OH)2D in 
hospital laboratories have mostly relied on the use of manual immunoassays with a radioisotopic 
(I-125) or enzyme label. Two commercially available methods have recently been launched by 
Diasorin and IDS, both developed to be run on their own proprietary automated systems. The 
DiaSorin LIAISON® XL chemiluminescent immunoassay utilises the ligand-binding domain 
(LBD) of the vitamin D receptor for the capture of 1,25(OH)2D molecule, followed by a murine 
monoclonal antibody detection system that recognises the conformation change produced by the 
LBD-1,25(OH)2D complex29. The method exploits the reaction conditions where binding 
differential of VDR highly favours 1,25(OH)2D over other forms of hydroxylated vitamin D, thus 
negates the need for immunoextraction. The Immunodiagnostic Systems (IDS) iSYS 1,25 
VitDXp method involves an onboard immunopurification that has been modified from the IDS 
mini-immunocapsule extraction approach. The two-stage assay utilises an anti-1,25(OH)2D 
antibody-coated magnetic particles to extract and enrich 1,25(OH)2D in the sample, followed by 
competitive binding against a 1,25(OH)2D-labelled conjugate with a sheep anti-1,25(OH)2D 
antibody for detection and amplification30. 
Due to the low concentration of 1,25(OH)2D in circulation (reference intervals 48-150 pmol/L) 
and its poor ionisation properties, LC-MS/MS methodology for 1,25(OH)2D require high-end 
mass spectrometry instruments. To achieve adequate assay sensitivity, extensive sample 
preparation to enrich sample load by either a manual immunoaffinity step31,32 or online two-
dimensional chromatography33,34. Alternatively, assay sensitivity can be boosted by increasing 
the ionisation efficiency of 1,25(OH)2D using a derivatisation agent. Several described in the 
literature are based on a substituted form of 1,2,4‐triazoline‐3,5‐dione (TAD) at the 4-position (4-
X-TAD). Most commonly used derivatisation agents are PTAD (4-phenyl-1,2,4-triazoline-3,5-
dione), DMEQ-TAD (4‐[2‐(3,4‐dihydro‐6,7‐dimethoxy‐4‐methyl‐3‐oxo‐2‐quinoxalinyl)ethyl]‐
TAD)35 and AmplifexTM Diene36. These Cookson-type dienophilic agents react to the s-cis-diene 
moiety of vitamin D molecule via the Diels-Alder reaction to form a larger complex with 
increasing ionisation potential depending on the number of proton-affinitive functional groups 
available in the resultant reaction. The improvement in sensitivity and specificity enable 
differential analysis of vitamin D metabolites, expanding the applicability in research and 
diagnostic investigations. 
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1.3.4 24,25-dihydroxyvitamin D 
24,25(OH)2D is formed via C24-hydroxylation of 25(OH)D by cytochrome P450 24-hydroxylase 
enzyme CYP24A1 (cytochrome P450, family 24, subfamily A, polypeptide 1). CYP24A1 plays 
an important role in vitamin D catabolism, however, the biological function of 24,25(OH)2D 
remains unclear besides being the apparent inactive catabolite of 25(OH)D. A recent publication 
suggested the measurement of serum 24,25(OH)2D in conjunction with 25(OH)D shows promise 
as a novel marker of 25(OH)D catabolism and predictor of serum 25(OH)D response to vitamin 
D supplementation37. 24,25(OH)2D is quantitatively most abundant circulating vitamin D 
metabolite besides 25(OH)D, with human serum concentrations between 0.7 and 24 nmol/L38. 
Studies have shown serum 24,25(OH)2D correlated positively with serum 25(OH)D levels37. It is 
important to note the difference between the R- and the S- form, 24S,25(OH)2D is the epimer 
form of 24R,25(OH)2D (Fig. 1.4).  
 
a. b.  
Figure 1.4 Structure of (a) 24R,25-dihydroxyvitamin D3 and (b) 24S,25-dihydroxyvitamin 
D3. 
Measurement of serum 24,25(OH)2D was first reported in the late 1970s using competitive protein 
binding assays39,40 in animal and in vitro models to study the healing properties of 24,25(OH)2D 
on bone41. When HPLC methods with UV detection became the method of choice for 25(OH)D, 
the improvement in assay sensitivity had remained insufficient to detect serum 24,25(OH)2D, 
which circulates at concentrations between 1-13 nmol/L42-44, 10-fold lower than 25(OH)D. 
Shimizu et al. first reported a chemical derivatisation method for 24,25(OH)2D using a Cookson-
type dienophilic agent which reacts to the s-cis-diene moiety of vitamin D via the Diels-Alder 
reaction; forming a conjugated diene derivative for detection by HPLC with a fluorometric 
detector45. However, despite the improvement in assay sensitivity, studies in the 1980-90s have 
found limited biological activity of 24,25(OH)2D in humans46-48, and it was considered to be an 
inactive catabolic product of the vitamin D pathway49. The revival of interest in 24,25(OH)2D 
measurement was brought about after Genome-wide studies have pinpointed CYP24A1 as one of 
the major genetic determinants of variability in 25(OH)D50. Publications have shown CYP24A1 
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defects in children with IIH51; in adults with nephrolithiasis and nephrocalcinosis52; and in patients 
with chronic kidney disease53, are associated with low serum 24,25(OH)2D concentration, and the 
genetic defect can be highlighted by an elevated 25(OH)D:24,25(OH)2D VMR. 
25(OH)D:24,25(OH)2D VMR can indicate the vitamin D catabolic status of an individual and 
highlight 24-hydroxylase deficiency due to genetic abnormalities of CYP24A1. In a healthy 
population, 25(OH)D:24,25(OH)2D VMR is between 7-23, and increases when vitamin D status 
becomes insufficient54. A ratio of >80 is associated with patients with heterozygous or biallelic 
mutations of CYP24A143,55. Moderate elevation of 25(OH)D:24,25(OH)2D VMR due to partial 
inactivity of CYP24A1 is associated with renal impairment53,56 and bone disorders57. 
25(OH)D:24,25(OH)2D VMR has an advantage for being less susceptible to seasonal 
fluctuation58; allowing interpretation using fixed reference intervals irrespective of the time of the 
year. 
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1.4 Current Issues relating to the measurement of vitamin D metabolites 
 
25(OH)D 
The dramatic explosion of interests in vitamin D sparked a massive increase in the number of 
laboratory requests for the measurement in serum. This, in turn, has highlighted problems of the 
methodologies available for measuring vitamin D metabolites. The ability to measure the two 
major forms of vitamin D (Cholecalciferol (D3) and ergocalciferol (D2) with precision and 
accuracy are essential to correctly identify the vitamin D status of an individual and to monitor 
the effectiveness of vitamin D treatment. Proficiency testing bodies such as the International 
Vitamin D External Quality Control Scheme (DEQAS)59 have been monitoring the accuracy of 
25(OH)D and 1,25(OH)2D assays. Their recent report suggests measurement of 25(OH)D by a 
liquid chromatography tandem mass spectrometry (LC-MS/MS) method using NIST-aligned 
calibration standards exhibits the least inter-laboratory imprecision in comparison with 
immunoassays60. LC-MS/MS methods are capable of distinguishing the D3 and D2 form of 
vitamin D by their mass-to-charge (m/z) ratio, allowing the source of vitamin D to be identified. 
Immunoassays have variable cross-reactivity with 25(OH)D2 and D3, some methods may 
significantly underestimate an individual’s true vitamin D status. In the literature, comparison 
studies between commercial immunoassays with LC-MS/MS methods have shown negative 
biases in the results generated by immunoassay in samples containing 25(OH)D2, reflecting the 
varying degree of antibody cross-reactivity with the D2 metabolite61-63. Discrepancies in the 
interpretation of vitamin D status from different immunoassays were also reported64; with some 
methods identified significantly more hypovitaminosis cases than others. Disparity can also occur 
in specific population groups; Dowling et al. had reported over-estimation of 25(OH)D 
measurements in the Roche assay due to the presence of elevated 24,25(OH)2D in patient 
samples65. Hara et al. had reported falsely elevated 25(OH)D in serum samples from in infants 
and postpartum women produced by the Diasorin radioimmunoassay (RIA)66. Several studies 
have reported low serum concentration of 25(OH)D in pregnant women are associated with 
increased risk of pre-eclampsia, gestational diabetes and other complications of pregnancy67. The 
negative association could be exaggerated by the method of 25(OH)D quantitation. Vitamin D 
binding protein (VDBP) is known to be elevated during pregnancy; incomplete dissociation of 
25(OH)D from VDBP by immunoassays can result in under-recovery of 25(OH)D and thus 
underestimate the actual value. Heijboer et al. had reported an inverse relationship between VDBP 
concentrations and deviations of 25(OH)D values from the LC-MS/MS assay68. Elevated VDBP 
can also be observed in patients presenting with inflammatory disease such as rheumatoid arthritis 
and acromegaly69. The use of oestrogen-containing hormonal contraceptive can increase the 
serum concentration of VDBP similar to pregnancy. Chemical solvents used in the sample 
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pretreatment step in LC-MS/MS methods ensure complete dissociation of 25(OH)D from its 
binding proteins, hence LC-MS/MS technique offers higher specificity than immunoassays, thus 
the capability to recognise different forms of vitamin D simultaneously. It is therefore considered 
to be the reference method for measuring 25(OH)D. 
 
C3-epi-25(OH)D 
In the DEQA 2012 review70 published the results of an experimental study conducted to assess 
the ability of the methods to distinguish C3-epi-25(OH)D3 from 25(OH)D3. Two serum samples 
were sent out to the scheme participants, both originated from the same base pool, with one 
sample spiked with exogenous C3-epi-25(OH)D3 (51 nmol/L).  The study report (Fig 1.5) showed 
that all commercial immunoassays, except for the Roche competitive protein binding (CPB) based 
assay, did not cross-react with the epimer and produced similar results on the base and spiked 
samples. For chromatography-based methods (HPLC and LC-MS/MS), due to the identical 
molecular weight and structure, routine methods that employ the use of a C18 analytical column 
are unable to chromatographically resolve the epimer forms from 25(OH)D. Instead, the epimer 
peaks co-elute with 25(OH)D3 and 25(OH)D2. The report showed major positive bias in the 
sample spiked with C3-epi-25(OH)D3, overestimating the concentration of 25(OH)D3. 
 
Figure 1.5 DEQAS returns of the base pool (sample 404) and the base pool spiked with C3-
epi-25(OH)D3 (sample 405) illustrating positive bias observed in HPLC, LCMS and Roche CPB 
method groups. (Graph was adapted from70) 
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Despite the alarming concerns over the isobaric interference that may cause overestimation of 
total 25(OH)D by HPLC, LC-MS/MS and Roche CPB methods, it is not clear the impact this 
interference may have on the assessment vitamin D status in patients. There was little evidence 
on the clinical significance and the prevalence of endogenous C3-epi-25(OH)D3, which had been 
shown to behave differently to the exogenous form of the same compound. Van den Ouweland et 
al. had reported that the Roche CPB method displayed minimal recognition in samples containing 
natural endogenous C3-epi-25(OH)D3; whereas the cross-reactivity to exogenous C3-epi-
25(OH)D3 added to human serum was approximately 51%71. There are several evaluation studies 
in the literature that reported variable differences in the significant of C3-epi-25(OH)D using a 
plethora of ‘in-house’ chromatography-based UV or MS/MS methods, but the lack of 
standardised calibration material and appropriate isotopic-labelled internal standard have 
undermined the accuracy of the results produced. 
 
1,25(OH)2D 
Long term assay performance between all the immunoassay and LC-MS/MS methods are closely 
monitored by DEQAS. The lack of cross-assay reference standards has yet to be addressed. Since 
the introduction of fully automated platforms by DiaSorin and IDS, manual radioisotopic 
immunoassays have been on a gradual decline. The shift has reduced inter-laboratory variability, 
but raised concern over the dominance of the two methods, particularly with the DiaSorin method 
placing a heavy influence on the DEQAS scheme and potentially masking method-specific bias. 
One study compared the IDS iSYS, Diasorin LIAISON assays with a LC-MS/MS method found 
a marked difference in the assay performance. The DiaSorin assay performed better in terms of 
accuracy, sensitivity and imprecision compared to the IDS iSYS assay. Total imprecision was 
5.2% or less for the DiaSorin assay but reached 20.1% for the IDS iSYS assay. 1,25(OH)2D 
concentrations measured with the DiaSorin assay showed a strong correlation with 1,25(OH)2D 
levels measured by LC-MS/MS and a good agreement with method-specific means on DEQAS 
samples. By contrast, the IDS iSYS method overestimated 1,25(OH)2D concentrations in human 
serum, particularly at higher concentrations72. 
Reference ranges have been established using immunoassays in healthy adults and patient 
groups73,74, but wide intervals reported cast concerns over assay specificity, given circulating 
concentration is tightly regulated by the body. Higgins et al.75 reported high disparity between the 
DiaSorin and LC-MS/MS methods in pooled neonates and infants samples with elevated 
1,25(OH)2D; a positive bias of up to 26.5% was observed in immunoassay results, 3-epi-
1,25(OH)2D was ruled out as a potential source of bias. 
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LC-MS/MS methodologies for 1,25(OH)2D has remained confined to few laboratories with high-
end instruments. Using a SCIEX 6500+ instrument, Ivison et al. have developed an LC-MS/MS 
method that employs the use of immunoaffinity extraction followed by derivatisation with 
Amplifex™ reagent76. The method performed with imprecision CV of <15.6%. Analysis of 
DEQAS samples showed a negative bias compared with the all lab trimmed mean of –13.8% and 
the specific method group (average –7.75%). A negative bias was observed across the 
concentration range found in 78 patient samples in comparison to a commercial RIA (mean –
47.8%). 
 
24,25(OH)2D 
Efforts to standardise and improve inter-laboratory comparability of 24,25(OH)2D assays are in 
working progress. NIST SRM972a and 2973 in frozen human serum are available with certified 
values for 24,25(OH)2D3 between 3.39-7.51 nmol/L77. DEQAS has introduced a pilot scheme 
since April 2015, but due to the small number of participants, albeit using LC-MS/MS methods, 
high inter-laboratory variability was observed, with CVs ranging between 19-29%78. Wise et al. 
reported lower variability in five laboratories using isotopically labelled 24,25(OH)2D3 as internal 
standard79. The availability of a reference-traceable, matrix-matched, multi-point calibration 
standards would improve method accuracy and commutability of results between laboratories. 
1.5 Conclusion 
Over the past decade there have been major advances in the development of analytical techniques 
for measuring vitamin D metabolites. The breakthrough in LC-MS/MS technology; with its 
superior sensitivity and specificity, has created new grounds for improving assay methods. New 
metabolites have been identified, and some known metabolites that were previously thought to 
have little biological actions have remerged with new evidence. Much more work remains to be 
done to better our understanding and appreciation of vitamin D metabolism, its role in 
calcium/bone homeostasis, and clinical significance in health and pathological conditions. 
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Chapter 2 Aims and objectives 
 
The aim of this PhD thesis was to develop and validate quantitative assays for serum vitamin D 
metabolites by LC/MS-MS, and utilise the newly developed methods to perform analysis on study 
samples to investigate the relationships between the metabolites of interests. This research has 
focused on the major circulating vitamin D metabolites; 25(OH)D, C3-epi-25(OH)D, 
24,25(OH)2D, 1,25(OH)2D, and their respective D3/D2 forms. The performance characteristic of 
the assays must satisfy industry standards for method validation. The assays will be accurate, have 
excellent reproducibility (low inter and intra assay), have sufficiently low quantification/detection 
limits, show correlation with existing methodologies and perform well in an external proficiency 
testing scheme. The project poses many challenges; due to the complex nature of the sample 
matrix, small sample volume, potential interference from other endogenous and exogenous 
components within the sample matrix such as phospholipids must be addressed. Development of 
effective sample extraction strategy is a key component of this research. The scope of 
development includes the use of dried blood spots and novel microsampling techniques. 
Once the assays are established, the objectives that followed were to determine the serum 
concentration and reference intervals of the vitamin D metabolites in adults and children from 
both healthy and patient populations. Using samples collected from three vitamin D3 
supplementation studies with contrasting dosage regimen; the changes in metabolite 
concentration in response to the dose and frequency of administration were investigated. 
This thesis provides evidence on the intricate relationships between active and catabolic forms of 
vitamin D metabolites, giving insights into the mechanism and consequences of vitamin D status, 
and potential interactions in various pathophysiological conditions. 
  
15 
 
Chapter 3 Materials and Methods 
3.1 Materials 
3.1.1 Reagents 
LCMS grade water, acetonitrile and methanol, and analytical grade formic acid, n-heptane and 
propan-1-ol were obtained from Fisher Scientific (Loughborough, UK). Zinc sulphate was 
purchased from Sigma-Adrich (Dorset, UK). Isolute® SLE+ 96-well Supported Liquid Extraction 
plates were supplied by Biotage (Uppsala, Sweden). 
 
3.1.2 Standard materials and calibration solutions 
Stock solutions were prepared by spiking certified reference 25(OH)D3, 25(OH)D3, C3-epi-
(OH)D3, 1,25(OH)2D3 1,25(OH)2D2, 24R,25(OH)2D3 and 24,25(OH)2D2 (IsoSciences, King of 
Prussia, PA, USA) in LCMS grade methanol and were stored at -20˚C. NIST SRM 972a traceable 
human lyophilised multilevel serum calibrators for 25(OH)D3/D2 and C3-epi-(OH)D3/D2 were 
purchased from Chromsystems (München, Germany). 1,25(OH)2D3/D2 lyophilised calibrators 
and LC-MS/MS ImmuTube® (Immundiagnostik AG, Bensheim, Germany) were used in the 
immunoaffinity extractions. 
 
3.1.3 Preparation of calibration standards 
Methanolic stock calibration standard solutions were prepared by dissolving 1 mg of the powder 
compound or 1 mL of the aqueous standards in 1 mL of LCMS grade methanol. Working 
standards were made from diluting the stock solutions in two consecutive 1 in 100 dilutions by 
methanol followed by vitamin D depleted serum to achieve the top serum calibration standard. 
The spiked serum standards were aliquoted into 0.5 mL portions and stored at -20ºC until the day 
of analysis. Each batch of aliquoted standards was assigned with a lot number and date of 
preparation recorded. Lyophilised commercial serum calibrators (Chromsystems) were made up 
by reconstituting in 1 mL of LCMS grade water and allowed to stand for 15 minutes before use. 
Reconstituted standards were aliquoted into 100 µL microcentrifuge tubes and frozen at -20˚C for 
use at a later date. 
 
3.1.4 Internal quality control 
Lyophilised Internal quality control (IQC) materials for 25(OH)D3/D2 were purchased from 
Chromsystems (München, Germany) and UTAK (Grifols, Valencia, CA, USA). C3-epi-
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25OHD3/D2 bi-level controls were supplied by Chromsystems. Calf serum pool containing 
endogenous 25(OH)D3/D2 was obtained from Lorne Laboratories (Danehill, Berkshire, UK). 
Vitamin D depleted serum purchased from BBI Solutions (Cardiff, UK) was used as the base pool 
for spiking in-house vitamin D metabolites standards and controls. 
 
3.1.5 Preparation of internal quality control 
All commercially available quality control materials were prepared in accordance with 
manufacturer instructions. Chromsystems bi-level serum controls and UTAK serum controls were 
prepared by reconstituting with 1 mL and 5 mL of LCMS grade water, respectively. Before a new 
batch of IQC material was introduced the new materials were analysed over 20 separate runs for 
each analyte to obtain the mean, SD and %CV values. Aliquots were stored at -20˚C before use. 
 
3.1.6 Isotopic labelled internal standards 
Isotopic labelled 25-hydroxy vitamin D3-[26,26,26,27,27,27,-2H6], 25-hydroxy vitamin D2-
[13C3], 3-Epi-25-Hydroxyvitamin-D3-[6,19,19-2H3], 1α,25-dihydroxyvitamin D3-[6,19,19,2H3] 
and 24R,25-dihydroxyvitamin D3-[2H6] (IsoSciences, King of Prussia, PA, USA) were used as 
internal standards. 
 
3.1.7 Human sera 
Human serum samples containing endogenous vitamin D metabolites, used during method 
validation for the determination of assay recovery, limit of quantification, method comparison 
and assessment of concentrations in adults were obtained from the Department of Laboratory 
Medicine at the Norfolk and Norwich University Hospital NHS Trust. The samples were treated 
in agreement with the local ethical guidelines for assay development80. All samples were stored 
at -20˚C before use. 
 
3.1.8 Material and laboratory instrumentation 
1.5mL microcentrifuge tubes (Starlab, Milton Keynes, UK) and 96-well propylene microtitre and 
2 mL deep well plates (Corning Life Sciences, Amsterdam, Netherlands) were used in sample 
pre-treatment steps. Sample homogenisation was performed using a roller (Bibby Scientific, 
Stone, UK), microtitre plate shaker (Heidolph, Schwabach, Germany) and multi-tube vortexer 
(Luckham, USA). The mobile phase was degassed using an ultrasonic bath (Fisher Scientific, 
Loughborough, UK). Stock standard solutions were weighed using analytical balance (Sartorius, 
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Goettingen, Germany), calibrated using test weights traceable to UKAS metrology certification, 
allowing the lowest measurements at 0.1 mg. Centrifugation was performed using Heraeus 
Megafuge 40R refrigerated centrifuge (Thermo Scientific, Finland). The temperature of the 
fridges, freezers, room temperature cabinets and laboratory preparation area were continuously 
monitored and recorded by wireless temperature probes (t-Scan, London, UK). 
 
3.2 Instrumentation and conditions 
3.2.1 Instrumentation 
The instrument setup for LC-MS/MS analysis was performed using a Rheos Allegro UPLC pump 
(Flux Instruments, Switzerland) connected to a Micromass Quattro Ultima Pt mass spectrometer 
(Waters Corp., Manchester, UK) (Fig. 3.1). The UPLC system was equipped with a binary solvent 
manager operated via Janeiro® II software. A Waters® 2777 Sample manager (Waters Corp., 
Milford, MA, USA) equipped with 3-drawer cooler stack regulated at 10˚C was used for sample 
injection. 
 
 
Figure 3.1 Micromass Quattro Ultima Pt tandem mass spectrometer (picture right) with 
Rheos Allegro UPLC pump (left). 
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3.2.2 Liquid chromatography conditions 
Serum extracts were injected into the liquid chromatography system via a sample manager into 
the UPLC system. Chromatographic separation of 25(OH)D3/D2 was achieved using the Sunfire® 
C18 50 × 2.1mm, 3.5 µm column (Waters Corp., Milford, MA, USA) reversed-phase column 
heated at 55˚C and protected by a 2µm, 6.35mm × 24mm guard cartridge. A gradient elution 
profile was set up with a column flow rate at 0.4 mL/min. At the start of the gradient, the mobile 
phase consisted of 12%:88% (A) LCMS grade Water in 0.1% formic acid and (B) LCMS grade 
methanol in 0.1% formic acid, gradually increased to 99% (B) then returned back to starting 
gradient in 4.5 minutes. Chromatographic separation of C3-epi-25(OH)D3/D2 required the use of 
a solid core phenylfluoropropyl (PFP) 100 × 2.1mm, 2.6 µm column (Restek, PA, USA). The 
gradient elution profile was optimised at (A) at 25% and (B) 75%. Solvent divert was employed 
to divert the ion suppression region of the separation to waste in order to minimise contamination 
to the source of the mass spectrometer. 
 
3.2.3 Mass spectrometric conditions 
Mass spectrometric analysis of vitamin D metabolites and their respective internal standards 
was performed using triple quadrupole tandem mass spectrometer with an integrated 
Electrospray ionisation (ESI) source operated in positive mode. The capillary voltage was kept 
at 3.0 kV and RF lens 1 and 2 were set at 0.1. Source temperature was maintained at 85˚C. 
Nitrogen was used as both nebuliser gas and as desolvation gas, the flow rate was set at 30 L/hr 
and 850 L/hr, respectively. Desolvation temperature was kept at 250˚C. Sample cone voltage 
and collision energies were optimised for each compound (Table 3.1). Argon was used as the 
collision gas. Sample analysis was performed in multiple reaction monitoring (MRM) mode 
with a dwell time of 0.2 seconds. The transitions of each of the compounds were identified by 
direct infusion of methanolic standards into the ion source via a T-connector to determine their 
respective precursor to product quantifier and qualifier ion transitions (Table 3.1). 
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Compound 
voltage (kV) m/z 
Cone Collision Precursor Product 
25(OH)D3 / C3-Epi-25-25(OH)D3 35 12 401 
383 (Quan) 
365 (Qual) 
25-(OH)D3-[26,26,26,27,27,27,-2H6] 35 22 407 107 
C3-Epi-25(OH)D3-[6,19,19-2H3] 35 22 415 107 
25(OH)D2 / C3-Epi-25(OH)D2 35 8 413 
270 (Quan) 
395 (Qual) 
25(OH)D2-[13C3] 35 22 416 107 
1,25(OH)2D3 35 10 399 
381 (Quan) 
135 (Qual) 
1,25(OH)2D2 35 8 411 
392 (Quan) 
135 (Qual) 
1,25(OH)2D3-[6,19,19,2H3] 35 8 402 384 
24R,25(OH)2D3 35 10 417 
398 (Quan) 
121 (Qual) 
24R,25(OH)2 D3-[2H6] 35 8 423 121 
 
Table 3.1 The precursor to product quantifier and qualifier ion transitions of vitamin D 
metabolites and their respective isotopic labelled internal standards. 
 
3.2.4 Software 
MassLynx v4.1 and QuanLynx software (Waters Corp., Milford, MA, USA) were used for system 
control, data acquisition, baseline integration and peak quantification. 
 
3.2.5 Statistical Data analysis 
Results were recorded in Microsoft Excel spreadsheet. Statistical analysis for determination of 
inter and intraassay coefficient of variation (%CV), linear regression graphs, box and whisker 
plots and Bland-Altman plots were generated using SPSS v.23 (IBM Corporation, NY, USA) and 
GraphPad Prism 8 (GraphPad, San Diego, CA, USA). All data were visually examined and 
checked for transcriptional, pre/post analytical errors before statistical analysis. 
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3.3 Analytical procedures 
3.3.1 Sample pre-treatment procedures 
Before the start of each experiment, all reagents were mixed thoroughly by gentle inversion before 
use. For solvent-based reagents, all refrigerated reagents were left on the bench to reach room 
temperature (18-25˚C). Frozen serum/plasma samples were thawed, mixed, and centrifuged at 
4000 ×g for 5 minutes before use. 
 
3.3.2 Isotopic dilution protein precipitation 
100 µL of calibration/quality control/sample was placed in 1.5 mL microcentrifuge tubes, 
followed by 100 µL of 0.1 M zinc sulphate in water. 200 µL of cold LCMS grade acetonitrile 
containing [2H6]-25(OH)D3 and [13C2]-25(OH)D2 at concentrations of 450 nmol/L was added to 
each tube. All tubes were immediately capped and mixed vigorously on a vortex mixer for one 
minute to ensure homogeneity, and then incubated in 4˚C for 45 minutes. After incubation, all 
tubes were mixed and centrifuged at 10,000 ×g for 5 minutes. 200 µL of the supernatant was 
transferred to a microtitre plate which was then heat sealed with aluminium foil before injection 
into the LC system. 
 
3.3.3 Phree™  Phospholipid depletion plate 
100 µL of calibration/quality control/sample was placed directly onto the bed of the plate, 
followed by 600 µL of internal standard mixture in 60% (v/v) acetonitrile and water. The plate 
was placed on a waste collection plate and mixed vigorously on a plate vortexer for 10 minutes. 
Nitrogen gas was applied at 6 bar of pressure on a positive pressure manifold to remove the eluent 
to waste. The plate was then transferred onto a fresh 2 mL 96-deep well collection plate with 100 
µL of 0.1 M zinc sulphate dispensed into each well. 300 µL of acetonitrile was added onto the 
bed of the phospholipid removal plate; nitrogen pressure was applied to push the eluent into the 
collection plate containing the zinc sulphate. The plate was heat-sealed with aluminium foil after 
a brief vortex and then placed onto the sample manager for analysis. 
 
3.3.4 Supported liquid extraction (SLE) 
100 µL of calibration/quality control/sample was placed in 1.5 mL microcentrifuge tubes, 
followed by 200 µL of internal standard mixture in 50% (v/v) propan-1-ol and water. The mixture 
was mixed before loading onto the SLE plate, the plate was placed on top of a 2 mL 96-deep well 
collection plate and left to stand for 5 minutes to allow the mixture to soak into extraction bed. 
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The plate was washed twice with 750 µL of n-heptane and the eluent collected. A positive pressure 
manifold delivering nitrogen gas at 6 bar of pressure was applied to the bed of the plate after each 
wash step to remove residual eluent. The collected eluents were dried down under a constant 
stream of nitrogen gas on a sample concentrator heated at 37 ˚C. The dried plate was reconstituted 
in 70% (v/v) methanol in water and then vortexed and heat sealed with aluminium foil before LC-
MS/MS analysis. 
  
22 
 
3.4 Method Validation 
Method validation criteria is based on the 2018 U.S. Food and Drug Administration (FDA)81 and 
2012 European Medicines Agency (EMA)82 guidelines on bioanalytical method validation 
3.4.1 Ion suppression 
An Ion suppression experiment was performed by post-column infusion of a methanolic vitamin 
D mixture containing approximately 1 µg/mL of each metabolite via a T-junction at a flow rate 
of 20 µL/min, during which samples of extracted phosphate buffered saline (PBS) and human 
serum were injected via the liquid chromatography system at 0.4 mL/min. 
 
3.4.2 Imprecision 
Intra and inter-assay imprecision of the assay were assessed by running QC materials a minimum 
of 6 times within a single run and separately over a defined period. Variation was expressed in 
terms of standard deviation (SD) and coefficient of variation percentage (%CV). The acceptance 
criteria defined that %CV should not exceed 10% and 15% at the lower limit of quantification. 
 
3.4.3 Linearity 
The linearity of the method was evaluated by analysing stock standards made up from reference 
calibration solutions. 25(OH)D3/D2 and C3-epi-25(OH)D3 concentrations ranging from 0 to 500 
nmol/L were prepared and analysed. The calibration curve was constructed by plotting the ratio 
of analyte peak area to the internal standard peak area against the concentration of their respective 
standards. Calibration curves were accepted as linear if the weighted linear regression produced 
a correlation coefficient (r2) value of >0.950000. 
 
3.4.4 Extraction efficiency 
Serum samples containing low, medium and high endogenous concentrations of vitamin D 
metabolites were aliquoted and spiked with two different concentrations of 25(OH)D3/D2 and 
C3-epi-25(OH)D3 at 50 nmol/L and 150 nmol/L. Assay recovery was determined by calculating 
the percentage of the measured value against the sum of endogenous value plus spiking 
concentration. 
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3.4.5 Lower limit of quantification and detection 
Lower limit of quantification (LLoQ) was determined by the lowest concentration quantifiable 
with a precision CV of 15% over a minimum of 3 replicates with a minimum analyte peak area 
10x the response compared to a blank (signal:noise ratio of 10:1). The lower limit of detection 
(LLoD) was determined by the lowest concentration that produced a peak signal-to-noise ratio of 
10:1. 
 
3.5 Assay acceptance criteria 
 
3.5.1 LC-MS/MS measurement procedures and assay acceptance criteria 
Calibration standards and IQC materials were analysed with each batch of samples. The 
concentration of the QCs ranged from the lowest level (within 20% of the LLoQ) to the high 
end of the analytical limit (within 20% of the top calibration standard). The QCs provided the 
basis of accepting or rejecting the batch. The assay was accepted when QC  results fall within 
±2SD from the target value. An assay is rejected when a QC failed to fulfil one of the 
following Westgard83 rejection criteria. 
 13s Rejection rule: detection of random error. If one data point exceeds ±3SD the 
run is considered out of control. 
 22s Rejection rule: detection of systematic error. If two data points for the same 
level in a single run exceed ±2SD, the run is considered out of control. 
 R4s Rejection rule: detection of random error. If two data points in the same run are 
separated by 4SD the run is considered out of control. 
 10X Rejection rule: detection of systematic error. If 10 data points in or across runs 
were on the same side of the mean the run is considered out of control. This violation 
often indicates the deterioration of assay reagents and should trigger recalibration or 
equipment maintenance. 
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Chapter 4 The prevalence of C3-epimer 25-
hydroxyvitamin D in adult and paediatric samples 
4.1 Background 
C-3 epimer of 25 hydroxyvitamin D3 (C3-epi-25(OH)D3) is produced in the liver by the 
epimerisation pathway of 25-hydroxy vitamin D3. It differs from 25(OH)D3 in the configuration 
of the hydroxyl group at the third carbon (C-3) position (Fig. 4.1). Reddy et al. first described that 
vitamin D3 can alternatively be metabolised through a C-3 epimerisation pathway that parallels 
the standard metabolic pathway in neonatal human keratinocytes84. Both in vitro and in vivo 
studies have shown that intermediate metabolites of vitamin D3 can be epimerised and that these 
epimers can be further metabolised by the same enzyme responsible for hydroxylation and 
oxidation events as in the standard pathway, producing C3-epi-25(OH)D3 and subsequently C3-
epi-1α,25(OH)2D3 and C3-epi-24(R),25(OH)2D316,84-86. 
 
 
 
Figure 4.1 Structural configuration of C3-epi-25(OH)D3 differs from 25(OH)D3 in the 
hydroxy group at the third carbon (C-3) position. 
 
The biological relevance of C3-epi-25(OH)D remains to be elucidated. It has been documented 
that C3-epi-25(OH)D3 is present in children and adults18,87,88. Although higher concentrations 
have been observed in neonates, C3-epi-25(OH)D3 has been reported to be present in adults and 
children under 1 year of age at 3-5% of the respective 25(OH)D3 concentrations87. 
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Despite the lack of evidence on the clinical significance of C3-epi-25(OH)D, concerns have been 
raised that isobaric interference may result in over-estimation of total 25(OH)D when measured 
by liquid chromatography tandem mass spectrometry (LC-MS/MS). As both forms share the same 
m/z precursor to product ion transitions, standard triple quadrupole instruments are unable to 
distinguish the epimeric form by the m/z. The alternative is to perform chromatographic 
separation before MS detection. C3-epi-25(OH)D3 co-elutes with 25(OH)D3 on all C18 reverse 
phase analytical columns commonly used in routine clinical laboratories. If not 
chromatographically separated, C3-epi-25(OH)D3 present in serum can contribute significantly 
to the total 25(OH)D3 concentration. In the literature, studies on the prevalence of C3-epi-
25(OH)D3 in human infant and adult sera have used relative percentages22,89, others used absolute 
concentrations C3-epi-25(OH)D3 but often the analytical methods are poorly characterised. To 
achieve baseline separation of C3-epi-25(OH)D3 from 25(OH)D3, the use of chiral columns18,21, 
cyano-propyl (SB-CN)20,87,90 and pentafluorophenyl (PFP)71,88,91,92 columns have been used. 
Accurate quantitation of C3-epi-25(OH)D3 also requires reference-traceable calibration standards 
to be analysed on each run, ideally with the use of deuterated C3-epi-25(OH)D as internal 
standard. At the time of writing this report, a commercial source of NIST-aligned standards 
materials for C3-epi-25(OH)D3/D2 and isotopic labelled C3-epi-25(OH)D3-[6,19,19-2H3] 
standards (Fig 4.2) have recently become available. 
 
 
Figure 4.2 Molecular structure of C3-epi-25(OH)D3-[6,19,19-2H3]. MW = 415.63, 
molecular formula = C28H44O2. D indicates the location of the deuterium (2H) label. 
 
The aim of the study was to assess the occurrence of C3-epi-25(OH)D3 in adult and paediatric 
serum samples. The first objective was to develop and validate a LC-MS/MS method to resolve 
and quantify C3-epi-25(OH)D3 from 25(OH)D3 using the newly available NIST SRM972a 
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traceable C3-epi-25(OH)D3 commercial standards to calibrate the assay. The second objective 
was to analyse adult and paediatric serum samples to establish the prevalence of C3-epi-
25(OH)D3. The results were compared against non-epimer resolving method to assess the effect 
of C3-epi-25(OH)D3 on the interpretation of vitamin D status in the chosen populations. 
 
4.2 Materials and methods 
4.2.1 Serum sample collection 
Serum from 839 adults (age mean, range: 37 yrs, 25-57) and 179 paediatric samples (age mean, 
range: 8 yrs, 0-14) were selected at random from end of healthcare requests at the Department of 
Laboratory Medicine, Norwich and Norfolk University Hospital. Blood samples were collected 
in serum vacutainer tubes (Becton Dickinson, Oxford, UK) and centrifuged for 10 minutes at 
3,000x g to obtain the serum. The serum layer was aliquoted into a polystyrene tube and stored at 
-20C until analysis. All samples were anonymised at point of access and processed in accordance 
with generic ethical approval for assay development80.  
 
4.2.2 Materials, calibration standards and controls 
NIST SRM972a traceable C3-epi-25(OH)D commercial standards and quality control materials 
(Chromsystems, München, Germany). LCMS grade water, acetonitrile, methanol and formic acid 
were obtained from Fisher Scientific (Loughborough, UK). Zinc sulphate was purchased from 
Sigma-Adrich (Dorset, UK). Certified C3-epi-25(OH)D3 ethanolic standard and isotopic labelled 
[2H3]-C3-epi-25(OH)D3 (IsoSciences, King of Prussia, PA, USA). 
 
4.2.3 Sample preparation and LC-MS/MS procedures 
Serum was extracted by isotopic dilution protein precipitation procedure as described in Chapter 
3.3.2 Isotopic dilution protein precipitation. LC conditions for non-epimer resolving method 
using C18 column as described in Chapter 3.2.2. For epimer method, [2H3]-C3-epi-25(OH)D3 
(500 nmol/L) was added to the acetonitrile mixture that contains [2H6]-25(OH)D3 and [13C2]-
25(OH)D2. To resolve C3-epi-25(OH)D3/D2 from 25(OH)D3/D2, the extracted samples were 
chromatographed using a pentafluorophenyl (PFP) 2.6µm 100 x 2.1mm I.D. solid core particle 
column (Restek, PA, USA). A new gradient elution program was developed (Table 4.1); the 
mobile phase consisted of 25:75 (A) water and (B) methanol in 0.1% formic acid for the first 9 
minutes of run time, then increased to 100% B to cleanse and remove residue from the column. 
The flow rate was maintained at a constant rate of 0.4 mL/min. The total run time was 13 minutes.  
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Mass spectrometer conditions were performed in positive electrospray ionisation with MS/MS in 
multiple reaction monitoring mode as described in 3.2.3 Mass spectrometric conditions. The 
precursor to product ion transitions of 401>383 was used for detection and quantification. 
 
Steps 
Time 
(minute) 
Water with 0.1% 
formic acid (A) 
% 
Methanol with 
0.1% formic acid 
(B)% 
Flow rate 
(mL/min) 
1 Initial 25 75 0.4 
2 9.0 25 75 0.4 
3 9.1 0 100 0.4 
4 11.0 0 100 0.4 
5 11.1 30 70 0.4 
6 13.0 30 70 0.4 
 
Table 4.1 Gradient elution program for the C3-epi-25(OH)D3 assay 
 
4.2.4 Method validation and quality control procedures 
Assay validation criteria is described in Chapter 3.4 and 3.5. Four pools of human sera were 
collected to form the base pool for spiking experiments and to test for extraction efficiency. 
 
4.2.5 Statistical data analysis 
Data exploration, frequency distribution histograms, and statistical analyses were performed 
using Statistical Package for Social Science (SPSS) version 22.0.0.2 (IBM, NY, USA) and 
GraphPad Prism 8 (GraphPad, San Diego, CA, USA). Method comparisons were assessed using 
Passing-Bablok regression. A correlation is deemed satisfactory if the regression produced an r2 
0.9. 
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4.3 Results 
Full mass spectra from direct infusion of pure C3-epi-25(OH)D3 were recorded and compared 
against the spectra separately obtained from 25(OH)D3 (fig. 4.3). The two compounds produced 
identical precursor m/z 401 and water loss product ions m/z at 383 and 365. This confirms the 
MS is unable to distinguish between the two compounds. 
 
Figure 4.3 Mass spectrums of (a) 25(OH)D3 and (b) C3-epi-25(OH)D3 with identical 
precursor ion m/z of 401 and product ion m/z of 383 (x1 H2O loss) and 365 (x2 H2O loss). 
 
Chromatographic separation of 25(OH)D from C3-epi-25(OH)D was necessary to quantify these 
compounds. A serum sample spiked with internal standards was extracted and analysed using the 
new gradient elution programme on the pentafluorophenyl (PFP) column. The chromatographic 
peaks obtained were authenticated against the pure aqueous standards. The PFP analytical column 
produced clean, well-defined C3-epi-25(OH)D3 and C3-epi-25(OH)D2 peaks that were fully 
resolved from 25(OH)D3 and 25(OH)D2 at the baseline (Fig. 4.4).  
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Figure 4.4 Chromatogram depicts the separation of a sample containing C3-epi-
25(OH)D3/D2, 25(OH)D3/D2 and the respective isotopic internal standards recorded 
simultaneously in a single injection. 
 
30 
 
7.3.1 Method validation 
 
Ion suppression study 
An ion suppression study was performed by post column infusion of a pure methanolic C3-epi-
25(OH)D3 solution via a T-junction at a flow rate of 20 µL/min, during which samples of an 
extracted phosphate buffered saline (PBS) blank and a human serum were injected into the source 
via the LC system at 0.4 mL/min. Results showed a region of baseline suppression occurred 
during the first 3.2 minutes. Analyte peaks were eluted from 3.6 min onwards. Solvent divert was 
subsequently employed to set the period of ion suppression to waste. A 100% methanol column 
wash step was introduced at the end of gradient cycle to remove residual waste. 
 
 
 
Figure 4.5 Ion suppression study. Reduction in baseline signal was observed during co-
injections of extracted serum sample (a), phosphate buffered saline blank (b), with post-column 
infusion of 25(OH)D3 (c). Ion suppression occurred during 0-3.2 min, prior to the elution of [2H6]-
25(OH)D3 peak at 3.6 min. 
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Assay imprecision 
The imprecision of the LC-MS/MS assay is summarised in Table 4.3 and 4.4. Intra and inter-
assay imprecision were assessed by running QC materials 10 times within a single run and 
separately over a two month period. The intra-assay run imprecision (%CV) ranged from 5.6 to 
9.9%. The inter-assay imprecision (%CV) ranged from 6.8 to 12%. 
 
 Level 1 (nmol/L) Level 2 (nmol/L) 
 
C3-epi-
25(OH)
D3 
C3-epi-
25(OH)
D2 
25(OH)
D3 
25(OH)
D2 
C3-epi-
25(OH)
D3 
C3-epi-
25(OH)
D2 
25(OH)
D3 
25(O
H)D2 
Mean 42.4 45.3 32.5 43.9 64.8 61.9 101.8 88.1 
SD 3.0 2.5 3.0 3.1 6.4 4.9 5.7 5.7 
%CV 7.1 5.6 9.3 7.0 9.9 7.8 5.6 6.5 
 
Table 4.2 Intra-assay imprecision of the LC-MS/MS method (n=10). 
 
 Level 1 (nmol/L) Level 2 (nmol/L) 
 
C3-epi-
25(OH)
D3 
C3-epi-
25(OH)
D2 
25(OH)
D3 
25(OH)
D2 
C3-epi-
25(OH)
D3 
C3-epi-
25(OH)
D2 
25(OH)
D3 
25(OH
)D2 
Mean 43.6 35.4 34.5 37.0 62.5 60.8 107.6 94.6 
SD 3.0 3.0 3.2 4.4 5.9 6.6 10.2 11.3 
%CV 6.8 8.4 8.3 12.0 9.4 10.8 9.5 11.9 
 
Table 4.3 Inter-assay imprecision of the LC-MS/MS method (n=10). 
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Linearity 
Standard curves of C3-epi-25(OH)D3, C3-epi-25(OH)D2, 25(OH)D3 and 25(OH)D2 were 
generated by plotting the analyte peak area over the internal standard peak area ratio against the 
concentration of standards ranging from 0-200 nmol/L (Fig. 4.6). Linear regression analysis 
consistently gave r2 value of >0.998. 
 
 
Figure 4.6 Typical standard curves of C3-epi-25(OH)D3. (×) represents standards points 
and () represent quality controls. 
 
Extraction efficiency 
Extraction recovery was evaluated by determining the concentration of C3-epi-25(OH)D3 
recovered from the spiked prior to extraction. Mean recovery was 103.3% (range 97.0-107%) 
(Table 5). Results indicated that the extraction procedure was able to efficiently extract C3-epi-
25(OH)D3 from matrix. 
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 Endogenous C3-epi-
25(OH)D3 present 
(nmol/L) 
Amount spiked 
(nmol/L) 
Measured 
value (nmol/L) 
% Recovery 
Sample 1 15 50 67.0 103.1 
Sample 2 33.2 50 81.0 97.4 
Sample 3 19.2 100 112.0 94.0 
Sample 4 34.8 100 126.0 93.5 
 
Table 4.4 Spiked recovery of C3-epi-25(OH)D3. 
 
The lower limit of quantification (LLoQ) 
Aliquots of vitamin D depleted serum were spiked with C3-epi-25(OH)D3 at concentrations 
ranged between 0.1 to 10 nmol/L. Each standard was analysed five times to determine the 
reproducibility of the measured value. The lowest C3-epi-25(OH)D3 concentration that produced 
a peak signal-to-noise ratio of 10:1 with CV of 15% was 2.1 nmol/L. The upper limit of 
quantification (ULoQ) was defined by the highest standard of the calibration curve.  
 
Interference study 
To investigate possible interference from other vitamin D metabolites the LC-MS/MS method 
was subjected to cross-reactivity testing. An aliquot of vitamin D depleted serum was spiked with 
100 nmol/L of 25(OH)D3, 25(OH)D2, 1α,25 (OH)2D3, 1α,25 (OH)2 D2 and 24(R),25 (OH)2 D 
was analysed for C3-epi-25(OH)D3. No peak signal was detected at the m/z values corresponding 
with the precursor to product transitions for C3-epi-25(OH)D3 (401 > 383, 401 > 365) and C3-
epi-25(OH)D2 (413 > 270, 413 > 395). 25(OH)D3/D2 peaks were detected on the epimer 
transitions but not present at the retention time window of C3-epi-25(OH)D3 and C3-epi-
25(OH)D2. 
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4.3.2 Prevalence and concentration of C3-epi-25(OH)D in adult serum samples and the 
relative proportion to 25(OH)D 
Serum from 839 clinical samples for routine 25(OH)D measurement were analysed for C3-epi-
25(OH)D. Results showed 25(OH)D3 was present in all 839 sera [mean (±SD) 45.9 (25.5), ranged 
from 1.9 to 165 nmol/L and normally distributed (Fig.4.7). C3-epi-25(OH)D3 was present in 733 
(87.4%) of samples. The median (±SD) C3-epi-25(OH)D3 concentration was 1.9 (2.8) nmol/L 
(Fig. 4.8). The distribution of C3-epi-25(OH)D3 concentration was left-skewed; 98% of samples 
were observed with values <10 nmol/L. No C3-epi-25(OH)D2 was detected in any samples. The 
highest C3-epi-25(OH)D3 value observed was 45.6 nmol/L in a patient supplemented with 
vitamin D in whom no 25(OH)D2 was detected and the 25(OH)D3 was 141 nmol/L. 
The percentage proportion of C3-epi-25(OH)D3 to 25(OH)D3 was calculated in all the samples. 
The mean percentage of C3-epi-25(OH)D3/25(OH)D3 was 4.8%, range up to 37.8%. A 
concentration-dependent relationship (r2=0.3988, p<0.001) was observed between the two 
compounds. In general, higher concentrations of C3-epi-25(OH)D3 can be found in samples 
containing high concentration of 25(OH)D3, but varied greatly between individuals. (Fig. 4.9). 
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Figure 4.7 Distribution of 25(OH)D3 concentration in the adult cohort. 
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Figure 4.8 Distribution of C3-epi-25(OH)D3 concentration in the adult cohort. 
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Figure 4.9 Relationship between serum concentrations of C3-epi-25(OH)D3 and 25(OH)D3  
in the adult cohort. Linear regression showed goodness of fit r2 of 0.3998, p<0.001. 
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4.3.3 Prevalence and concentration of C3-epi-25(OH)D in paediatric serum  
Analysis of 179 paediatric samples (age mean, range: 8 yrs, 0-14) showed C3-epi-25(OH)D3 was 
present in 157 out of 179 (87.7%) of samples. The 25(OH)D3 concentration was normally 
distributed, with a mean (range) of 74.5 (7.9-314.4) nmol/L (Fig. 4.10). The C3-epi-25(OH)D3 
distribution was left-skewed similar to the adults, with a higher median concentration (range) of 
7.7 (1.0-50.8) nmol/L than adults. 47.2% of samples had C3-epi-25(OH)D3 >10 nmol/L. No C3-
epi-25(OH)D2 was detected in samples.  
The mean percentage of C3-epi-25(OH)D3/25(OH)D3 was 12%, range up to 54.4%. A 
concentration-dependent relationship (r2=0.4497, p<0.001) was observed between the two 
metabolites. A substantial inter-dividual variability existed across the concentration range (Fig. 
4.12) . 
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Figure 4.10 Distribution of 25(OH)D3 concentration in the paediatric cohort. 
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Figure 4.11 Distribution of C3-epi-25(OH)D3 concentration in the paediatric cohort. 
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Figure 4.12 Relationship between serum concentrations of C3-epi-25(OH)D3 and 25(OH)D3  
in the paediatric cohort. Linear regression showed a goodness of fit r2 of 0.4497, p<0.001. 
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4.3.4 Changes to the interpretation of vitamin D status with resolving C3-epi-25(OH)D 
All adult and paediatric samples were retested by LC-MS/MS using a C18 column, which does 
not resolve the epimer forms of 25(OH)D. The 25(OH)D values obtained by the non-epimer 
resolving method and the epimer resolving method (excluded C3-epi-25(OH)D) were grouped 
according to the Institute of Medicine (IOM) vitamin D thresholds93, which defined the vitamin 
D status of an individual with serum 25(OH)D <30 nmol/L as deficient; between 30-50 nmol/L 
as insufficient; and >50 nmol/L as sufficient. Based on these definitions, in the adult cohort of 
733 out of 837 samples with detectable C3-epi-25(OH)D, resolving the epimer had reduced the 
percentage of the cohort identified with vitamin D sufficient status by 4.4%, and increased those 
interpreted as deficient and insufficient by 1.8% and 2.6% respectively. In the paediatric cohort 
of 157 out of 179 samples (undetectable C3-epi-25(OH)D were excluded), resolving the epimer 
had decreased the percentage of the cohort classified as vitamin D sufficient status by 10.4%, and 
increased those categorised as deficient and insufficient by 10% and 0.4% respectively (Table 
4.4). 
 
Table 4.4 Interpretation of vitamin D status in the adult (n=733) and paediatric (n=157) 
samples according to the U.S. Institute of Medicine guidelines. The number of cases classified as 
vitamin D deficient, insufficient and sufficient based on their respective serum 25(OH)D3 
concentration. Resolving C3-epi-25(OH)D from 25(OH)D resulted in a reduction of the number 
of cases identified as vitamin D sufficient and increased the number of insufficient and deficient 
cases. 
  
Vitamin D 
status 
definitions 
Adults Children 
Non-epimer 
resolved 
(no. of cases, % in 
cohort) 
Epimer 
resolved (n, 
%) 
Non-epimer 
resolved 
(no. of cases, % in 
cohort) 
Epimer 
resolved (n, 
%) 
<30 nmol/L, 
Deficiency 
181 (24.7%) 194 (1.8%) 6 (3.8%) 23 (10.0%) 
30-50 nmol/L, 
Insufficiency 
245 (33.4%) 265 (2.6%) 36 (22.9%) 39 (0.4%) 
>50 nmol/L, 
sufficiency 
307 (41.9%) 275 (4.4%) 115 (73.2%) 105 (10.4%) 
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4.4 Discussion and conclusion 
This chapter describes the development and validation of a LC-MS/MS method that utilised 
gradient chromatography by PFP bonded phase column to separate and quantify C3-epi-
25(OH)D3/D2 and 25(OH)D3/D2 in human serum. Positive electrospray ionisation (ESI) coupled 
with tandem quadrupole MS/MS mass analyser provided sensitive detection of low concentration 
of C3-epimer present in serum, whereas the PFP column provided the selectivity to distinguish 
the structural difference of the epimeric form of 25(OH)D. 
The fluorinated stationary phase in the PFP column interacts with the compounds based on 
multiple retention mechanisms, including hydrophobic interactions, -, dipole-dipole, H-
bonding and shape selectivity, hence able to distinguish the epimeric form of 25(OH)D which 
proved problematic on C18 columns. The non-porous, solid core particles were capable of rapid 
column equilibration, thus enabling fast recovery of column back pressure. As a result, the total 
injection-to-injection run time of 13 minutes was achieved. 
The assay satisfied the acceptance criteria for precision, linearity, extraction recovery and lower 
limit of quantification, as described by guidelines commonly adopted by the industry as standards 
of performance. Using SRM 972 traceable calibration standards ensures all significant 
components that may give rise to analytical measurement uncertainty are minimised; thus the 
components of uncertainty that do not contribute significantly to the bias of the test result can be 
neglected. The use of [2H3]-C3-epi-25(OH)D3 as internal standard further enhanced assay 
recovery and accuracy of the results produced. 
Although the concentration of serum C3-epi-25(OH)D3 in both adult and paediatric samples were 
found to be low, it was present in the majority (87.4% and 87.7%) of the samples tested. The 
biological activity of C3-epi-25(OH)D3 remains unclear; Brown et al. had found C3-epi-
25(OH)D3 can be converted to C3-epi-1,25(OH)2D3 with similar potency as 1,25(OH)2D3 in 
suppressing PTH section, but with lower calcaemic properties17,94. Many studies have reported a 
higher concentration of C3-epi-25(OH)D3 in infants and adolescent populations than in adults89,95-
98. Findings from the paediatric samples collected in this study from patients in the Norfolk region 
echoed those reported in the publications; the median C3-epi-25(OH)D concentration was found 
to be 4-fold higher in the paediatric cohort than the adults, at a rate that is 2x higher than the 
difference observed in 25(OH)D. The relationship between C3-epi-25(OH)D and 25(OH)D 
exhibited in a concentration-dependent manner, in which greater concentration of C3-epi-
25(OH)D3 were often found in higher concentrations of 25(OH)D3. However, the relationship 
between the two metabolites do not correlate in a linear fashion, and high inter-individual 
variability existed. A common observation made from the clinical information obtained on the 
adult samples with a concentration of C3-epi-25(OH)D3 >25 nmol/L revealed all the patients 
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were receiving vitamin D supplementation, though the exact dosage and frequency of intake were 
unclear. Upon review of publications found case reports of substantial serum levels of C3-epi-
25(OH)D3 and C3-epi25(OH)D2 were found in patients taking high doses of over-the-counter 
cholecalciferol26 and ergocalciferol27. A probable explanation is that some patients may have 
higher epimerase activity than found in most individuals, thus produce considerably more 
epimeric forms of 25(OH)D from vitamin D supplementation. The high inter-individual 
variability observed are likely to be influenced by the regulating genes and the level of enzyme 
expression/activity. 
The clinical utility of C3-epi-25(OH)D3 remains to be clarified. However, given C3-epi-
25(OH)D3 possesses a degree of biological activity, it would be beneficial to the interpreting 
clinicians to know the serum concentration of C3-epi-25(OH)D3 in their patients; either as a 
standalone measurement or inclusion into the 25(OH)D result as “total”. The concerning issue is 
over the standardisation of 25(OH)D3 measurements across all clinical laboratories. 
Immunoassays are unable to determine the epimer forms of 25(OH)D, whereas chromatography 
methods (HPLC and LC-MS/MS) are able to distinguish or combine C3-epi-25(OH)D with 
25(OH)D. The difference in the method’s capability to detect C3-epi-25(OH)D will affect method 
harmonisation and therefore must be addressed as part of the ongoing effort to standardise 
measurements across all assay types. 
The final objective of this study was to determine how resolving the epimer might change the 
interpretation of vitamin D status. In the adult samples, a small percentage of patients (4.4%) 
classified as vitamin D sufficient were re-classed as insufficient (2.6%) and deficient (1.8%) when 
C3-epi-25(OH)D3 is separated. A higher percentage was observed in the paediatric samples;  
10.4% of patients were recategorised into a class below. More concerning is the increase in the 
number of cases identified as vitamin D deficient. The finding showed C3-epi-25(OH)D3 had 
resulted in an overestimation of patient’s vitamin D status, particularly in the infant and paediatric 
population where the changes were considerably greater. It would be advisable for laboratories 
that provide routine vitamin D testing service to the paediatric population to quantify C3-epi-
25(OH)D3 using the method as described in this study. 
A major strength of the study is the large sample size used in the adult and paediatric cohorts. It 
allows observations to be made with confidence and subtle changes to be identified. Also, the use 
of LC-MS/MS, which has emerged as the ‘gold-standard’ methodology for 25(OH)D 
measurement, together with the use of reference-traceable standard materials and isotopic-
labelled internal standards ensures the commutability of the result findings from this study to the 
broader scientific community. The limitations are that the two groups of samples were chosen 
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based on the age of the patients as the only inclusion criteria; influencing factors such as ethnicity, 
pregnancy, pathology and use of mediation/supplementation were not controlled. 
In conclusion, this chapter described a method for the sensitive detection and quantification of 
C3-epi-25(OH)D3 in human sera. The epimer form of 25(OH)D3 was found to be present in the 
majority of patient samples tested, and higher concentration was observed in the paediatric 
samples than in the adults. A concentration-dependent relationship exists between C3-epi-
25(OH)D3 and 25(OH)D3, though with substantial variability between individuals. The study has 
highlighted the potential for non-epimer resolving methods to overestimate the vitamin D status 
of an individual, particularly in the paediatric population. Current clinical evidence does not 
provide sufficient support for routine C3-epi-25(OH)D3 measurement as part of the vitamin D 
status assessment. The described LC-MS/MS method would facilitate future studies into the 
physiological importance of the epimeric forms of 25(OH)D. 
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Chapter 5 Improved LC-MS/MS method for 
measurement of serum 25(OH)D using phospholipids 
depletion and derivatisation techniques 
 
5.1 Background 
In recent years, the field of Clinical mass spectrometry has been making fast progress, Liquid 
chromatography tandem mass spectrometry (LC-MS/MS) has now become the preferred method 
for routine hospital and pharmaceutical industry for analysis of biological fluids. Analysis of 
endogenous biological compounds poses many challenges; the complex nature of sample matrix, 
low analyte concentration, potential interference from other similar endogenous and exogenous 
components within the sample matrix, all of which require a high level of theoretical knowledge 
and practical skills and application in liquid chromatography and mass spectrometry techniques 
to tackle these issues. Instrument manufacturers offer powerful and ultra-sensitive LC-MS/MS 
equipment but at high prices that are often out of reach for most hospital and academic research 
laboratories. Alternative strategies to gain analytical sensitivity can be through reducing 
interference from sample matrix (i.e. background noise) and enhancing compound signal strength, 
resulting in a net increase in signal-to-noise ratio.  
Phospholipids are highly abundant in biological membranes; their strong presence in the 
biological matrix can be a significant source of analytical errors99. Phospholipids are a major 
component of all cell membranes forming the lipid bilayers (Fig.5.1). It is composed of ester or 
amide derivatives of glycerol (phosphoglycerides) or sphingosine (sphingomyelins) with fatty 
acids and phosphoric acid. The structure constitutes a hydrophilic phosphate head and one or two 
hydrophobic fatty acid ester tails. The choline-esterified form called phosphatidylcholine, 
commonly referred to as lecithin was one of the first phospholipid identified in biological tissue, 
and considered the dominant form of phospholipids in plasma that cause significant matrix 
ionisation effects during LC-MS/MS analysis100. Lysophospholipid is referred to any 
phospholipids with one fatty acid chain; whereas sphingomyelin is composed of an amide-linked 
fatty acid, and a phosphatidylcholine (Fig. 5.2).  
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Sources: http://biology4alevel.blogspot.ro/2014/08/10-lipids.html 
https://biologydictionary.net/semipermeable-membrane/ 
 
Figure 5.1 Schematic illustration of a phospholipid. 
 
 
 
Figure 5.2a-b Structure of (a) Lysophosphtidic acid and (b) Sphinogsine-1-phosphate. 
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Endogenous phospholipids in biological fluids present a major problem in LC-MS/MS analysis. 
Due to their strong retention characteristics in reverse phase chromatography, phospholipids tend 
not to elute as discrete peaks and are often very difficult to separate from analytes of interest. This 
co-elution often leads to areas of suppression or enhancement in the chromatogram, that in turn 
can cause analytical errors. The Guidance for Industry on Bioanalytical Method Validation 
published by the U.S. Food and Drug Adminstration81 states that “Matrix effects on ion 
suppression or enhancement or on extraction efficiency in LC-MS and LC-MS/MS based 
procedures should be addressed.” However, the specific methods to evaluate matrix effects are 
left to the discretion of the investigator. In this regard, many researchers have described methods 
to study and control matrix effects100-105. Numerous approaches have been presented in the 
literature mostly involving the use of solid phase extraction (SPE), such sample clean-up 
techniques provide effective removal of phospholipids and other interfering compounds, but the 
procedures are often time-consuming and involve the use of expensive extraction columns and 
solvents. Recently, new sample phospholipids depletion tools in a 96-well plate format have 
become commercially available, offering fast and effective matrix clean up at a fraction of the 
cost of SPE. The first objective of this study was to investigate ways to detect and monitor 
phospholipids in serum samples and to develop sample clean-up procedures using plate-based 
phospholipid depletion tools for LC-MS/MS analysis of 25(OH)D3.  
The second objective was to study the use of chemical derivatisation technique to enhance the 
ionisation strength of 25(OH)D3. The sensitivity or detectability of a compound depends upon 
the number of ionisable groups available in the analyte. The hydrophobic nature of 25(OH)D with 
two hydroxyl groups (Chapter 1 fig. 1.0) meant ion generation in the harsh LC-MS/MS 
environment is often suboptimal and result in loss of water (Chapter 4 figure 4.3). Shimizu et al. 
first reported a chemical derivatisation method for 25(OH)D using a Cookson-type dienophilic 
agent. It reacts to the s-cis-diene moiety of vitamin D via the Diels-Alder reaction; forming a 
conjugated diene derivative for detection by HPLC with a fluorometric detector45. Derivatisation 
enhances the MS detection by increasing the molecular weight of the analyte, moving it away 
from the low molecular weight compounds, and increases the number of reactive functional 
groups available for ionisation and fragmentation. 
This chapter presents the development of methods for eliminating phospholipids and sample 
derivatisation for measurement of 25(OH)D3. The newly developed method was evaluated for 
the improvement shown in the quality of the results produced.  
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5.2 Materials and methods 
5.2.1 Serum samples 
All fresh and stored serum samples used for method development, comparison and storage studies 
were obtained from clinical research studies with ethical approvals. All samples were anonymised 
at the point of access and processed in accordance with generic ethical approval for assay 
development80. Method comparison was conducted using serum samples previously analysed for 
25(OH)D3 and 25(OH)D2 by isotopic dilution protein precipitation LC-MS/MS method 
(described in Chapter 3.32) and then retested by the new methods. Aliquots of serum sample were 
stored at -20°C unless obtained fresh. Before each batch of analysis, samples were defrosted at 
room temperature, mixed and centrifuged at 2000 x g for 10 minutes. 
 
5.2.2 Materials and preparation of calibration standards, controls and samples. 
Preparation procedures are detailed in Chapter 3. In brief, isotopic dilution protein precipitation 
method was performed using zinc sulphate and acetonitrile (Chapter 3.3.2). Depletion of 
phospholipids was performed using Phree™ (Phenomenex, Torrance, USA) in 96-well format 
(Chapter 3.3.3) and Isolute® SLE+ Supported Liquid Extraction plate (Biotage, Uppsala, Sweden) 
with bed mass of 400 µL (Chapter 3.3.4). 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) and 
methylamine were used for derivatisation and adduct formation (Sigma-Aldrich, Dorset, UK). 
Preparation of 25(OH)D3 calibration standards, quality control materials, and isotopic-labelled 
internal standards are as described in Chapter 3.1.2-5. 
 
5.2.3 Detecting phospholipids in samples 
Phospholipids transitions were acquired in positive electrospray ions (ESI+) multiple reaction 
monitoring (MRM) mode using common product ion trimethylammonium-ethyl phosphate (m/z 
184). The 18 most abundant phospholipid precursor ions (Table 5.1) were identified from the 
literature and chosen in this study. 
Sample clean-up procedures developed using Phree phospholipid depletion plate and SLE are 
described in Chapter 3.3.3 and 3.3.4. Sample extraction was carried out on a PRESSURE +96® 
positive pressure manifold (Biotage, Uppsala, Sweden) with nitrogen gas supplied from a nitrogen 
generator (Peak, Scotland, UK) at a flow rate of 30 L/min. Sample evaporation was carried out 
on a microplate evaporator (Evaporex, Apricot designs, Ca, USA) distributing heated nitrogen 
gas at 50˚C via a stainless steel needle assembly into the deep well plate. 
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m/z transitions 
Lysophospholipids Phospholipids 
494.4 > 184 
496.4 > 184 
520.4 > 184 
522.4 > 184 
524.4 > 184 
184 > 184 
701.7 > 184 
703.7 > 184 
732.8 > 184 
756.5 > 184 
758.5 > 184 
786.6 > 184 
760.5 > 184 
784.6 > 184 
786.6 > 184 
806.6 > 184 
808.7 > 184 
810.9 > 184 
 
Table 5.1 Phospholipids m/z transitions. 
 
5.2.4 Sample derivatisation with PTAD 
 PTAD was prepared by placing 1g of 4-phenyl-1,2,4-triazoline-3,5-dione into 500 mL of 
acetonitrile. Derivatisation took place by adding 50 L of PTAD in acetonitrile solution into dried 
down samples. The plate was vortexed and allowed to incubate for 30 minutes at room 
temperature in the dark. 50 L of LC-MS grade water was added and mixed to stop the reaction. 
 
 
Figure 5.3 The dienophilic reaction of 25(OH)D3 with PTAD and formation of 
methylamine adduct. 
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5.2.5 Liquid chromatography Tandem mass spectrometry 
Analytical equipment and instrumentation conditions for non-derivatised methods were 
unchanged from the details described in Chapter 3.2. For PTAD derivatised method, liquid 
chromatography was performed on reverse phase chromatography using a UHPLC binary pump 
(Flux Instruments, Switzerland) which delivered the mobile phases at a flow rate of 0.4 mL/min 
through a core-shell C18 50 × 2.1mm, 2.6 µm column (Restek, PA, USA) that was heated to 
+55°C. Chromatographic separation was performed using a solvent gradient which began at 50:50 
(v:v) of water containing 0.2 mM methylamine in 0.1% formic acid (A) and methanol containing 
0.2 mM methylamine in 0.1% formic acid (B). Mobile phase B was steadily increased to 99% 
over 2 minutes 10 seconds then returned to the original conditions after three minutes. Under 
these conditions, the 25(OH)D3 peak was eluted at 1.75 minutes. Micromass Quattro Ultima 
Pt tandem mass spectrometer (Waters Corp., Milford, MA, USA) operating in multiple reaction 
monitoring was used to analyse the samples with precursor to product transitions, 607>298 for 
25(OH)D3 and 613>298 for 25(OH)D3-[2H6] (Fig. 5.3) (Table 5.2). MassLynx version 4.1 and 
QuanLynx were used for data acquisition and peak integration. 
 
Parameters Setting 
Ion source Electrospray positive 
Capillary voltage 3.0 kV 
Cone energy 35 kV 
Collision energy 20kV 
Nebuliser gas flow rate 30 L/hr 
Desolvation gas flow rate 850 L/hr 
Source temperature 85°C 
Desolvation gas temperature 250°C 
 
Table 5.2 Mass spectrometer settings. 
5.2.6 Statistical analysis 
Data exploration, bar charts and box-whisker plots were performed using GraphPad Prism 8 
(GraphPad, San Diego, CA, USA). Passing-Bablok regression generated linear equations were 
used to derive the PEVs from raw DBS and VAMS values. Method comparisons were assessed 
using Passing-Bablok regression and residuals in Bland-Altman plots. A correlation is deemed 
satisfactory if the regression produced an r2 0.9.  
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5.3 Results 
5.3.1 Phospholipids in human sera 
An aliquot of human sera was extracted by isotopic dilution protein precipitation procedure, 
phospholipids and lysophospholipids were eluted using LC gradient conditions and MS/MS 
parameters optimised for 25(OH)D3/D2. Solvent divert valve was disabled to allow acquisition 
of the entire LC separation and all 18 phospholipid transitions to be recorded. Results showed 
phospholipids were present throughout the trace (Fig. 5.4), gradient elution from 88% 
methanol:water increased to 100% on a reverse phase C18 analytical column failed to resolve 
phospholipids into a distinct peak; no clear phospholipid-free region can be identified. The 
majority of lysophopholipids were eluted in the first 2 minutes of the gradient, followed by 
phospholipids. The late retention of phospholipids is due to the hydrophobicity of the two fatty 
acid chains present. 
 
Figure 5.4 Elution profile of phospholipids and Lysophospholipids in LC-MS/MS analysis 
of a protein-precipitated human serum. 
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To monitor 18 phospholipids ion transitions in every MRM experiment is not practical. To acquire 
such a large number of transitions would also decrease instrument sensitivity. For that reason, the 
most abundant phospholipid transition m/z 522 > 184 that co-eluted with 25(OH)D3 and 
25(OH)D2 was chosen to be the monitoring transition in all future sample analysis. This approach 
allowed phospholipids to be monitored by just one transition in an MRM experiment without 
affecting sensitivity. An example of a human serum sample extracted by isotopic dilution protein 
precipitation and then analysed by LC-MS/MS is shown (Fig.5.5).  
 
 
Figure 5.5 Chromatographic trace showing elution of lysophospholipids transition m/z 
522.4 > 184 during the separation of 25(OH)D3 and 25(OH)D2. 
 
5.3.2 Phospholipids in long term storage samples 
Fresh serum samples and samples stored for up to 72 months at -20˚C (n = 140) were analysed 
retrospectively using isotopic dilution protein precipitation method with lysophospholipids 
monitored using m/z transition 522 > 184 (Fig 5.6). The month 72 samples were re-tested using 
SLE+ extraction plates. 
Results showed an upward trend in phospholipids peak area count with the increasing length of 
sample storage. A near tenfold increase was observed in serum samples stored for 6, 12 and 18 
months compared with fresh samples; whereas an average 90-fold increase was observed in 24 
samples and ten thousand-fold increase in phospholipids were observed in 48 and 72 months 
samples. Re-analysis of the month 72 samples using SLE+ extraction plates showed a reduction 
of the phospholipids peak area count similar to those observed in fresh samples. 
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Figure 5.6 Bar chart showing the median and 95% CI of lysophospholipids present in serum 
samples stored up to 72 months. Month 0 to 72 samples were analysed using isotopic dilution 
protein precipitation method with lysophospholipids transitions monitored at 522>184. Month 72 
samples were re-tested using phospholipid depletion method (SLE), a reduction of 
lysophospholipids was observed. 
 
5.3.3 Phospholipids depletion method and the effects on analyte recovery 
The first phospholipids depletion procedure was developed using Phree extraction plates 
incorporating the isotopic dilution protein precipitation method. During initial experiments, in-
plate precipitation was trialled where human sera, zinc sulphate and acetonitrile internal standard 
mixture were placed directly into the 96-wells (Fig 5.7a). The mixture in the plate was vortexed 
vigorously for 10 minutes before eluted off by positive pressure using nitrogen gas. The procedure 
was simple to perform and produced clean extracts. LC-MS/MS analysis showed complete 
elimination of Lysophospholipids. However, the procedure failed to achieve adequate recovery 
for 25(OH)D3; peak shapes were poor and baseline noise was high. Repeat experiment found the 
viscosity of serum to be a key factor affecting sample flow through. Therefore, a sample dilution 
step with 60% (v/v) of acetonitrile/internal standard mixture in water solution was introduced to 
increase the solubility of the loading mixture. A neat acetonitrile wash step was also added to 
improve analyte recovery before injection into LC-MS/MS (Fig 5.7b). 
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Figure 5.7a-b Schematic presentation of the initial and modified procedures using the Phree 
phospholipid depletion plate. 
 
Figure 5.8 and 5.9 demonstrate the impact of phospholipid depletion and improvement observed 
in the analyte peak signal. Using the Phree plate, lysophospholipid was eliminated and a tenfold 
increase in 25(OH)D3 peak area count compared with isotopic dilution protein precipitation 
method was observed. A reduction in background noise was found in the Phree-extracted samples. 
In the long-term, removing phospholipids from samples will reduce contamination on the LC 
52 
 
column and MS source, allowing for longer intervals between instrument maintenance and reduce 
the risk of system downtime. 
 
Figure 5.8 Lysophospholipid trace monitored at m/z 522>184 was observed from a sample 
prepared by isotopic dilution protein precipitation method. It is eliminated by the Phree method. 
 
 
Figure 5.9 An overlap of two 25(OH)D3 peaks produced by Phree and protein precipitation 
procedure. 
 
 
53 
 
5.3.4 Measurement of 25(OH)D3 using SLE and comparison with isotopic dilution 
protein precipitation method.  
A second phospholipids depletion procedure was developed using SLE+ extraction plates. SLE 
was able to eliminate phospholipids and improve analyte peak signal as shown using the Phree 
plate. It was easier to perform as SLE and do not require a sample wash step and in-plate 
precipitation. SLE was therefore chosen to be the method for validation. Standard curves for 
25(OH)D3 were analysed using Chromsystems calibration standards. Over the 13 test batch 
performed, the calibration curves were linear with regression r2 value of >0.998. Intra-assay 
imprecision on repeat measurement of IQC (n = 6) showed %CV of <6% across the concentration 
range. Inter-assay imprecision determined by analysis of 13 runs of the tri-level IQC showed 
%CV (mean concentration, ±SD) for 25(OH)D3 were 7.3% (45 nmol/L, ±3.3) and 9.0% (100.3 
nmol/L, ±9.0), respectively. The method participated in the DEQAS scheme between 2014-2015, 
results produced by this method were within ±15% of target value (Fig. 5.10) and met the 
performance target set by the DEQAS advisory panel for proficiency certification. 
Method comparison was carried out using 135 fresh serum samples previously analysed for 
25(OH)D3 by isotopic dilution protein precipitation method. The comparison between the SLE 
and isotopic dilution protein precipitation methods showed good correlation with the line of best 
fit generated a slope of 1.0151 and r2 value of 0.9785 (Fig. 11a) Bland-Altman plot demonstrated 
a small negative bias of -0.1% produced by the SLE method (Fig. 11b). 
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Figure 5.10 Comparison of DEQAS returns with the LC-MS method group mean. 
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Figure 5.11a Comparison of 25(OH)D3 concentrations on fresh samples (n =135) measured 
using SLE and isotopic dilution protein precipitation methods. Linear regression is represented 
by the solid red line, the dashed grey line represents the line of identity (y = x). 
 
 
Figure 5.11b Bland-Altman plot showing the percentage bias between the two methods. The 
dashed red line represents the average bias of -0.1%. The dashed lines represent zero bias and 
±2SD limits of agreement. 
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A parallel comparison was performed on 158 serum samples stored at -20°C for 5 years (Fig 
5.12). Samples were analysed by SLE and isotopic dilution protein precipitation methods, results 
were compared against the original values obtained when the sample was fresh. Protein 
precipitation method showed 32% positive bias against the original values (p <0.001) (Fig 5.13a).; 
whereas SLE method did not show a significant difference (Fig 5.13b). It was concluded that the 
bias was caused by the high level of phospholipids present after prolonged storage. 
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Figure 5.12 Box-whisker plot comparing the difference in the distributions of 25(OH)D3 
values originally obtained fresh and re-analysed by phospholipids depletion (SLE) and non-
phospholipids depletion (protein precipitation) methods after five years of storage. Box represent 
median and interquartile; whiskers represent the minimum and maximum range. 
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Figure 5.13a-b Bland-Altman plots showing the difference in 25(OH)D3 concentrations between 
(a) protein precipitation, (b) SLE methods with the values obtained in the original analysis. The 
dashed line represents the average bias. 
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5.3.5 Combining SLE with PTAD derivatisation 
 The SLE method (Fig. 5.14a) was further modified to incorporate a PTAD derivatisation 
step (Fig. 5.14b). LC-MS/MS analysis of a serum sample showed the SLE with PTAD 
derivatisation produced a 25(OH)D3 peak area in the x106 region; increase in an order of 
magnitude compared with SLE without derivatisation. The preparation and extraction procedure 
were programmed into the Extrahera™ automation system (Biotage, Uppsala, Sweden) to enable 
high-throughput processing. Method validation results are described in Chapter 6 and 7. 
 
 
 
Figure 5.14a-b  Schematics of the sample preparation procedure for (a) the first SLE 
method developed and (b) modified with PTAD derivatisation steps added. 
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5.4 Discussion and conclusion 
Phospholipids are a major source of analytical interference in LC-MS/MS methods. Isotopic 
dilution protein precipitation may be a quick and easy sample preparation technique to perform, 
but it is not effective in removing phospholipids from human serum matrix. The results have 
shown that the high abundance of phospholipids accumulated with prolonged storage can have a 
profound effect on 25(OH)D measurements. In this study, two sample phospholipids clean-up 
procedures for the application of 25(OH)D3 quantification were successfully developed. Both 
SLE and Phree methods were found to be robust for routine use and can be automated with the 
use of a semi-automated plate processor to increase analytical precision and throughput. The SLE 
method had few steps than Phree and therefore chosen as the base method of further modification. 
Due to the lipophilic nature of 25(OH)D, it is not possible to separate lipids in a reversed phase 
chromatography system. Reduction of phospholipid content was necessary in order to reach the 
low circulating concentration of vitamin D metabolites. SLE is a new sample preparation tool that 
is similar to traditional liquid-liquid extraction (LLE). Each well is packed with a modified form 
of diatomaceous earth. Serum samples were pre-treated with 1:2 sample/aqueous mixture of 
propan-1-ol and water 50% (v/v). Propan-1-ol disrupts and releases 25(OH)D from binding 
protein; whereas water increases the solubility of the serum, allowing the diatomaceous earth 
layer to retain the aqueous portion, leaving serum behind in a simple partition. A number of 
organic solvents were investigated in the elution step including acetonitrile, methyl tert-butyl 
ether and dichloromethane. n-heptane was found to give cleaner extract and higher recovery and 
was therefore selected as an optimum solvent for elution. A combination of single, double and 
triple washing steps was also investigated; double washing with 750µL of n-heptane was found 
to be sufficient to elute 25(OH)D from the plate. Analysis of the third eluent collection confirmed 
the absence of residual analyte. 
Derivatisation with PTAD greatly enhanced the sensitivity of the assay. Vitamin D metabolites 
have low ionisation efficiency and readily dissociate into water loss product ions at low collision 
energy. The advantage of the PTAD derivatisation is that it adds proton-affinitive oxygen and 
nitrogen molecules (Fig. 5.3) to the structure of vitamin D, increasing the ionisation potential. 
Derivatisation shifts the compound to a higher mass range, where background interference from 
low molecular weight species is relatively low. The combination of SLE with PTAD 
derivatisation had substantially improved assay sensitivity. It is possible to detect  25(OH)D in 
samples with sub-10 nmol/L concentrations that were previously undetectable with isotopic 
dilution protein precipitation method, suggesting better analyte recovery. Also notable was the 
increase in the presence of 25(OH)D2 in samples. 25(OH)D2 is thought to have quicker clearance 
than 25(OH)D3106,107 and lower tissue bioavailability108; hence serum concentrations of the plant-
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derived vitamin D is much lower than 25(OH)D3. Serum concentration 25(OH)D2 in non-
supplemented individuals are often close to the lower limit of the analytical range that it is 
undetectable in the majority of clinical specimens. Improvement in assay detection and 
quantification of 25(OH)D3 and 25(OH)2 achieved by using the newly developed phospholipid 
depletion methods will provide better quality results for the assessment of vitamin D status. 
Individuals with total 25(OH)D <30 nmol/L and <50 nmol/L as defined by the Institute of 
Medicine (IOM)11 as the thresholds for vitamin D deficiency and insufficiency may be 
reinterpreted as such the consequence may impact on the clinical management of patient 
treatment. 
In conclusion, this chapter describes a series of method developments on sample preparation to 
enhance LC-MS/MS detection of 25(OH)D3. Sample clean-up using supported liquid extraction 
(SLE) is highly effective for the removal of proteins and phospholipids. Derivation with a 
Cookson-type dienophilic agent increased the ionisation efficiency and greatly enhanced the peak 
signal. 
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Chapter 6 Development and validation of an LC-
MS/MS method for 25-hydroxyvitamin D3 in dried 
blood samples using a volumetric microsampling device 
 
6.1 Background 
The high prevalence and the increasing awareness of vitamin D deficiency as a public health 
concern have led to an increase in demand for measurement of 25-hydroxyvitamin D 
(25(OH)D)109. Many laboratories offer services directly to the general public for the assessment 
of vitamin D status110,111. The use of finger prick dried blood spot (DBS) microsampling 
techniques for general wellness assessment and in clinical diagnostics has gained popularity as an 
alternative to venous sampling. 
DBS microsampling techniques are commonly used in epidemiological studies and clinical/pre-
clinical pharmacokinetic studies112. In hospital laboratories, DBS analysis is routinely performed 
for screening programmes such as neonatal inborn errors of metabolism113. DBS sampling is a 
convenient and less invasive blood sampling method than venepuncture; whilst the low sample 
volume requirement (typically 10-50 L) is ideally suited for use in paediatric practice and elderly 
population114. A phlebotomist or nurse would not be required to perform venepuncture for patients 
who are able to self-sample; reducing time and the inconvenience of attending hospital 
appointments. The reduced storage and shipping requirements allow patients to send their samples 
via the post, which could streamline the process of transporting samples to the laboratory and 
improve efficiency. Also, dried blood samples carry a lower risk of infection from pathogens than 
a wet sample as some viruses are deactivated on the filter paper due to disruption of the viral 
envelope115. 
There are limitations that have prevented the widespread use of DBS sampling techniques; 
difficulty in controlling the amount of blood applied onto the filter paper and the level of 
haematocrit (Hct) present can affect the spot size. The viscosity of the blood sample can influence 
the dispersion on the filter paper;  low Hct samples can disperse more easily on the filter paper 
than those with high Hct, creating a larger spot size116. Variability in analyte concentrations 
between central and peripheral punches has been reported117, which could reduce the accuracy of 
measurements when sub-punches are taken118. 
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This chapter describes a liquid-chromatography mass spectrometry (LC-MS/MS) method for 
measurement of 25-hydroxycholecalciferol (25(OH)D3) in dried blood samples. Measurements 
of 25(OH)D3 from blood samples collected by Mitra® volumetric absorptive microsampler 
(VAMS) (Neoteryx, Torrance, CA, USA) were compared against a conventional paper-based 
method against plasma concentrations. LC-MS/MS is considered the gold standard technique for 
the measurement of vitamin D metabolites due to its high sensitivity and specificity119, hence the 
method of choice in this study. 
 
6.2 Materials and methods 
6.2.1 Serum sample collection 
Whole blood samples collected in K3EDTA vacutainer tubes (Becton Dickinson, Oxford, UK) 
from 167 patient samples were selected at random from routine full blood count requests at the 
Department of Laboratory Medicine, Norwich and Norfolk University Hospital. Blood samples 
were stored at room temperature. All samples were anonymised at point of access and processed 
in accordance with generic ethical approval for assay development80. The plasma samples were 
obtained by centrifugation for 10 minutes at 3,000x g. Plasma was aliquoted into a polystyrene 
tube and stored at -20C until analysis. 
 
6.2.2 Materials, calibration standards and controls 
LCMS grade water, formic acid, methanol, isopropanol (IPA) and analytical grade n-heptane were 
purchased from Fisher Scientific (Loughborough, UK). 4-phenyl-1,2,4-triazoline-3,5-dione 
(PTAD) and methylamine (Sigma-Aldrich, Dorset, UK) were used for derivatisation and adduct 
formation. Whatman® 903 Protein saver cards and Harris UniCore 3.0mm puncher were 
purchased from GE Healthcare (Cardiff, UK). Mitra® VAMS were provided by Neoteryx 
(Torrance, CA, USA). ISOLUTE SLE+ plates were purchased from Biotage (Uppsala, Sweden). 
Certified 25(OH)D3 and 25(OH)D3-[2H6] standards were purchased from IsoSciences (PA, 
USA). 
 
Preparation of whole blood 25(OH)D3 calibration standards and quality controls 
Matrix-matched calibration standards were prepared from certified standards spiked into vitamin 
D-free whole blood. Vitamin D-free whole blood was prepared in-house from washing packed 
cells using 0.9% saline solution; a 50 mL pool of EDTA whole blood was centrifuged at 1500 x 
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g for 15 minutes, the plasma layer was removed and replaced with an equal volume of 0.9% saline 
solution. The packed cells were washed with the saline on a carousel rotator for 20 minutes and 
then centrifuged again under the same conditions. This procedure was repeated three times. After 
the final wash, the saline layer removed was replaced with vitamin D depleted serum (BBI 
solutions, Cardiff, UK) and made up to the volume equivalent to the original discarded plasma. 
Certified 25(OH)D3 standards were spiked into vitamin D-free whole blood to concentrations of 
125, 100, 75, 50, 25 and 17 nmol/L. All the standards including a sample of the blank (vitamin 
D-free whole blood) were analysed in singleton in each run. 
 
Blood spot and VAMS microsampling procedure 
Whole blood samples were thoroughly mixed before microsampling to ensure homogeneity. For 
VAMS sampling, the 10 µL fixed volume (product number 10006) was used. The device was 
placed on the surface of blood until the absorbent tip became red indicating full saturation (Figure 
6.1a). For DBS filter paper, 10 µL of whole blood was pipetted into the centre of the spotting 
circle. Samples collected by both devices were left to dry for 18 hours at room temperature before 
being stored at -20oC and analysed within 24 hours. Prior to analysis, DBS samples were obtained 
from the DBS spot by one of two extraction techniques; 1) cutting a disc around the edge of the 
blood spot to obtain the whole blood spot (wDBS) (Figure 6.1b), and 2) by making two 3 mm 
sub-punches (spDBS) (Figure 6.1c). The spots were then placed into separate glass tubes. The 
absorbent tip from the VAMS was detached and placed into a glass tube. 
Three patient sample pools containing low (10.6 nmol/L), medium (57.7 nmol/L) and high (82.0 
nmol/L) concentrations of 25(OH)D3 were prepared. Each QC sample was analysed over ten 
separate runs to obtain a mean target value and ±2SD limits. Westgard QC rules83 were applied 
as acceptance criteria for each batch of analysis. 
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Figure 6.1a-c  (a) a 10 µL Mitra VAMS before and after saturation with blood (b) 
cutting a whole blood spot (c) two 3 mm DBS sub-punch discs. 
 
6.2.3 Sample preparation procedure for LC-MS/MS 
Sample preparation procedure was modified from the derivatisation method described in Chapter 
5.3.5. To each glass tube containing a DBS or VAMS sample, 20L of internal standard solution 
consisting of 50 nmol/L of 25(OH)D3-[2H6] in IPA: water 50:50 (v:v) was added, followed by 
150µL of H2O. The tubes were sonicated in a water bath (Fisher Scientific, Loughborough, UK) 
at +60oC for 60 minutes. The aqueous extracts were transferred into a new set of glass tubes, 
leaving behind the extracted spots/VAMS tips in the primary tubes. 150 µL of IPA was added to 
the primary tubes, vortexed by an orbital shaker at 300 rpm for 30 mins at room temperature, then 
transferred to the corresponding secondary tubes containing the aqueous extracts. The combined 
IPA/aqueous extracts (300µL), together with the spots/VAMS tips were loaded onto an ISOLUTE 
SLE+ plate. The plated samples were eluted twice with 750µL of n-heptane using the Extrahera 
automation system (Biotage, Uppsala, Sweden). Positive pressure was applied after each wash. 
The eluent was collected into a 96 deep well plate and then dried for 30 minutes under nitrogen 
heated at +45°C. 
The dried extracts were reconstituted using 50 µL of 1.1 mmol/L of PTAD in acetonitrile and 
incubated for 30 minutes while protected from light. The reaction was stopped by the addition of 
50 µL of H2O. After a brief vortex, the plate was heat sealed using a 20 µm pierceable foil. 20 µL 
of the extract was injected into the LC-MS/MS. 
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6.2.4 Liquid chromatography Tandem mass spectrometry 
Liquid chromatography was performed as described in Chapter 5.2.5. In brief, chromatographic 
separation was performed using a core-shell C18 50 × 2.1mm, 2.6 µm column (Restek, PA, USA) 
that was heated to +55°C. Mobile phase (A) was water and methanol (B), both contained 0.2 mM 
methylamine in 0.1% formic acid containing. Gradient started at a flow rate of 0.4 mL/min with 
50% Mobile phase B increased to 100% over 2 minutes 10 seconds then returned to the original 
conditions after three minutes. The 25(OH)D3 peak was eluted at 1.75 minutes. Micromass 
Quattro Ultima Pt tandem mass spectrometer (Waters Corp., Milford, MA, USA) was used to 
analyse the samples with precursor to product transitions, 607>298 for 25(OH)D3 and 613>298 
for 25(OH)D3-[2H6]. MassLynx version 4.1 and QuanLynx were used for data acquisition and 
peak integration. 
 
6.2.5 Method validation 
For method validation, the guidelines on linearity, accuracy, precision, recovery and cross-
validation procedures from the 2013 guidance produced by the U.S Food and Drug 
Administration (FDA)81 and the 2012 guideline from the European Medicines Agency (EMA)82 
were followed. In addition, the effects from Hct in the blood matrix on 25(OH)D3 measurements 
and sample storage stability were investigated. 
 
6.2.6 Linearity, accuracy, precision and recovery 
Calibration standards prepared in wDBS, spDBS and VAMS, ranging from 0-125 nmol/L were 
included at the start of each run. Calibration curves were constructed by the ratio of analyte peak 
area to internal standard peak area on the y-axis against the weighted concentration (1/x) of the 
standards on the x-axis. The acceptable limit of linearity was defined as r2 >0.98. Accuracy was 
assessed by the deviation of the assayed value of a calibration standard against its nominal value. 
Acceptance criteria are ≤15% of the nominal values, and ≤20% at the lower limit of quantification 
(LLoQ)82. 
Recovery was determined by analysing extracted samples spiked with fixed concentrations of 
25(OH)D3 and repeated three times on separate runs. The percentage recovery was calculated 
using the expected concentration for each sample. The average recovery was determined from the 
mean of the three runs. 
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6.2.7 Lower limit of quantification and detection 
To evaluate the intra-assay precision, ten replicates of the four samples covering concentrations 
between 7.6-70.9 nmol/L of 25(OH)D3 were analysed within a single run. The precision was 
expressed in percentage of coefficient of variation (%CV) for each sample. To assess the inter-
assay precision, three QC pools were analysed across eleven runs over a 50-day period. The 
acceptance criteria were an intra-assay and an inter-assay CV of <15%. LLoQ was determined by 
analysis of a series of eleven standards, with concentrations ranging from 1.2 to 95.7 nmol/L of 
25(OH)D3. Each standard was tested six times within a run. The LLoQ was defined as the lowest 
concentration with a CV of ≤20%, with the peak signal-to-noise ratio >5. The lower limit of 
detection (LLoD) was determined by the lowest concentration that produced a peak area of at 
least five times the area produced by the blank. 
 
6.2.8 Effects of haematocrit on 25(OH)D3 measurements 
The effects of Hct on plasma 25(OH)D3 concentrations were determined by two volume 
displacement studies. Firstly, three patient whole blood EDTA samples containing 25(OH)D3 
(Hct) concentrations of 7.0 nmol/L (0.40 L/L), 27.6 nmol/L (0.40 L/L) and 43.2 nmol/L (0.51 
L/L) were centrifuged for 5 minutes at 4000 rpm to separate the plasma. 10% of the plasma 
volume was removed from the top layer, and the residual sample was re-homogenised by gentle 
rotation for 10 minutes. Duplicate wDBS, spDBS and VAMS samples were taken from the 
homogenised blood. The process was repeated, taking 10% of plasma volume until the plasma 
layer was removed. DBS and VAMS samples were dried overnight at room temperature and 
extracted as described in 6.2.3. Secondly, washed plasma-free packed cells were added to patient 
blood samples in stepwise increments until full saturation. At each step after homogenisation, 
DBS and VAMS samples were collected for analysis. 
 
6.2.9 Method comparison 
EDTA blood samples from 97 patients with Hct level ranging between 0.32-0.55 L/L were 
sampled by wDBS, spDBS and VAMS. 25(OH)D3 concentrations from each microsampling 
technique were compared against the plasma concentrations. The validated plasma 25(OH)D3 
assay described in Chapter 5.3.4 was calibrated using commercial 25(OH)D3 standards 
(Chromsystems, Müchen, Germany) traceable to reference source NIST SRM972a77. The inter-
assay CV was ≤9%, the analytical range was 0.5-200 nmol/L, with an LLoQ of 0.1 nmol/L. The 
mean assay recovery was 96 2%. The assay showed <8% accuracy bias against NIST reference 
method on the Vitamin D external quality assessment (DEQAS) scheme. 
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6.2.10 Establishing the DBS-to-plasma equivalency values 
To determine the DBS-to-plasma equivalent values (PEV) for wDBS (PEVwDBS), spDBS 
(PEVspDBS) and VAMS (PEVVAMS), raw DBS and VAMS 25(OH)D3 concentrations were plotted 
against their respective plasma concentrations using a simple linear regression model. The 
regression equations from the microsampling techniques were used to transform raw DBS and 
VAMS 25(OH)D3 concentrations from a new second set of patient samples (n=70) into PEVs. 
Passing-Bablok regression, Lin’s concordance correlation (CCC) and Bland-Altman difference 
plots were constructed for PEVwDBS, PEVspDBS and PEVVAMS against the plasma 25(OH)D3 
concentrations to assess the strength of the correlation. 
 
6.2.11 Storage stability 
To test the stability of 25(OH)D3 in storage, multiple DBS and VAMS samples from three pools 
of blood at 25(OH)D3 concentrations of 8.5, 27.9 and 72.1 nmol/L were prepared. Samples were 
dried for 18 hours and stored at -20°C and analysed at intervals up to 209 days. Changes in 
25(OH)D3 concentration were expressed as the average percentage difference from day 0 to the 
day analysed. 
 
6.2.12 Statistical analysis 
Data exploration, scatter plots, and statistical analyses were performed using Statistical Package 
for Social Science (SPSS) version 22.0.0.2 (IBM, NY, USA). Passing-Bablok regression 
generated linear equations were used to derive the PEVs from raw DBS and VAMS values. 
Method comparisons were assessed using Passing-Bablok regression, CCC analysis and Bland-
Altman plots. A correlation is deemed satisfactory if the regression produced an r2 0.9. 
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6.3 Results 
6.3.1 Assay validation 
Calibration curves for wDBS, spDBS, VAMS and the plasma assay were linear from 0-125 
nmol/L (r2 >0.98). Precision profiles of both intra- and inter-assays CVs were <10% except for 
wDBS and spDBS at the lowest 25(OH)D3 concentrations (Table 6.1 and 6.2). The average intra- 
and inter-assay CVs were higher in spDBS than wDBS and VAMS across the concentrations 
tested. VAMS showed the least variability in comparison with wDBS and spDBS. LLoQ for 
wDBS, spDBS and VAMS were 1.6, 2.6 and 1.5 nmol/L, respectively. LLoD for wDBS, spDBS 
and VAMS were 0.8, 1.4 and 0.5 nmol/L, respectively. VAMs showed the best recovery results 
(Table 6.3). The lowest analyte recovery was observed in wDBS (78.9%) and the highest was 
found in spDBS (120%). 
 
 
Sample 
Mean 25(OH)D3 nmol/L (%CV) 
wDBS SpDBS VAMS 
1 7.5(16.1) 8.5 (13.6) 7.0 (7.6) 
2 23.4 (8.8) 23.2 (9.0) 20.5 (6.7) 
3 43.6 (9.2) 45.0 (12.0) 40.3 (6.4) 
4 64.2 (6.5) 66.5 (11.0) 59.5 (7.7) 
 
Table 6.1 Intra-assay precision. Ten replicates of four samples were analysed within a 
single run. The precision is expressed in percentage of coefficient of variation (%CV) for each 
sample. 
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wDBS SpDBS VAMS 
Mean 25(OH)D3 nmol/L (%CV) 
Low QC 9.7 (12.9) 12.6 (14.8) 10.3 (9.5) 
Medium QC 59.0 (6.9) 60.8 (13.5) 64.2 (7.1) 
High QC 81.1 (7.2) 95.7 (10.8) 91.4 (5.7) 
average %CV 9.0 13.0 7.5 
 
Table 6.2 Inter-assay precision. Three QC pools containing 25(OH)D3 analysed in eleven 
runs over a 50-day period 
 
Expected 
25(OH)D3 nmol/L 
Mean recovery (%) 
wDBS SpDBS VAMS 
8.5 94.5 110.2 98.4 
21.0 90.0 108.6 104.0 
37.5 93.3 97.1 101.7 
62.5 89.2 96.7 100.7 
87.5 90.3 104.6 95.4 
106.3 91.8 102.5 99.6 
Overall average 
(range, %CV) 
91.5 
(78.9-102.4, 6.0) 
103.8 
(88.3-120, 9.2) 
101.0 
(93.4-112.4, 5.9) 
 
Table 6.3 Assay recovery of the microsampling techniques. Fixed quantities of 25(OH)D3 
were spiked into whole blood before microsampling, recovery is determined by the amount of 
25(OH)D3 recoverable from the spiked amount. Each spiked sample was assayed three times over 
separate runs. 
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6.3.2 Volume displacement effects by haematocrit 
25(OH)D3 concentrations showed a linear correlation with the decrease in plasma volume in 
wDBS, spDBS and VAMS (Fig. 6.2a). It demonstrates that 25(OH)D3 in blood is present 
primarily in the extracellular fluid (ECF) compartment, the intracellular space contained <1.7%. 
When plasma-free packed cells were added to a whole blood sample until saturation, a reduction 
in 25(OH)D3 concentrations were found in all three microsampling techniques that were 
proportional to the increase in Hct in blood (Fig 6.2b). The results demonstrated the displacement 
effect of plasma volume by Hct; whilst the plasma volume remained unchanged, the increasing 
level of Hct prevented the uptake of 25(OH)D3 into the microsampling devices. The finding 
indicated the concentration of 25(OH)D3 in the whole blood sample is dependent upon the level 
of Hct present, and that measurements using microsampling devices must be corrected for the 
level of Hct.  
 
a)  
 
Figure 6.2a The effect of plasma volume on whole blood 25(OH)D3 concentration. (a) 
Stepwise removal of plasma volume from the packed cells proportionally reduced 25(OH)D3 
concentrations in wDBS, spDBS and VAMS samples.  Results are represented as mean  SEM. 
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b)  
 
Figure 6.2b The displacement effect of plasma volume by Hct. Plasma-free packed cells were 
added to a whole blood sample in incremental steps until full saturation. Reduction in 25(OH)D3 
concentrations were found to be proportional to the increase in Hct in blood. 
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6.3.3 Comparison between dried blood and plasma 25(OH)D3 measurements 
EDTA samples (n = 97) with Hct values ranging from 0.32-0.55 L/L had 25(OH)D3 
concentrations measured in DBS/VAMS and plasma. wDBS, spDBS and VAMS were positively 
correlated with plasma concentration with r2 = 0.893; r2 = 0.917 and r2 = 0.870, respectively (Fig. 
6.3a-c). A negative bias was found in values produced using microsampling devices. On average, 
the 25(OH)D3 concentrations in wDBS, spDBS and VAMS were 41%, 33% and 44% lower 
respectively than in plasma. 
 
 
 
 
72 
 
 
 
Figure 6.3a-c Comparison of 25(OH)D3 concentrations from 97 patient samples (Hct range 
0.32-0.55 L/L) collected in (a) wDBS, (b) spDBS, and (c) VAMS with plasma. 25(OH)D3 
concentrations produced from microsampling devices were negatively biased against plasma 
concentration. On average, the bias between the microsampling devices (solid colour lines) 
against the line of identity (grey dashed line) was -39.3%.  
 
6.3.4 Dried blood-to-plasma equivalency values and their interpretability of vitamin D 
status 
Linear regression analyses obtained the following dried blood-to-plasma equivalency 
equations: PEVwDBS = (wDBS + 1.26)/0.54; PEVspDBS = (spDBS + 1.88)/0.6; and 
PEVVAMS = (VAMS − 0.45)/0.56. Using these equations, the raw 25(OH)D3 concentrations of 
wDBS, spDBS and VAMS obtained from a new set of 70 samples had their respective PEVs 
calculated. Passing-Bablok regression, correctional bias factor (Cb) and CCC analyses performed 
on PEVwDBS, PEVspDBS and PEVVAMS against the plasma concentrations (Fig. 6.3d-f) showed good 
agreements with minimal deviation from the line of identity (y = x). However, the Bland-Altman 
plots showed overestimation of 25(OH)D3 concentrations by PEVs compared with plasma 
25(OH)D3 concentrations(Fig. 6.3g-i). The average bias for PEVwDBS and PEVVAMS were +12.3% 
and +9.2%, respectively; PEVspDBS showed the highest bias at +24.3%. The assay bias was 
negatively associated with the increase in Hct levels (Fig. 6.4a-c). For PEVVAMS and PEVwDBS 
zero assay bias was observed at Hct level of 0.48 L/L and 0.51 L/L respectively. In PEVspDBS, a 
constant positive bias was observed across the entire Hct range. 
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Figure 6.3d-f Passing-Bablok regression and Lin’s concordance correlation analyses 
performed on (d) PEVwDBS, (e) PEVspDBS and (f) PEVVAMS against plasma concentrations (n=70). 
CI: confidence interval; CCC: concordance correlation coefficient; r: Pearson correlation 
coefficient; Cb: correctional bias.  
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Figure 6.3g-i Bland-Altman plots showing the percentage difference between (g) PEVwDBS, (h) 
PEVspDBS and (i) PEVVAMS with plasma 25(OH)D3 concentrations of each microsampling 
methods. 
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a)  
 
b)  
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c)  
 
Figure 6.4a-c  The percentage difference between a) PEVwDBS, b) PEVspDBS and c) 
PEVVAMS with plasma concentration against the respective haematocrit level in each sample. 
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The  Institute of Medicine (IOM) guidelines93 defined the vitamin D status of an individual with 
serum 25(OH)D (sum of 25(OH)D3 + 25(OH)D2) <30 nmol/L as deficient; between 30-50 
nmol/L as insufficient; and >50 nmol/L as sufficient. Based on these definitions, in this cohort of 
70 samples with none detectable 25(OH)D2, measurements of plasma 25(OH)D3 concentrations 
identified 27 (38.6%) cases of vitamin D deficiency, 24 (34.3%) cases of insufficiency, and 19 
(27.1%) individuals with sufficient vitamin D status (Table 6.4). PEVs showed an overall 
underestimation of individuals with deficient vitamin D status, and an overestimation of 
individuals with insufficient and sufficient vitamin D status. Between the three microsampling 
techniques, PEVVAMS showed the least difference in the interpretation of vitamin D status. 
 
 
Table 6.4 Interpretation of vitamin D status in the cohort (n=70) according to the U.S. 
Institute of Medicine guidelines. The number of cases classified as vitamin D deficient, 
insufficient and sufficient by the respective plasma 25(OH)D3 concentration and the 
corresponding PEV produced from each sampling method. 
  
Vitamin D status 
definitions 
Plasma 
(no. of cases, 
% in cohort) 
PEV
wDBS
 
(n, %) 
PEV
spDBS
 
(n, %) 
PEV
VAMS
 
(n, %) 
<30 nmol/L, 
Deficiency 
27 (38.6%) 20 (10%) 15 (17.1%) 24 (4.3%) 
30-50 nmol/L, 
Insufficiency 
24 (34.3%) 29 (↑7.1%) 31 (10%) 26 (2.9%) 
>50 nmol/L, 
sufficiency 
19 (27.1%) 21 (2.9%) 24 (7.1%) 20 (1.4%) 
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6.3.5 Storage stability over 209 days 
25(OH)D3 in both wDBS and VAMS was stable up to 209 days when stored at -20°C. No 
significant differences were observed between day 0 and each time point (Fig. 6.5). 
 
 
 
Figure 6.5 A 209-day stability plot. Each time point represents the mean (range) percentage 
change of 25(OH)D3 concentration from day one in samples collected by wDBS and VAMS 
stored at -20°C. 
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6.4 Discussion and conclusion 
The prime objective of the study was to develop an LC-MS/MS method to determine 25(OH)D3 
concentrations in DBS from filter paper and VAMS. A robust sample extraction procedure was 
developed with derivatisation to enhance the sensitivity of the LC-MS/MS method and improve 
the precision of 25(OH)D3 measurements. The assay was validated against published acceptance 
criteria for clinical and research use. The method demonstrated excellent linearity, recovery and 
intra/inter-assay precision. The quality of measurements can be affected by pre-analytical factors 
associated with the use of dried blood samples. Kvaskoff et al.120 showed that due to the non-
uniform nature of blood diffusion on the filter paper, 25(OH)D3 concentrations from a sub punch 
taken from the centre of the blood spot could vary to a sub punch of the same sample taken from 
around the edge of the spot. To address this issue, this study evaluated two common approaches 
for the extraction of blood spots; sub punches (spDBS) and removal of the entire blood spot from 
a fixed volume of sample (wDBS). wDBS showed better performance than spDBS; with lower 
intra- and inter-assay CVs, lower variability in recovery, and the respective PEVwDBS showed a 
stronger correlation with plasma concentration. 
In comparison with wDBS and spDBS, VAMS was superior in both reproducibility and recovery 
of 25(OH)D3; the fixed volumetric device also produced better assay precision. spDBS and 
wDBS showed higher intra/inter-assay CVs than VAMS and greater variability in assay recovery, 
despite the fact that DBS samples were prepared from a fixed 10 L of blood pipetted directly 
onto the filter paper in a controlled laboratory environment. In practice, a person carrying out self-
sampling would not be able to control the blood volume on the filter paper; the variability in 
sample volume and spot sizes would likely have a greater negative impact on assay performance 
and compromise the quality of results. 
The effects of blood sample Hct on 25(OH)D3 measurements was tested, by adding packed red 
cells and removing plasma in incremental steps. The results showed that 25(OH)D3 
concentrations decreased proportionally as Hct increased; and also when plasma volume is 
reduced. The findings are consistent with those of Kvaskoff et al.120 who, using isotopic I-125 
labelled 25(OH)D3, showed that 98% of 25(OH)D3 was present in the serum fraction, and 
concluded that because the majority of 25(OH)D3 is bound to vitamin D binding protein, 
25(OH)D3 is virtually absent from intra-cellular and membrane components of the erythrocytes. 
However, despite assurance from the fact that Hct does not alter the physiological concentration 
of 25(OH)D3 in circulation, the displacement effect of Hct can prevent the uptake of 25(OH)D3 
into the microsampling devices, resulting in biased correlations between raw DBS and VAMS 
values with plasma concentrations as shown in Figure 6.3a-c. To adjust for the bias, regression 
models were established to transform values into a clinically-relevant scale. The accuracy of the 
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DBS/VAMS-to-plasma equivalent PEVs were blindly tested on a new set of samples; the results 
showed a strong agreement with the plasma values suggesting that the proposed equation models 
can be used to obtain reliable and interpretable measurements of 25(OH)D3. 
The use of mathematical conversions to adjust for Hct in LC/MS-MS assays for DBS have been 
reported120-123, but the use of VAMS was not studied. The formulae also require measurement of 
individual Hct, unlike the proposed formula which can be applied without the need for Hct 
measurement. Using the exact Hct value may improve the diagnostic accuracy of the results, but 
venous blood is required. The results demonstrated the suitability of using PEV in the 
interpretation of vitamin D status and found PEVVAMS to be the most accurate method in 
comparison to PEVspDBS and PEVwDBS. Therefore, VAMS is recommended as the microsampling 
method of choice for the determination of 25(OH)D3 and the assessment of vitamin D status. 
A limitation of the study was that this study did not determine the rate of absorption of Hct into 
VAMS and assumed equal uptake of intra and extracellular contents. Given 25(OH)D3 exists 
primarily in the ECF compartment of blood, and the uptake of sample by the microsampling 
device is dependent upon the amount of Hct present. Denniff and Spooner123 demonstrated that 
there is no preferential absorption of plasma over blood cells when using VAMS. Similarly, a 
multi-laboratory study118 showed no notable change of blood volume absorbed by VAMS across 
the Hct range. This supporting evidence suggests that VAMS can provide an accurate 
representation of the sample constituents. 
This study was limited to the use of venous blood samples, in order to obtain Hct measurements. 
Further study will be required to cross-validate agreement between capillary and venous samples, 
and to investigate the potential effects which may result from bacterial or tissue fluid 
contamination at the site of puncture. Jensen et al.124 demonstrated using LC-MS/MS, a strong 
agreement of 25(OH)D3 concentrations between capillary and venous blood (r2 = 0.9963), with 
a small average positive bias of 2.0 nmol/L in capillary blood. 
A major strength of the study was the large sample size. However, the samples were selected at 
random; hence a limited Hct range between 0.32-0.55 L/L was obtained. Low or high Hct levels 
may result from blood transfusion, the use of medications and pathological conditions125-128. 
In conclusion, this study provides validation of microsampling methodologies for measurement 
of 25(OH)D3 and interpretation of vitamin D status. VAMS demonstrated benefits over the 
conventional paper-based method; the consistency in sampling volume, ease of use without the 
need for sub punches, and preservation of sample constituency are all advantages of VAMS. The 
results provided evidence that samples collected from VAMS produced better assay performance 
for the assessment of vitamin D status. The use of an empirically-derived model to transform DBS 
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values into clinically-relevant equivalency improves the interpretability and may broaden the 
applicability of DBS sampling particularly in vulnerable populations. 
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Chapter 7 Reference intervals for serum 24,25-
dihydroxyvitamin D and the ratio with 25-
hydroxyvitamin D established using LC-MS/MS profile 
analysis 
 
7.1 Background 
The vitamin D endocrine system plays a major role in human biological functions. The vitamin 
D pathway produces a large number of metabolites including 25-hydroxyvitamin D (25(OH)D), 
and 1α,25-dihydroxyvitamin D (1,25(OH)D). Each vitamin D metabolites exists in two major 
forms: cholecalciferol (D3) is derived from sunlight (UVB) exposure on the skin and meat 
products, and ergocalciferol (D2) is derived from dietary plant sources. The synthesis of the 
metabolites are controlled by 25-hydroxylase in the liver and 1-hydroxylase in the kidney. Severe 
deficiency of serum 25(OH)D results in decreased production of 1,25(OH)2D which is strongly 
associated with bone and neuromuscular diseases9. Epidemiological studies have shown an 
inverse relationship between serum 25(OH)D concentrations with a broad spectrum of disease 
states, including cardiovascular, cancer, diabetes, immunological and psychiatric 
disorders4,5,7,8,129-131. However, evidence from vitamin D intervention trials supporting the 
beneficial effects of vitamin D supplementation on disease outcome is largely inconclusive132-135. 
The contradictory evidence indicates that the catabolism of 25(OH)D is a multistep process. 
Recent attention has centred on an alternative pathway of 25(OH)D metabolism driven by 24-
hydroxylase producing 24,25-dihydroxyvitamin D (24,25(OH)2D). Studies have found limited 
biological activity of 24,25(OH)2D in humans, and similarly the metabolite 1,24,25-
trihydroxyvitamin D (1,24,25(OH)3D) which was considered to be an inactive excretory product 
of the vitamin D pathway136. The revival of interest in 24,25(OH)2D is partly as a result of altered 
vitamin D catabolism discovered in patients with chronic kidney disease (CKD)137, where 
impaired renal production of 1,25(OH)2D was found to be associated with decreased CYP24A1 
(cytochrome P450, family 24, subfamily A, polypeptide 1) activity. The CYP24A1 gene is 
expressed in most tissues in the body138,139; it encodes the 24-hydroxylase enzyme that catalyses 
the conversion of 25(OH)D and 1,25(OH)2D into 24-hydroxylated products136. The transcription 
of the CYP24A1 gene is stimulated by the phosphate-regulating hormone fibroblast growth factor-
23 (FGF23) and suppressed by PTH137,140. As 24,25(OH)2D is the main product of 25(OH)D 
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catabolism by CYP24A1, the measurement of serum 24,25(OH)2D concentration can be useful in 
identifying patients with loss-of-function mutations in CYP24A1. The relative ratio of serum 
25(OH)D to 24,25(OH)2D concentration may serve as an indicator of vitamin D catabolic status. 
Recent advances in methods for measurement of vitamin D metabolites, in particular with assays 
for measurement 25(OH)D, have led to the development of a range of semi- and fully automated 
assays capable of measuring large numbers of samples. Competitive protein binding assays and 
enzyme immunoassays using chemiluminescent detection-based systems in fully automated 
platforms appeal to hospital laboratories due to their ease of use, speed and efficiency141. 
However, immunoassays have variable cross-reactivity with other vitamin D metabolites and are 
unable to distinguish the two major forms of vitamin D (D3 and D2). This results in some 
immunoassays significantly underestimated an individual’s true vitamin D status61. Liquid 
chromatography tandem mass spectrometry (LC-MS/MS) methods quantify vitamin D 
metabolites based on the compound-specific precursor to product ion mass-to-charge (m/z) 
transitions. They can distinguish each hydroxylation metabolite and their respective D3 and D2 
forms. Proficiency testing bodies such as the International Vitamin D External Quality Control 
Scheme (DEQAS) have reported that measurement of 25(OH)D by LC-MS/MS methods using 
traceable calibration standards from the National Institute of Standards and Technology (NIST) 
exhibit the lowest inter-laboratory imprecision in comparison with immunoassays60. LC-MS/MS 
is now considered to be the reference method for measurement of 25(OH)D. 
The aim of the study was to develop a robust and sensitive assay to measure 25(OH)D and 
24,25(OH)2D simultaneously in human serum samples. The objective was to apply the assay to 
measure vitamin D metabolites in a large cohort of healthy individuals and patients to examine 
the clinical correlation of 24,25(OH)2D with 25(OH)D. The goal was to establish from a cohort 
of healthy individuals: 1) reference intervals for serum 24,25(OH)2D and 25(OH)D:24,25(OH)2D 
ratio; 2) to determine the diagnostic accuracy of 24,25(OH)2D measurement as an indicator for 
vitamin D status; and 3) to identify a 24,25(OH)2D cut-off threshold when vitamin D status is 
sufficient; i.e. serum 25(OH)2D concentration ≥50 nmol/L, as defined by the U.S Institute of 
Medicine (IOM) and the UK Royal Osteoporosis Society (ROS)10,11. Recent publications have 
reported reference intervals of 25(OH)D:24,25(OH)2D ratio on smaller cohorts42,142,143, or post-
menopausal women supplemented with vitamin D55. This chapter describes the reference intervals 
from a large cohort of unsupplemented individuals using a statistical approach supported by the 
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) working 
group144. 
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7.2 Materials and methods 
7.2.1 Serum sample collection 
The characteristics of the subjects included in the study are shown in Table 7.1. Serum samples 
used in the healthy cohort (n=1996) were obtained from young British Army recruits during initial 
training (ClinicalTrials.gov Identifier NCT02416895). The study was approved by the UK 
Ministry of Defence research ethics committee (MODREC). Written informed consent was 
obtained from all study participants. The participants were from Caucasian population and each 
required to complete details in a health questionnaire, including the use of medications and 
supplements. Individuals taking calcium and vitamin D supplements were excluded from the 
study. Samples were collected between June 2014 and March 2016.  
Serum samples from patients (n=294) were collected from residual samples following their course 
of routine care in accordance with generic ethical approval80. The patient samples collected were 
routine requests for 25(OH)D measurement received by the Department of Laboratory Medicine 
at the Norfolk and Norwich University Hospital between February 2015 to March 2016.  From 
the clinical information available, the cohort contained patients from Caucasian population 
presented with fatigue/wellness-check (42.6%), osteoporosis (23.9%), primary 
hyperparathyroidism (19.9%), liver disease (5.7%), chronic renal failure (6.2%) and unknown 
(1.7%). Use of vitamin D supplements or drugs known to affect mineral metabolism were reported 
in 32% of the patients. All samples were anonymised to the researchers at the point of access. 
Blood samples were collected into serum gel separator tube (BD Vacutainer) and centrifuged 
immediately. After a 10 minute centrifugation at 3,000 x g, serum layer was aliquoted into a 
separate polystyrene tube and stored at -20C until analysis. 
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 Healthy subjects Patients 𝛒-value 
n 1996 294 0.001 
Gender 
Male 1492 177 0.001 
Female 504 117 0.001 
Age, years (range) 23 (18-32) 52 (2-95) 0.001 
25(OH)D3, nmol/L 63.7±29.4 50.4±50.7 0.001 
25(OH)D2, nmol/L ND 5.4±9.5  
24,25(OH)
2
D3, nmol/L 5.7±3.4 4.1±5.2 0.001 
24,25(OH)
2
D2, nmol/L ND 2.4±1.1  
25(OH)D:24,25(OH)
2
D 13±4.3 17±7.4 0.001 
*Data are shown in mean±SD, ND: none detected  
Table 7.1 Characteristics of the subjects included in the study. 
 
7.2.2 Materials, calibration standards and controls 
SRM972a traceable 25(OH)D3 and 25(OH)D2 serum based calibrators (Chromsystems, 
München, Germany) and internal quality controls (IQC) (UTAK Laboratories, CA, USA) were 
analysed in each run. Certified pure standards for 24,25(OH)2D3, 24,25(OH)2D2 were used for 
the preparation of spiked standards and deuterated standards 25(OH)D3-[2H6] and 24,25(OH)2D3-
[2H3] (IsoSciences, King of Prussia, PA, USA) were used as internal standards. Deionised water, 
methanol, acetonitrile and formic acid were LCMS grade, n-heptane and isopropanol were 
analytical grade (Fisher Scientific, Loughborough, UK). 4-phenyl-1,2,4-triazoline-3,5-dione 
(PTAD) and methylamine (Sigma-Aldrich, Dorset, UK) were used for derivatisation and adduct 
formation. Vitamin D metabolites in frozen human serum (Standard Reference Material 972a) 
was purchased from the National Institute of Standards and Technology (Gaithersburg, MD, 
USA). 
 
7.2.3 Sample preparation procedure for LC-MS/MS 
Sample preparation and extraction procedures were based on the PTAD derivatisation method 
described in Chapter 5.3.5. Samples were processed using the Extrahera™ automation system 
(Biotage, Uppsala, Sweden), under positive pressure supplied from a nitrogen generator (Peak, 
Scotland, UK) at a flow rate of 30 L/min. In a 96 position 2mL deep well plate, 100 L of 
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calibration standards, IQC materials or serum samples were diluted with 200 L of pre-treatment 
solution consisting of deuterated internal standards in isopropanol:water 50:50 (v/v). After 
mixing, the samples were loaded onto ISOLUTE® supported liquid extraction (SLE+) 400 L 
plate (Biotage). Elution was carried out by adding two cycles of 750 L of n-heptane, both cycle 
of eluents were collected into corresponding deep well plate. Positive pressure was applied at 
each stage to remove residual solvent. Samples were then dried under a gentle stream of nitrogen 
gas heated to 45C. Derivatisation took place by adding 50 L of 1.1 mmol/L PTAD in 
acetonitrile, into all wells. The plate was vortexed and allowed to incubate for 30 minutes at room 
temperature in the dark. 50 L of water was then added and mixed to stop the reaction. 20 L of 
the derivatised extracts was injected into the LC-MS/MS. Using this sample preparation 
procedure, a batch of 96 samples was processed in one hour. 
 
7.2.4 Liquid chromatography 
Extracted samples were injected into LC-MS/MS by Waters® 2777 Sample manager (Waters 
Corp., Milford, MA, USA) equipped with 3-drawer cooler stack regulated at 10˚C. 
Chromatographic separation was achieved using a core-shell C18 50 × 2.1mm, 2.6 µm, reversed-
phase (Restek, Bellefonte, PA, USA) column heated at 55˚C. An in-line 2µm, 6.35mm × 24mm 
guard filter was used to protect the column. A gradient elution profile was set up using a binary 
UPLC pump (Flux Instruments, Switzerland) to deliver mobile phase at a flow rate of 0.4 mL/min. 
At the start of the gradient, the mobile phase consisted of 50:50 (v/v) of (A) water containing 0.2 
mM methylamine in 0.1% formic acid and (B) methanol containing 0.2 mM methylamine in 0.1% 
formic acid. The gradient was gradually increased to 99% of methanol mobile phase (B) then 
returned to the starting gradient at 4 minutes. Solvent divert was employed to divert ion 
suppression regions of the separation to waste in order to minimise contamination to the source 
of the mass spectrometer. 
 
7.2.5 Tandem mass spectrophotometry analysis 
LC-MS/MS analysis of vitamin D metabolites was performed using Micromass Quattro Ultima 
Pt electrospray ionisation (ESI) tandem mass spectrometer (Waters Corp., Milford, MA, USA). 
MassLynx version 4.1 and QuanLynx software (Waters Corp., Milford, MA, USA) were used for 
system control, data acquisition, baseline integration and peak quantification. Optimisation of 
MS/MS parameters was accomplished by direct infusion of derivatized standards (Table 7.2). The 
capillary voltage was set at 3.0 kV and RF lenses 1 and 2 were set at 0.1. Source temperature was 
maintained at 90˚C. Nitrogen was used as both nebuliser gas at a flow rate of 30 L/hr and as 
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desolvation gas at a flow rate of 850 L/hr at 120˚C. Sample cone voltage and collision energy for 
all vitamin D metabolites were 35kV and 25kV respectively. Argon gas was applied to the 
collision cell during the Collision Induced Dissociation (CID) process. The precursor to product 
ion transitions for each compound was ascertained based on the molecular weight of the 
methylamine adduct of PTAD derived products (Fig. 7.1a and b). 
 
Parameter Setting 
Ion source Electrospray positive 
Capillary voltage 3.0 kV 
Cone energy 35 kV 
Collision energy 20kV 
Nebuliser gas flow rate 30 L/hr 
Desolvation gas flow rate 850 L/hr 
Source temperature 85C 
Desolvation gas temperature 250C 
m/z transitions 
25(OH)D3 607>298 
25(OH)D3 619>298 
24,25(OH)2D3 623>298 
24,25(OH)2D2 635>298 
25(OH)D3-[2H6] 613>298 
24R,25(OH)2D3-[2H3] 626>316 
 
Table 7.2 Mass spectrometer parameter settings and MRM precursor to product ion 
transitions for 25(OH)D3/D2 and 24,25(OH)2D3/D2. 
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a)  
 
b)  
Figure 7.1a-b  (a) Collision-induced dissociation spectra of PTAD-derivatized 
24,25(OH)2D3 (M+CH3NH3+ at m/z 623). The precursor to product ion transition m/z 623>298 
was utilised for MRM. (b) The dienophilic reaction of 24,25(OH)2D3 with PTAD and formation 
of methylamine adduct. 
 
7.2.6 Method validation 
Method validation guidance was partially followed from the 2013 U.S Food and Drug 
Administration (FDA)145 and the 2012 European Medicines Agency (EMA)146. Human sera based 
calibration standards for 25(OH)D3 and 25(OH)D2 (Chromsystems) were used to ensure 
traceability to SRM972. Where commercial calibration material was not available for 
24,25(OH)2D3 and 24,25(OH)2D2, certified pure standards were spiked gravimetrically into 
vitamin D depleted human serum, representing the same biological matrix as samples. IQC 
materials were incorporated into each batch, the concentrations of IQCs were spread across the 
analytical range; from the base level at three times the concentration of lower limit of 
quantification (LLoQ) to top level at the upper assay limit145. IQC provided the basis of accepting 
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or rejecting the batch, the assay acceptance criteria require over half of the IQC samples analysed 
in each batch produce results within 15% from their respective target value, and 20% at LLoQ146. 
 
7.2.7 Linearity 
Serum standards with known concentrations ranged from 0-180 nmol/L for 25(OH)D3 and 
25(OH)D2, and 0-19.3 nmol/L for 24,25(OH)2D3 and 24,25(OH)2D2 were analysed at the start 
and end of every batch. A standard curve was generated by plotting the ratio of analyte peak area 
to internal standard peak on the y-axis against the weighted (1/x) concentration of their respective 
standards on the x-axis. The goodness-of-fit of a standard curve is justified by linear regression 
that produced a correlation coefficient (r2) value of >0.980. 
 
7.2.8 Accuracy, precision and recovery 
The accuracy of an analytical method can be influenced by sample matrix102,103, endogenous 
components such as phospholipids in biological fluids are a major source of ion suppression in 
LC-MS/MS analysis147. Spike and recovery experiments were performed at low, medium and 
high concentrations across the analytical range to test the effects of biological matrix and sample 
types (serum and EDTA plasma) on the efficiency of sample extraction. A multiple reaction 
monitoring (MRM) transition using the 184 Da product ion of phospholipids was included in the 
acquisition method to monitor the level of phospholipids present in the sample matrix. 
Imprecision of the assay was assessed by ten consecutive measurements of IQC materials within 
a single run (intra-assay) and repeatedly (n = 53) over a three month period (inter-assay). Precision 
is expressed as coefficient of variation (CV), acceptance criteria defined the intra-assay CV limit 
of <10% and cumulative inter-assay CV limit <15%. Accuracy was assessed using NIST SRM 
972a materials; method bias was measured against the certified values for 25(OH)D3, 25(OH)D2 
and 24,25(OH)2D3. 
 
7.2.9 Lower limit of quantification and detection 
A precision profile was carried out to determine the lower limit of quantification (LLoQ) and 
detection (LLoD) of the assay. Samples containing 25(OH)D3, 25(OH)D2, 24,25(OH)2D3 and 
24,25(OH)2D2 at concentrations of 0.05, 0.12, 0.19, 0.41, 0.81 and 1.24 nmol/L were each 
analysed six times, the CVs of each sample were plotted against their respective concentration. 
The analyte peak must produce a signal-to-noise (s/n) ratio of 10:1, the LLoQ was defined as the 
concentration at which the CV 22%. 
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7.2.10 Method comparison 
The 25(OH)D3 values generated by the new multi-analyte, PTAD derivatised method was 
compared against the single analyte non-derivatised LC-MS/MS method previously described in 
Chapter 5.3.4. Serum samples (n=630) that were previously analysed for 25(OH)D3 were retested 
by the new method. Samples from the vitamin D external quality assurance scheme (DEQAS)148 
were analysed, and results compared against the LC/MS method mean. 24,25(OH)2D3 
measurements from samples distributed between April 2015 to January 2019 (n = 75) were 
submitted to the proficiency testing scheme for variability assessment. NIST-certified  SRM 972a 
standards were tested for accuracy. Passing-Bablock regression was used to assess the 
comparability of results between methods; a correlation is deemed satisfactory if the linear 
regression produced a correlation coefficient (r2) value of >0.90. 
 
7.2.11 Statistical data analysis 
Scatterplots, residual plots, box-whisker graphs and Loess curve were constructed and analysed 
by Statistical Package for the Social Science (SPSS) version 22.0.0.1 (IBM, New York, USA). 
Passing-Bablock regression analysis and one-way ANOVA were used to establish the inter-
quartile range and compare variables. Loess curve fitting was employed to explore nonlinear 
relationships between variables and identify inflection points. Statistical significance was defined 
as p <0.05.  Frequency distribution histograms of the data were visually examined and checked 
for transcriptional, pre/post analytical errors before exclusion for statistical analysis. Outliers 
were identified as outside the 2.5% and 97.5% of the population and removed to establish the 
Trimmed Mean. 
 
7.2.12 Partitioning for gender 
The mean and standard deviation of the data were divided according to gender. Harris and Boyd’s 
standard deviate test149 was used to determine the need for gender partition. 
Deviate test: 𝑍 = ?̅?2 − ?̅?1 [(𝜎12 𝑛1⁄ ) +  (𝜎22 𝑛2⁄ )]1/2⁄  
𝑍(𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙) = 3[(𝑛1 + 𝑛2 240⁄ )]1/2 
(?̅?: mean, 𝜎: standard deviation, 𝑛: sample size, 1: male, 2: female) 
Partitioning is required if the statistical 𝑍 ≥ 𝑍(𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙). In this study, the 𝑍(𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙) value is 
8.65. 
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7.2.13 Establishing the reference intervals and cut-off value for clinically significant 
change 
The approach followed for the determination of reference intervals was supported by the 
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) working 
group144. Statistical analysis was performed using SPSS Statistical package, based on non-
parametric method, which does not assume Gaussian distribution. Assessment of the lower and 
upper reference limits were estimated at 2.5th and 97.5th percentiles of the reference distribution. 
Determination of the cut-off value for clinically significant change was estimated using the 
Jacobson and Truax method of analysis150,151. By categorising the total 24,25(OH)2D 
concentrations obtained from the cohort of healthy subjects into two subgroups of serum total 
25(OH)D concentration 1) less than 50 nmol/L (vitamin D deficient/insufficient) or 2) greater 
than 50 nmol/L (vitamin D sufficient), the decision cut-off value was calculated as follows: 
 
𝑑𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 =
(?̅?1 × 𝜎2) + (?̅?2 × 𝜎1)
𝜎2 + 𝜎1
 
 
(?̅?: mean, 𝜎: standard deviation, 1: vitamin D deficient/insufficient , 2: vitamin D sufficient group) 
 
The diagnostic sensitivity and specificity of the cut-off was assessed by using the Receiver 
Operating Characteristics (ROC) curve. In this method, the total 24,25(OH)2D concentrations 
obtained from the healthy subjects were grouped according to total 25(OH)D concentration of 1: 
greater (true negatives), or 0: less than 50 nmol/L (true positives). The ROC curve was generated 
by plotting sensitivity (true positive rate) against 1  specificity (false-positive rate). The accuracy 
of the test is measured by the area under the ROC curve (AUC), an AUC value of >0.9 is classified 
as a highly accurate test. 
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7.3 Results 
Chromatographic peaks for 24,25(OH)2D3, 24,25(OH)2D2, 25(OH)D3 and 25(OH)D2 were eluted 
at 1.39, 1.42, 1.68 and 1.73 minutes respectively (Fig. 7.2). Total injection-to-injection run time 
was achieved in 4 minutes. An ion suppression test was conducted by post-column infusion of an 
aqueous mixture of vitamin D metabolites with simultaneous injection of an extracted pooled 
serum. Baseline signals were found to be depressed during 0 - 0.8 minutes of the chromatographic 
run and elevated between 2.8 – 3.2 minutes. A switch valve was employed to divert parts of the 
sample where ion suppression and ion enhancement occurred to waste. 
 
 
Figure 7.2 Chromatogram from an extracted serum sample containing 64.7 nmol/L of 
25(OH)D3, 46.1 nmol/L of 25(OH)D2, 6.4 nmol/L of 24,25(OH)2D3 and 4.5 nmol/L of 
24,25(OH)2D2. 
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7.3.1 Method validation, recovery efficiency and removal of phospholipids 
Assay validation is summarised in Table 7.3a-b. The assay achieved adequate linearity (Fig. 7.4a-
d), sensitivity, precision, accuracy, and demonstrated reproducible recovery to satisfy method 
validation criteria. Injections of aqueous blank after running samples of spiked standards 
containing 1 mol/L of 24,25(OH)2D3, 24,25(OH)2D2, 25(OH)D3 and 25(OH)D2 affirmed the 
absence of carry-over of analytes. Injection of a single analyte standard confirmed no cross 
interference in the other analyte transitions. Levels of phospholipids in the sample matrix were 
monitored by the acquisition of m/z transitions 522>184 that co-eluted with the vitamin D 
metabolites (re. Chapter fig. 5.5). Lysophospholipid peak was completely eliminated in samples 
extracted using the supported liquid extraction method.  
 
  24,25(OH)2D3 24,25(OH)2D2 25(OH)D3 25(OH)D2 
Linearity, nmol/L  0-25 0-25 0-250 0-250 
Typical r
2
 0.985 0.983 0.997 0.995 
Intra assay 
imprecision mean 
(±SD) in nmol/L, 
%CV 
1.9 (±0.19) 
10.3% 
5.8 (±0.44) 
7.6% 
2.1 (±0.16) 
7.6% 
6.5 (±0.5) 
7.7% 
32.5 (±3.0) 
9.3% 
88.1 (±5.7) 
6.5% 
180.4 (±16.5) 
9.1% 
24.8 (±1.6) 
6.6% 
64.9 (±3.2) 
4.9% 
140.6 (±4.7) 
3.3% 
Inter assay 
imprecision mean 
(±SD) in nmol/L, 
%CV 
2.0 (±0.21) 
10.5% 
6.1 (±0.51) 
8.3% 
14.8 (±1.16) 
7.9% 
1.8 (±0.20) 
11% 
5.7 (±0.61) 
10.7% 
19.4 (±1.95) 
10.0% 
27.1 (±2.9) 
10.9% 
66.2 (±6.0) 
9.1% 
169.7 (±15.2) 
8.9% 
25.0 (±2.0) 
8.0% 
72.3 (±5.7) 
7.9% 
148.9 (±9.4) 
6.3% 
LLoQ, nmol/L 0.1 0.8 0.1 0.1 
Bias against NIST 
972a values, mean 
(range) 
-1.2% 
(-7.5 to +4.4%) 
- 
-0.4% 
(-7.5 to +2.6%) 
+3.3% 
(+1.5 to +5%) 
 
Table 7.3a LC-MS/MS assay characteristics. 
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Sample matrix + 
concentration spiked 
in nmol/L 
Mean % recovery (±SD) 
24,25(OH)2D3 24,25(OH)2D2 25(OH)D3 25(OH)D2 
Depleted serum + 1.2 97% (±4) 108% (±3) 96% (±2) 102% (±4) 
Depleted serum + 
12.2 
94% (±4) 97% (±2) 101% (±4) 107% (±2) 
Depleted serum + 250 - - 103% (±1) 95% (±4) 
Pooled EDTA plasma 
+ 1.2 
96% (±5) 107% (±3) 99% (±2) 94% (±3) 
Pooled EDTA plasma 
+ 12.2 
103% (±3) 99% (±2) 91% (±2) 104% (±2) 
Pooled EDTA plasma 
+ 250 
- 
- 
 
98% (±2) 101% (±3) 
Concentrations of pooled EDTA plasma: 14.3 nmol/L 25(OH)D3, 10.2 nmol/L 25(OH)D2, 1.3 
nmol/L 24,25(OH)2D3, 1.2 nmol/L 24,25(OH)2D2. 
 
Table 7.3b Recovery efficiency was determined by spiking known quantities of each 
compound into vitamin D depleted serum and into a base pool of EDTA plasma containing 
endogenous vitamin D metabolites. Each spiked sample was aliquoted and analysed over ten 
separate runs. 
 
a)  
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b)  
 
c)  
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d)  
Figure 7.3a-d  Typical standard curves constructed by plotting the response of each 
standard on the y-axis against their respective concentrations (nmol/L) on the x-axis. The response 
of each compound was determined by the ratio of the peak area of the standards to the peak area 
of the deuterated internal standards. Regression analysis showed a typical correlation coefficient 
r2 > 0.99. 
 
  
98 
 
7.3.2 Method comparisons 
To assess the comparability of the new method, 630 serum samples previously analysed for 
25(OH)D3 by the non-derivatised LC-MS/MS method were retested using the new method. 
Passing-Bablock regression analysis (Fig. 7.5a) showed a strong correlation with the previous 
method; the line of best fit generated a slope of 1.04 (r2 = 0.962, p<0.001). Residual plot (Fig. 
7.5b) showed no systematic bias. Evaluation of variability in measurements of 24,25(OH)2D3 was 
performed by comparing the results produced from DEQAS samples against mean concentrations 
submitted by other participants. Passing-Bablock Regression (Fig. 7.6a) and residual plots (Fig. 
7.6b) illustrated the correlation and difference in values measured by the new method with other 
registrants of DEQAS. A significant linear association (r2 = 0.926, p<0.001) was found and, the 
residual plot showed no systematic bias or concentration-dependent variance between the 
methods. 
 
a)  
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b)  
Figure 7.5a-b (a) Comparison of 25(OH)D3 of the new method (n=630) showing a strong 
correlation (r2 =0.962) with the previous method. (b) Standardised residual plot showing the 
variability of 25(OH)D3 measurements between the new and previous method. The dashed lines 
represent ±SD limits of agreement. 
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Figure 7.6a-b (a) Comparison of 24,25(OH)2D3 values submitted to DEQAS between April 
2015 to Jan 2019 (n=75) with other DEQAS participants. The red line in the graph represents the 
fitted regression line. (b) Standardised residual plot showing the variability of 24,25(OH)2D3 
measurements. The dashed lines represent 95% limits of agreement. All values were within ±2SD.  
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7.3.3 Partitioning for gender 
The healthy male and healthy female groups were subjected to the Harris and Boyd deviate test. 
The 𝑍 values determined for total 25(OH)D, total 24,25(OH)2D, and 25OHD:24,25(OH)2D ratio 
were 1.61, 4.0 and 5.86, respectively. Each calculated 𝑍 value is ≤ 𝑍(𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙) value of 8.65. 
Therefore, partitioning for gender is not required in establishing the reference intervals. 
 
7.3.4 Reference intervals in a healthy population 
Samples from healthy individuals with plasma intact parathyroid hormone (PTH) or adjusted 
serum calcium concentration (ACa) of greater or less than the healthy reference range (PTH: 1.6-
6.9 pmol/L, ACa 2.2-2.6 mmol/L) were excluded. Based on the exclusion criteria, 1996 samples 
(1492 male, 504 female, age 18-32yrs, mean BMD T-score 1.2±0.1) were included in the 
statistical study. The upper 97.5th and lower 2.5th reference limits for total (sum of D3 + D2) 
25(OH)D, 24,25(OH)2D, and 25OHD:24,25(OH)2D ratio were established according to the non-
parametric method of analysis (Table 7.4). No outlier was found. The ROC curve (Fig. 7.7) 
produced an AUC value of 0.943, which classified 24,25(OH)2D as an excellent test to 
discriminate individuals with vitamin D insufficiency from adequate status. 
 
 
Parameters 
Total cohort 
(n = 1996) 
Reference interval 
(2.5-97.5 percentile) 
Diagnostic cut-
off for vitamin D 
replete 
24,25(OH)
2
D, nmol/L 0.4 - 51.1 1.1 - 13.5 >4.2* 
25(OH)D, nmol/L 6.9 – 293.7 18.9 – 126.4  
25(OH)D: 
24,25(OH)
2
D ratio 
2 - 59 7 - 23  
*At sensitivity = 88.8%,  specificity 86.3% 
 
Table 7.4 Summary of reference intervals and cut-off values for adequate vitamin D status. 
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Figure 7.7 Diagnostic performance of 24,25(OH)2D in the assessment of vitamin D status. 
Receiver Operating Characteristic (ROC) curve depicts diagnostic performance sensitivity and 
specificity levels. () represents the decision threshold for vitamin D replete at 24,25(OH)2D 
concentration of 4.2 nmol/L (sensitivity = 88.8%, specificity = 86.3%). The diagonal line is the 
line of no discrimination. 
 
7.3.5 24,25(OH)2D cut-off value for clinically significant change in vitamin D status. 
Determination of the cut-off value for clinically significant change using the Jacobson and 
Truax150,151 method approach has estimated total 24,25(OH)2D of >4.2 nmol/L to be the threshold 
value for vitamin D replete status, i.e. serum total 25(OH)D concentration 50 nmol/L. The 
decision cut-off has a true positive rate (sensitivity) of 88.8%, and false positive rate (specificity) 
of 86.3%, as indicated by the ROC curve (Fig. 7.7). 
7.3.6 Relationship between serum 25(OH)D, 24,25(OH)2D and 25(OH)D:24,25(OH)2D 
ratio among the healthy and patient population 
In total, 2290 samples collected from healthy volunteers (n = 1996) and patients (n = 294) were 
analysed for serum vitamin D metabolites and included in the statistical analysis. 25(OH)D3 was 
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quantified in all samples with a concentration range (mean±SD) between 3.1 – 349.8 nmol/L 
(62±33.2 nmol/L), from which 24,25(OH)2D3 were quantified in 99.8% of samples. 
24,25(OH)2D3 concentrations ranged between 0.2 – 51.1 nmol/L (5.5±3.7 nmol/L). 25(OH)D2 
was present in 12.9% of samples, with a range between 0.1-74.5 nmol/L (5.4 ±9.5 nmol/L), of 
which 1.1% contained 24,25(OH)2D2 concentrations between 1.3 – 5.0 nmol/L (2.4 ±1.1 nmol/L). 
Statistical analyses were performed on total (sum of D3 + D2) values, the distributions were 
untrimmed, and no outlier was removed. A concentration-dependent relationship was observed 
between serum 24,25(OH)2D and 25(OH)D (Fig. 7.8a), linear regression analysis indicated 
[24,25(OH)2D] = 0.1 x  [25(OH)D] -0.64; r2 value of 0.754. In contrast, the ratio of 
25(OH)D:24,25(OH)2D (Fig. 7.8b) showed an indirect relationship with 25(OH)D; Loess fitting 
showed a downward trend in the ratio of 25(OH)D:24,25(OH)2D as serum 25(OH)D 
concentrations increased. Analysis of variance between the subgroups showed 25(OH)D and 
24,25(OH)2D concentrations in patients were significantly lower than healthy individuals 
(p<0.001), whereas the relative ratio of 25(OH)D:24,25(OH)2D was significantly higher in 
patients (p<0.001). The Box-whisker plots of total 25(OH)D:24,25(OH)2D ratio against serum 
total 25(OH)D grouped into eight concentration categories with an equal number of cases (Fig. 
7.9) revealed a highly significant increase (p<0.001) in ratio occurred at 25(OH)D concentration 
below 50 nmol/L. 
 
a)  
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b)  
 
Figure 7.8a-b  The relationship of serum total 25(OH)D with (a) serum total 
24,25(OH)2D, (b) total 25(OH)D:24,25(OH)2D ratio. Sample from a cohort of mixed patients and 
healthy individuals (n = 2290). The solid red line in (a) represents the linear regression line, with 
95% confidence intervals (dashed lines). Loess fitted curve in (b) depicted in the solid red line 
(99% point fit), dashed lines represent the lower and upper reference intervals (7-23). 
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Figure 7.9 25(OH)D:24,25(OH)2D ratio profile of 1996 healthy subjects against 25(OH)D 
bins. Each bin contains an equal number of subjects to illustrate the significantly elevated ratio 
found in those with serum 25(OH)D <50 nmol/L. Box and whiskers represent the median, 
interquartile range and 95% population intervals. 
 
7.3.7 CYP24A1 mutation on patients with elevated 25(OH)D:24,25(OH)2D ratio. 
Using the established reference intervals, a sample from the patient group was identified with an 
elevated 25(OH)D:24,25(OH)2D ratio of 32; clinical records revealed the patient presented with 
hypercalcaemia and elevated serum 1,25(OH)D of 293 pmol/L (reference range 43-144 pmol/L). 
Retrospective genetic analysis confirmed biallelic pathogenic mutations in CYP24A1 (c.823T>C, 
p.W275R and c.1315C>T p.R439C). 
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7.4 Discussion and conclusion 
This chapter describes a robust LC-MS/MS assay for simultaneous measurement of 
24,25(OH)2D3, 24,25(OH)2D2, 25(OH)D3 and 25(OH)D2. Sample clean-up using supported 
liquid extraction (SLE) and PTAD derivatisation first described in Chapter 5 enabled detection of 
24,25(OH)2D3 and 24,25(OH)2D2. Assay sensitivity is paramount in order to achieve the 
detection limit required to measure 24,25(OH)2D; particularly in CYP24A1 deficient patients with 
low total 25(OH)D. The new method has demonstrated good recovery, intra/inter-assay precision, 
linearity and accuracy against international reference standards. Certified standards spiked into 
vitamin D depleted human sera were used to maintain matrix composition between calibration 
standards and samples. Evaluation of the DEQAS 24,25(OH)2D3 returns from 2015-2019 
distributions were compared against the mean values from all participants. The new assay showed 
good agreement with other methods; all returned values were within ±2SD of the mean 
concentration from other laboratories. The author must stress that the small number of participants 
currently in the DEQAS 24,25(OH)2D3 scheme and the disparity in results between laboratories 
undermine the reliability of the statistics. NIST standard reference materials used in this study 
provided a mean to assess method accuracy; however the certified values for 24,25(OH)D3 were 
limited between 3.39-6.38 nmol/L77. The availability of reference materials covering a wider 
concentration range would improve method accuracy and commutability of results between 
laboratories. 
The strong association between serum concentrations of 25(OH)D and 24,25(OH)2D 
demonstrated in this study echo the findings from the previous reports37,42,53,55,143. The 
concentrations of 24,25(OH)2D exhibited a positive, concentration-dependent relationship, which 
was on average 10% of the concentrations of 25(OH)D. A significant increase in 
25(OH)D:24,25(OH)2D ratio at serum 25(OH)D concentration below 50 nmol/L was observed. 
The decrease in relative production of 24,25(OH)2D may result from downregulation of 
CYP24A1 in response to the decline in circulating 25(OH)D3, in order to facilitate catabolism to 
1,25(OH)D. The reverse is observed in individuals with high concentrations of serum 25(OH)D; 
where production favours 24,25(OH)D at the expense of 1,25(OH)2D which may act to prevent 
toxicity. 
The usefulness of 24,25(OH)2D measurement as a surrogate marker of vitamin D status was 
investigated. It showed high diagnostic accuracy. The 24,25(OH)2D cut-off value of 4.2 nmol/L 
can predict an individual’s vitamin D status with good diagnostic sensitivity and specificity; a 
value below the cut-off indicating insufficiency and the likelihood of metabolism favouring 
1,25(OH)2D; whereas a value above the cut-off indicates sufficient vitamin D status with 
25(OH)D catabolism likely to favour 24,25(OH)2D production.  
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The clinical utility of dual measurements to obtain absolute values as well as a ratio of 25(OH)D 
to 24,25(OH)2D is valuable not only in the assessment of vitamin D catabolic status but also to 
provide an assessment of CYP24A1 activity. Based on a cohort of healthy young adult subjects, 
the normal reference interval for 25(OH)D:24,25(OH)2D ratio was defined between 7 to 23. In 
comparison with current publications, the upper limit is lower than those observed by 
others42,142,143, which may be reflective of the subject population, selection criteria, and analytical 
method employed in this study. The reference interval provides an indication of an individual’s 
vitamin D catabolism with a ratio value below 7 indicating elevated activity of 24-hydroxylase. 
Such individuals may be at risk of developing resistance to vitamin D treatment. A ratio above 23 
indicates enzyme under activity and possible genetic abnormalities of CYP24A1. One patient in 
the cohort was detected with an elevated ratio (32) and hypercalcaemia who on genetic testing 
turned out to have a biallelic mutation of CYP24A1. Molin et al.43 reported patients with 
heterozygous or biallelic mutations of CYP24A1 are associated with 25(OH)D:24,25(OH)2D 
ratios >80; whereas patients with a single mutant allele or no CYP24A1 mutation have ratio values 
<25. Moderate elevation of 25(OH)D:24,25(OH)2D ratio may be a result of substrate depletion 
from underlying diseases caused by renal impairment53, bone disorders57 or pathological 
conditions associated with an increased concentration of FGF2356, all of which affect calcium and 
phosphate homeostasis resulting in an imbalance state of vitamin D catabolism. Detection of an 
elevated 25(OH)D:24,25(OH)2D ratio, especially in patients with nephrocalcinosis or renal 
stones, may indicate a requirement to restrict or avoid vitamin D supplementation in order to 
prevent hypercalcaemia and further stone formation. 
In conclusion, a robust LC-MS/MS method for the simultaneous measurement of 25(OH)D and 
its metabolite 24,25(OH)2D have been successfully developed. The reference intervals of 
24,25(OH)2D and 25(OH)D:24,25(OH)2D ratio was determined from serum analysis of a large 
cohort of healthy young adults. The 25(OH)D:24,25(OH)2D ratio exhibited a remarkable 
consistency across the entire range of 25(OH)D concentrations. A significant increase in 
25(OH)D:24,25(OH)2D ratio in individuals with insufficient 25(OH)D was observed. The 
established reference intervals for 25(OH)D:24,25(OH)2D ratio can help clinician in the 
investigation of patients presenting with diseases and conditions resulted from loss of CYP24A1 
activity and help optimise supplementation therapy based on individual differences in serum 
vitamin D metabolite concentration ratio in order to achieve the best response. 
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Chapter 8 Profiles of 25 hydroxyvitamin D and its 
metabolites 24,25-dihydroxyvitamin D and 1,25-
dihydroxyvitamin D in vitamin D3 supplementation 
studies 
 
8.1 Introduction  
Vitamin D deficiency continues to be the subject of public health concerns. The lack of sunlight 
(UVB) exposure for the synthesis of vitamin D and the limited amount of vitamin D intake from 
diet lie behind the concerns about vitamin D deficiency in the UK. In 2016, the Scientific 
Advisory Committee of Nutrition (SACN) recommended that all adults in the UK have 400 IU 
daily vitamin D12, leading to the Public Health England recommendation that the general 
population should consider taking vitamin D supplements in the winter. This recommendation 
was based on structured literature reviews and metanalysis of population observational studies 
establishing beneficial associations between vitamin D status and many health outcomes; and 
intervention with vitamin D supplementation. Whilst the evidence on vitamin D deficiency-
associated negative impacts on health outcomes are overwhelming, vitamin D intervention and 
dose-ranging studies have been less convincing, therefore questioning the role of vitamin D in 
health152. In clinical settings, it is common practice to administer high doses of vitamin D to 
patients presented with osteomalacia and vitamin D deficiency to ameliorate symptoms153. In 
professional sports, it is commonplace to supplement athletes with vitamin D supplementation, 
often without basal concentrations being assessed. Perhaps even more concerning is the use of 
single, ultra-high dose vitamin D3 capsules up to 50,000 IU (1250 µg), being used on a weekly 
or monthly basis, to raise serum 25(OH)D level and achieve the perceived beneficial effects in a 
short amount of time. Such practices could lead to vitamin D toxicity and increase the risks of 
developing hypercalcaemia, hypercalciuria and renal stone formation154. 
Using vitamin D3 supplement to achieve a target 25(OH)D concentration is often the accepted 
approach in intervention studies. Studies have shown individuals with lower baseline 25(OH)D 
concentration (≤30 nmol/L) given vitamin D3 supplement benefitted from greater outcomes155,156. 
On the contrary, Smith et al. have shown that higher doses of up to 4800 IU/day increase the 
incidence of falls in elderly women157. The confounding effects of vitamin D supplement prompt 
for a better understanding of the metabolism of 25(OH)D, particularly in the active and catabolic 
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forms of vitamin D metabolites. 1,25(OH)2D is the active, hormonal form and has the highest 
biological activity among the circulating vitamin D metabolites. Insufficient clinical studies 
focused on the catabolic form 24,25(OH)2D, which circulates at 1/10 of the concentration of 
25(OH)D54, and is the first step of the degradation pathway (Fig. 8.1). 24,25(OH)2D is converted 
from 25(OH)D by enzyme 24-hydroxylase, the production of which is stimulated by the 
expression of CYP24A1 (cytochrome P450, family 24, subfamily A, polypeptide 1) found in most 
tissues in the body. The same enzyme also converts 1,25(OH)2D into 1,24,25-trihydroxyvitamin 
D (1,24,25(OH)3D); another key exit point in the vitamin D excretion pathway. Studies suggest 
the production of 1,25(OH)2D from 25(OH)D is 24,25(OH)2D dependent37,55,136. Genetic 
mutations of the CYP24A1 gene resulting in the reduced or total loss of 24-hydroxylase function 
are associated with hypercalcaemic conditions158-160. Measurement of serum 24,25(OH)2D can 
indicate CYP24A1 activity, and the vitamin D catabolic status of an individual. 
 
 
Figure 8.1 CYP24A1-induced conversion of 25(OH)D and 1,25(OH)2D by enzyme 24-
hydroxylase, indicated by red arrows. 
 
This chapter presents the profile of vitamin D metabolite measurements from three vitamin D3 
supplementation studies; with contrasting dosing regimen where participants were supplemented 
with either single high bolus, high weekly or a low daily dose of vitamin D3. The current study 
is aimed to characterise the serum responses of the major vitamin D metabolites; 25(OH)D, 
1,25(OH)2D3, 24,25(OH)2D, and the 25(OH)D:24,25(OH)2D vitamin D metabolite ratio (VMR) 
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to oral vitamin D supplementation. The previous chapter (ch. 7.3.6) described in non-
supplemented individuals, serum concentration of 24,25(OH)2D is strongly dependent upon 
25(OH)D. When the vitamin D status become insufficient, serum 24,25(OH)2D concentration is 
reduced significantly. The reverse is hypothesised that supplementation would increase serum 
concentrations of the three vitamin D metabolites, but a greater difference in 24,25(OH)2D 
response to high than low doses. 
 
8.2 Materials and methods 
 
The following three vitamin D supplementation studies carried out between 2013-2017 were led 
by Dr Lanja Saleh, University Hospital of Zurich, Switzerland (study 1161), Prof. Graeme Close, 
Liverpool John Moores University (study 2162), and Prof. Helen MacDonald, University of 
Aberdeen (study 3163). I was a major contributor and project co-investigator alongside Prof. 
William Fraser in all three studies. I performed samples analysis using the LC-MS/MS method 
described in Chapter 7 for measurements of 25(OH)D and 24,25(OH)2D54. Measurement of total 
1,25(OH)2D were performed using an enzyme immunoassay kit (IDS, Boldon, UK) according to 
the manufacturer instructions. 
 
8.2.1 Study 1 – A prospective, randomised, double-blinded, placebo-controlled study 
of single 100,000 IU bolus dose in healthy adults with vitamin D deficiency/insufficiency 
 
Study design 
 The clinical study was conducted at the University Hospital of Zurich, Switzerland 
(latitude 47°22′ N) (ClinicalTrials.gov Registry number NCT02022475) in accordance with the 
declaration of Helsinki and Good Clinical Practice guidelines; the study protocol was approved 
by the Zurich Cantonal Ethical Committee and Swissmedic. Informed consent was obtained from 
all participants before enrolment.  
Participants (n = 107) [age 20–50 years, body mass index (BMI) 18–25 kg/m2], who were 
identified at a screening visit with low vitamin D status (serum 25(OH)D3 <50 nmol/L, in 
accordance with the recommendation of the Institute of Medicine11), were randomised to receive 
either a single 100,000 IU oral dose of vitamin D3 (n = 52) or placebo (n = 55). Blood samples 
were obtained immediately before treatment and at four weeks after supplementation. All blood 
samples were collected into serum gel separator tube (BD Vacutainer) and centrifuged 
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immediately at 3,000 x g, serum layer was aliquoted into a separate polystyrene tube and stored 
at -80°C until analysis. All samples were anonymised to the researchers at the point of access. 
 
8.2.2 Study 2 – Prospective, randomised, 35,000 vs 70,000 IU/week over 12 weeks in 
elite athletes 
 
Study design 
 Elite male professional team sport athletes (n = 42) volunteered to participate in the study 
(mean ±SD; age 26±3 yr, height 1.86±0.6 m, weight 101.5±11 kg, fat mass 11.4%±3%). 
Participants underwent a medical screening and provided full informed consent before inclusion 
into the study. Volunteers who self-reported to be taking vitamin D supplements, using sunbeds, 
or injured at the time of the study were excluded from the study. Ethical approval was granted by 
the ethics committee of Liverpool John Moores University (Ethics code 12/SPS/047). The study 
was conducted at latitude 52°N during the winter months to limit sunlight exposure. 
 Participants were randomly allocated to either 35,000 or 70,000 IU per week supplement 
of vitamin D3 (Maxi Nutrition, UK). The supplemental doses chosen represent widely reported 
supplement strategies in elite sporting settings. Weekly supplements were taken orally as a bolus 
in capsule form, ingestion of capsules was monitored by the club staff to track compliance. 
Supplementation continued for 12 weeks at which point supplementation was ceased to monitor 
the response of vitamin D metabolites to withdrawal. Sunlight exposure was minimal during the 
trial because of the latitude at which the participants were based. Blood samples were collected 
before supplementation, at 6, 12, and 18 weeks (withdrawal). Blood was collected in serum gel 
separator tube (BD Vacutainer) and then separated by centrifugation at 3,000 x g for 15 min at 
4°C. Serum extracted was stored at -80°C until analysis. 
  
8.2.3 Study 3 - One year prospective 400 and 1000 IU/day in postmenopausal women 
 
Study design 
 The VICtORy (Vitamin D and cardiovascular risk) randomised controlled trial (RCT) 
was conducted at the University of Aberdeen, UK; ethical permission was obtained from 
Grampian ResearchEthics Committee (08/S0802/73), and the follow-up RECALL study was 
provided by North of Scotland Research Ethics Committee (12/NS/0013). All participants gave 
informed consent. 
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Participants (n = 287) were healthy, non-smoking postmenopausal women (mean±SD; age 
64.7±2.1 yr) residing in the northeast of Scotland (latitude 57°N). The women were randomised 
to receive either a daily dose of 400 IU, 1000 IU of vitamin D3 or placebo for 12 months. Blood 
samples were collected at 0, 2, 4, 6, 8, 10, 12 and 13 mth (withdrawal). The participants were 
invited for the RECALL visit at 2 and 3 years after the original study had ended. Those who took 
part (n = 159, mean±SD; age 67.6±2.3 yr) confirmed that they had not taken vitamin D 
supplements since the supplementation study concluded and did not take extended holidays 
abroad >1 month before the RECALL visits. Results of the VICtORy RCT showed no difference 
in markers of cardiovascular risk, inflammation, glucose tolerance (homeostatic model 
assessment) and blood pressure after one year between the two treatment groups164. 
 
8.2.3 Statistical analysis 
All statistical analyses and Box-whisker plots were constructed and analysed by GraphPad Prism 
7 (GraphPad, San Diego, CA, USA).  Frequency distribution histograms of the data were visually 
examined and checked for transcriptional, pre/post analytical errors before exclusion for statistical 
analysis. Outliers were identified as outside the 2.5% and 97.5% of the population and removed 
from statistical analysis. Non-parametric two-tailed t-test was used to determine the difference 
between groups. Statistical significance was defined as p <0.05. 
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8.3 Results 
Data analyses on 25(OH)D and 24,25(OH)2D were performed on the respective total (sum of D3 
+ D2) values. Immunoassay for 1,25(OH)2D cross-reacts 100% with 1,25(OH)2D3 but  under 
recovers 1,25(OH)2D2 at 39%. As none of the study samples was found to have significant 
25(OH)D2 and 24,25(OH)2D2 concentrations; effects from assay under-recovery was deemed 
negligible. 
 
8.3.1 Study 1 
 Vitamin D metabolites concentrations at baseline and 4 weeks after treatment with 
placebo (n = 52) or a single oral dose of 100,000 IU vitamin D3 (n = 55) are presented in Figure 
8.2. Increase in serum concentrations of vitamin D metabolites at week 4 in the supplement group 
was highly significant (p<0.001). The majority of participants in both groups began with vitamin 
D deficient/insufficient status (25(OH)D <50 nmol/L). Those received a single dose of 100,000IU 
had achieved 25(OH)D >50 nmol/L after 4 weeks; whereas no significant changes were observed 
in the placebo group (Fig 8.2a). The response to high dose vitamin D3 in the supplement group 
resulted in an average 2.4-fold increase in 25(OH)D (mean±SD; 33.4 ±11.7 to 80.2 ±20.8 nmol/L) 
and 24,25(OH)2D concentrations (mean±SD; 2.4 ±1.0 to 6.9 ±2.0 nmol/L)(Fig. 8.2b), and a 1.3-
fold increase in 1,25(OH)2D (mean±SD; 99.1 ±27.4 to 125.1 ±42.2 pmol/L) (Fig. 8.2c) compared 
to baseline. Of those participants received the high dose treatment, 21% had elevated 1,25(OH)2D 
above the upper reference interval of 150 pmol/L. Although 25(OH)D and 24,25(OH)2D showed 
a similar average increase, the 25(OH)D:24,25(OH)2D VMR in the supplement group showed a 
significant decrease (mean±SD; 15 ±3 to 12 ±3, p<0.001) (Fig. 8.2d), suggesting the increase in 
serum 24,25(OH)2D is relatively higher than 25(OH)D. 
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Figure 8.2 Serum concentrations of a) 25(OH)D, b) 24,25(OH)2D, c) 1,25(OH)2D, and d) 
25(OH)D:24,25(OH)2D VMR, at baseline and 4 weeks after a single 100,000 IU oral dose of 
vitamin D3 or placebo. Box and whiskers represent the median, interquartile range and 95% 
population intervals. Dotted lines represent a) b) the equivalent vitamin D insufficiency 
thresholds, c) d) the lower and upper reference intervals. ***denotes significance at the p<0.001 
level compared with baseline. 
 
8.3.2 Study 2 
 Vitamin D metabolite concentrations during the 18-week study are presented in Figure 
8.3. Participants in both treatment groups (35,000 IU/wk, n = 22) or (70,000 IU/wk, n = 19) began 
with sufficient vitamin D status (25(OH)D mean±SD, 86.0 ±19.2) at baseline (pre-treatment). 
Serum concentrations of 25(OH)D and 24,25(OH)2D increased progressively during the 12-week 
treatment phase by an average 1.3-fold at week 6 and 2.1-fold at week 12 compared to baseline 
(p <0.001) (Fig. 8.3 a-b). At week 18, six weeks after the last treatment, 25(OH)D concentrations 
decreased to the levels observed in week 6. In contrast, 24,25(OH)2D concentrations in both 
treatment groups did not show significant reduction after the withdrawal. 1,25(OH)2D (Fig. 8.3c) 
showed significant increase in concentration that peaked at week 6 for the 35,000 IU/wk group 
(mean±SD; baseline 88.7 ±44.2 to peak 141.3 ±57.8 pmol/L) and at week 12 for the 70,000 IU/wk 
group (mean±SD; baseline 104.8 ±35.9 to peak 141.6 ±51.6 pmol/L). By week 18, 1,25(OH)2D 
concentrations in both groups returned to baseline. Of those participants received the 35,000 
IU/wk treatment, 33.3% had elevated 1,25(OH)2D above the upper reference interval; 47.1% in 
the 70,000 IU/wk treatment group. 
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At baseline, the 25(OH)D:24,25(OH)2D VMR (Fig. 8.3d) in both groups began in the lower 
quartile of the reference interval (between 7-23), suggesting a pre-existed activation of 
24,25(OH)2D production. At week 6, the ratio remained unchanged in the 35,000 IU/wk group 
whereas a significant reduction in the 70,000 IU/wk treatment group was observed; evident of a 
further increase in 24,25(OH)2D production. At week 12, the 25(OH)D:24,25(OH)2D VMR in 
both group showed a contradictory increase, suggesting the production of 24,25(OH)2D had 
reached the limit of saturation. Once the supplement was withdrawn, the rapidly declining 
25(OH)D but continuously elevated 24,25(OH)2D resulted in a suppressed 
25(OH)D:24,25(OH)2D VMR that was significantly lower at week 18 than baseline in both 
treatment groups.  
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Figure 8.3 Serum concentrations of a) 25(OH)D, b) 24,25(OH)2D, c) 1,25(OH)2D, and d) 
25(OH)D:24,25(OH)2D VMR with treatment of either 35,000 or 70,000 IU/week from baseline 
to 12 weeks. Supplementation was stopped after week 12 in both groups. Box and whiskers 
represent the median, interquartile range and 95% population intervals. Dotted lines in 8.3(a-b) 
represent the equivalent vitamin D insufficiency thresholds, in 8.3(c-d) represent the lower and 
upper reference intervals. *denotes significance digits for p-value at 0.05(*), 0.002(**), <0.001 
(***) compared with baseline. No significant changes in 24,25(OH)2D were observed in both 
groups between week 12 (before final dose) and 18 (6 weeks post dose), as depicted by the dashed 
bracket in 8.3b. 
 
 
8.3.1 Study 3 
 In the VICtORy RCT, 265 of the 287 women (placebo n = 90, 400 IU/day n = 85, 1000 
IU/day n = 90) completed the 12-months supplemental phase, followed by a one-month 
withdrawal of treatment. Of the 265 women, 159 from each group (placebo n = 52, 400 IU n = 
49, 1000 IU n = 58) attended the RECALL visits at 37 and 49 months. The vitamin D metabolites 
concentrations throughout the VICtORy and RECALL visits are presented in Figure 8.4. At the 
start of the study (January), all the women had insufficient vitamin D status (25(OH)D mean±SD; 
43.6 ±21.1). Serum concentrations of 25(OH)D and 24,25(OH)2D increased steadily in the first 
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six months of treatment, to reach peak 25(OH)D (mean±SD; placebo 65.2 ±19.4, 400 IU 82.7 
±18.5, 1000 IU 89.8 ±20.9); and 24,25(OH)2D (mean±SD; placebo 4.7 ±2.0, 400 IU 6.1 ±1.6, 
1000 IU 7.7 ±2.2) (Fig. 8.4a-b). The increase in daylight hours from January to June contributed 
to the rise in 25(OH)D in all groups, with a greater increase observed in those received the active 
treatment than placebo. Serum concentrations of 25(OH)D and 24,25(OH)2D in the 400 IU and 
1000 IU groups had remained in a consistent state throughout month 8-12; whereas the placebo 
group saw a progressive decline back to baseline level. In the RECALL visits, 2 and 3 years post 
withdrawal of treatment, 25(OH)D and 24,25(OH)2D in all groups had returned to the baseline 
levels.  
Comparing between the 400 IU and 1000 IU groups, while there was no significant difference in 
the increase in 25(OH)D during the supplemental phase, there was a distinct difference in 
24,25(OH)2D concentrations. The 25(OH)D:24,25(OH)2D VMR plot (Fig. 8.4c) showed greater 
depression in the 1000 IU than 400 IU group; the data demonstrated that 400 IU/day dosing 
regime achieved similar serum 25(OH)D concentration as in the 1000 IU/day, but without 
stimulating 24,25(OH)2D production to the same extent. Serum 1,25(OH)2D concentrations 
across the time points were consistent; no significant changes were detected (Fig. 8.4d). 
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Figure 8.4 Serum concentrations of a) 25(OH)D, b) 24,25(OH)2D, and c) 
25(OH)D:24,25(OH)2D VMR, and d) 1,25(OH)2D at 0, 2, 4, 6, 8, 10, 12 mths(treatment phase), 
13 mth(withdrawal), 37 and 49 mths(RECALL). Participants received treatment of either placebo, 
400 or 1000 IU/day of vitamin D3 from baseline (January) for 12 months. Treatment terminated 
after month 12. Points on graphs represent mean serum concentration, and error bars represent 
95% confidence intervals. 
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Study 
Dosing 
regimen 
Mean percentage change from baseline to peak concentration 
25(OH)D 24,25(OH)2D 1,25(OH)2D 
25(OH)D: 
24,25(OH)
2
D VMR 
1 
Single 
100,000 IU 
+140 % +191.9 % +26.2% -19.3 % 
2 
35,000 
IU/week 
+88.3 % +41.4 % +59.3% -18.6 % 
70,000 
IU/week 
+118 % +134.6 % +35.1% -29.4 % 
3 
400 IU/day +84.6 % +6.6 % +5.1 % -10 % 
1000 IU/day +108.5 % +8.0 % +1.5 % -19.4 % 
 
Table 8.1 Summary of the percentage change in vitamin D metabolites and ratio from 
baseline to peak concentration in the studies. 
 
8.4 Discussion and conclusion 
 Dose and timing are two important factors to consider for vitamin D supplementation. 
Evidence in the literature to support effective vitamin D replacement therapy is inconsistent and 
continue to be a subject of debate. The three vitamin D supplementation studies described in this 
chapter demonstrate the effects of dosing modality on the three major circulating vitamin D 
metabolites. It also demonstrated the use of 25(OH)D:24,25(OH)2D VMR to obtain additional 
information on the efficacy of treatments that is not obvious when using absolute concentrations. 
 Daily administration of low dose vitamin D3 is a physiologically gentle approach to 
correct vitamin D deficiency. Participants in study 3 who received the active low dose treatments 
achieved vitamin D repletion without over stimulation of serum 24,25(OH)2D and 1,25(OH)2D 
(Table. 8.1). However, both daily 400 IU and 1000 IU regimens took six months to reach 
maximum concentration at steady state. In contrast, a single high dose of 100,000 IU of vitamin 
D3 in study 1 achieved similar 25(OH)D concentrations as in study 3 after four weeks. Single 
bolus administration has the advantage of better patient compliance with the treatment, but 
findings from study 1 showed high dose of vitamin D3 supplementation resulted in grossly 
elevated serum 24,25(OH)2D (+192% from baseline) and 1,25(OH)2D (+26.2% from baseline). 
The finding is evident that 24,25(OH)2D excretory pathway is ‘switched on’ by CYP24A1 to 
divert excess 25(OH)D to waste in order to prevent overproduction of 1,25(OH)2D. Such 
mechanism can be observed in study 2; where weekly high dose treatment on vitamin D replete 
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subjects had provoked a surge in 24,25(OH)2D and 1,25(OH)2D concentrations. In comparison 
with the single dose treatment study 1,  the continuous weekly treatment regimen in study 2 
showed a greater increase in 1,25(OH)2D (up to +59.3% from baseline). The notable lack of 
proportional response in 24,25(OH)2D by week 12 (Fig. 8.3b) suggests the excretory pathway had 
reached the breaking point of saturation, thus unable to stop the further increase in 1,25(OH)2D 
observed. More concerning is the profound elevation of 24,25(OH)2D had remained high six 
weeks after the withdrawal of treatment; where 25(OH)D and 1,25(OH)2D concentrations had 
receded to baseline levels, but 24,25(OH)2D showed no significant decrease beyond the expectant 
half-life of 7.5 days165. Such phenomenon suggests the counteracting measures for vitamin D 
toxicity had remained stimulated to protect against lateral effects from the aftermath of vitamin 
D overexposure. This mechanism appears to prevent toxicity was less evident in low and regular 
dosage of vitamin D in study 3. 
 There was no adverse event of vitamin D toxicity reported in all three studies, likely 
because the participants were recruited from healthy populations. Ultra-high doses of vitamin D 
administered annually or monthly had shown to be associated with increased incidents of falls 
and fractures in the older population14,15. Although higher doses of vitamin D supplement were 
more effective in reaching 25(OH)D concentration of 50 nmol/L, the greater risk of falls and 
fractures suggests the correlation of risks vs benefit effects of vitamin D exhibit a U-shaped curve, 
rather than a J-shaped curve. Based on the findings described in this chapter, and observations 
from literature, the best approach would be a loading dose followed by a daily maintenance dose, 
chosen based on the characteristics of the patient, in combination with baseline profile of vitamin 
D metabolite/ratio measurements. Such an approach represents an effort to define a tailored 
treatment to vitamin D replacement therapy. Vitamin D therapy should be optimised base on 
individual differences in serum vitamin D metabolite concentrations to give the best response. 
Blanket high-dose approaches to supplementation should be avoided. Future research should aim 
to establish the appropriate dose and frequency of administration to achieve a positive increase in 
both 25(OH)D and 1,25(OH)2D while limiting the increase in 24,25(OH)2D concentrations. 
In conclusion, increasing vitamin D supplementation results in an increase in metabolites, but 
relative difference in the production of 24,25(OH)2D and 1,25(OH)2D was observed with the 
modality of treatment. The results indicate that, in high supplementation of vitamin D, the 
metabolism favours the production of 24,25(OH)2D rather than 1,25(OH)2D to prevent toxicity. 
Such mechanism to prevent toxicity was less evident in low and regular dosage of vitamin D. 
Caution is advised when using extremely high supplementation levels can be detrimental to the 
patients. The use of vitamin D metabolite ratio can provide insight that may begin to explain the 
lack of optimal response to increasing supplementation with vitamin D.  
124 
 
Chapter 9 The dynamic relationships between the 
active and catabolic vitamin D metabolites, their ratios, 
and associations with PTH 
 
9.1 Background 
The vitamin D pathway is a dynamic system, and its functional role in bone health and other 
diseases is the subject of intense research. Associations of vitamin D deficiency with a broad 
spectrum of disease states have drawn attention from the scientific community and increasing 
awareness of the general population. Despite vitamin D deficiency being a global public health 
concern, the approach through improving vitamin D status by supplementation, dietary intake and 
increased sunlight exposure, has resulted in mixed outcomes152,166,167. The contradictory evidence 
has prompted studies on the metabolites of vitamin D. The most abundant metabolite in 
circulation is 25-hydroxyvitamin D (25(OH)D), which exists in two major forms: 25-
hydroxycholecalciferol (25(OH)D3) and 25-hydroxyergocalciferol (25(OH)D2). Measurement of 
serum total 25(OH)D (D3+D2) is the barometer of vitamin D status; concentrations ≤30 nmol/L 
and between 30-50 nmol/L are defined as deficient and insufficient, respectively by the U.S 
Institute of Medicine (IOM)11. 1,25-dihydroxyvitamin D (1,25(OH)2D) is synthesised by the 
hydroxylation of 25(OH)D through the actions of 1α-hydroxylase produced in the renal tubules. 
1,25(OH)2D is the most biologically active form of vitamin D and circulates in pmol/L 
concentration; it controls intestinal absorption of calcium and phosphate, stimulates osteoclast 
activity, and helps regulate the release of parathyroid hormone (PTH). Although 1,25(OH)2D is 
derived from 25(OH)D, there is no direct correlation in serum concentrations between the two 
vitamin D metabolites except in patients with chronic kidney disease (CKD)28, where a greater 
association is observed between 1,25(OH)2D and 25(OH)D, dependent upon the severity of the 
renal impairment. The lack of a direct relationship, despite their close proximity in the metabolic 
pathway, is due to the tight regulation of the hydroxylation enzymes expressed by the actions of 
CYP27B1 and CYP24A1. CYP24A1 produces 24-hydroxylase that converts 25(OH)D into 
24,25-dihydroxyvitamin D (24,25(OH)2D). The transcription of the CYP24A1 gene is stimulated 
by the phosphate-regulating hormone fibroblast growth factor-23 (FGF23), and when PTH is 
suppressed. The combination increases serum 24,25(OH)2D. In Chapter 7 (ch. 7.3.6) first 
described a concentration-dependent relationship between serum 25(OH)D and 24,25(OH)2D54. 
In Chapter 7.3.7 reported a patient, presenting with idiopathic infantile hypercalcaemia (IIH), who 
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was diagnosed with biallelic CYP24A1 mutations resulting in the inability to produce 
24,25(OH)2D from 25(OH)D, and had an elevated serum 1,25(OH)2D and a persistent state of 
hypercalcaemia. The use of 25(OH)D:24,25(OH)2D vitamin D metabolite ratio (VMR) can be a 
valuable tool in identifying such pathological conditions resulting from impaired CYP24A1 
function43,55. The use of VMR in the population can provide an assessment of the vitamin D 
catabolic status; thus allowing a targeted approach to vitamin D supplementation168. 
This chapter describes a novel approach to the interpretation of serum 25(OH)D and  1,25(OH)2D 
concentrations that incorporate 24,25(OH)2D values. Using data from a large cohort of healthy 
young adults as the reference population to provide evidence on the intricate relationships 
between active and catabolic forms of vitamin D metabolites, and the influence on PTH. 
 
9.2 Materials and methods 
 
The following study carried out between 2013-2018 was led by Prof. Julie Greeves OBE 
(Directorate of Manning (UK Ministry of Defence), Dr Sarah Jackson (Army Medical 
Directorate), Prof. William Fraser (University of East Anglia), and Prof Neil Walsh (Bangor 
University). I was a named contributor and project co-investigator in the study, and  I performed 
sample and data analysis using methods as described below. 
 
9.2.1 Study design 
The study received ethics approval from the UK Ministry of Defence Research Ethics Committee 
and was conducted in accordance with the Declaration of Helsinki (2013). The characteristics of 
the subjects included in the study are shown in Table 9.1. In total, 2252 new British Army recruits 
at the start of phase one training volunteered for the study. Written informed consent was obtained 
from all study participants, and each required to complete a detailed health questionnaire, 
including medical history and the use of supplements. All recruits undertook physical and 
cognitive testing, and a detailed medical examination before joining the army. The British Army 
entry requirements restrict individuals with chronic medical conditions; therefore, this study 
population represents a medically screened, disease-free, and physically fit population. In the 
analysis, individuals who reported the use of calcium and vitamin D supplements (including 
multivitamins and cod liver oil) were excluded from statistical analysis. Also excluded were 
participants who reported injury and illness before recruitment; conditions such as being 
underweight, eating disorders, or those with a history of bone fracture. 940 participants were 
included in the final statistical analyses. The majority of participants were from a Caucasian 
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population (92.9%), with a minority from a diverse ethnicity (Asian 1.6%, Black 1.7%, Chinese 
0.1%, mixed 3%, others 0.7%). 
 
 Male Female 
n 652 288 
Mean age, years (range) 21.7 (18-32) 22.1 (18-32) 
Height, m 1.77 (6.4) 1.66 (5.9) 
body mass, kg 75.9 (9.8) 64.7 (7.5) 
Body mass index (BMI) 24.1 (2.6) 23.4 (3.3) 
Total body BMD (g/cm2) 1.24 (0.10) 1.16 (0.09) 
*Data shown in mean ±SD otherwise stated 
 
Table 9.1 Baseline characteristics of the subjects included in the study. 
 
9.2.2 Sample collection 
Blood samples were collected during June 2014 to March 2016. Venous blood samples were 
obtained from the participants at the start of 14-week long basic military training. Sample 
collections were scheduled on a monthly basis to balance the seasonal variations. Each intake 
comprised, on average (range), 86 (43-120) participants. Blood samples were collected into serum 
gel separator tube and EDTA plasma container (BD Vacutainer). Samples were centrifuged 
immediately after collection at 3,000x g for 10 minutes. Plasma/serum layers were aliquoted into 
a separate polystyrene tube and stored at -20°C until analysis. All samples were anonymised to 
the researchers at the point of access. 
 
9.2.3 Ethical approval 
The study was approved by the UK Ministry of Defence research ethics committee (MODREC 
165/Gen/10 and 692/MoDREC/15). ClinicalTrials.gov Identifier NCT02416895. 
 
9.2.4 LC-MS/MS measurements of serum 25(OH)D and 24,25(OH)2D 
Liquid chromatography tandem mass spectrometry (LC-MS/MS) was performed as 
described54,161,162,169. The method quantified 25(OH)D3, 25(OH)D2, 24,25(OH)2D3 and 
24,25(OH)2D2 simultaneously from a single injection. 25(OH)D3 and 25(OH)D2 were calibrated 
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using commercial standards (Chromsystems, München, Germany)  traceable to standard reference 
material SRM972a from the National Institute of Science and Technology (NIST)77,79, and 
showed linearity between 0-200 nmol/L.  The inter/intra-assay coefficient of variation (CV) was 
≤9%, the lower limit of quantification (LLoQ) of 0.1 nmol/L. The assay showed <8% accuracy 
bias against NIST reference method on the Vitamin D external quality assessment (DEQAS) 
scheme. 24,25(OH)2D3 and 24,25(OH)2D2 were calibrated using in-house spiked standards 
traceable to NIST SRM972a. The assay is linear between 0-25 nmol/L; inter/intra-assay CV was 
≤11%, LLoQ of 0.1 nmol/L for 24,25(OH)2D3 and 0.8 nmol/L for 24,25(OH)2D2. 
 
9.2.5 Measurements of serum 1,25(OH)2D 
The DiaSorin LIAISON® XL 1,25(OH)2D chemiluminescent immunoassay (Stillwater, MN, 
USA) method was used. The sandwich assay utilises a recombinant fusion protein for the capture 
of 1,25(OH)2D molecule and a murine monoclonal antibody detection system. The assay 
measures total 1,25(OH)2D between 12-480 pmol/L, the inter/intra-assay CV was ≤9.2%. The 
mean assay recovery was 94±2%. On the Vitamin D external quality assessment (DEQAS) 
scheme, the assay showed ≤8.5% bias against method-specific mean and ≤9.1% bias against all 
method mean. 
 
9.2.6 Biochemical analysis 
Intact PTH and albumin-adjusted calcium (ACa) were analysed on the COBAS® (Roche 
Diagnostics, Mannheim, Germany) platform. PTH in EDTA plasma was measured using 
electrochemiluminescence immunoassay (ECLIA), the inter-assay CV was ≤3.8% across the 
analytical range of 1.2-5000 pg/mL. Total calcium and albumin were measured based on 
spectrophotometric methods. The inter-assay CV for Ca was ≤1.6%, albumin was ≤1.1%. ACa 
value is calculated using the equation 𝐴𝐶𝑎 = (−0.8 × [𝐴𝑙𝑏𝑢𝑚𝑖𝑛] − 4) + [𝑇𝑜𝑡𝑎𝑙 𝐶𝑎]. 
 
9.2.7 Statistical analysis 
Descriptive statistics, scatterplots, ROC and LOWESS curves were constructed and analysed by 
Statistical Package for the Social Science (SPSS) version 22.0.0.1 (IBM, New York, USA) and 
GraphPad Prism 8 (GraphPad, San Diego, CA, USA). Univariate and multivariable linear 
regression analyses and one-way ANOVA were used to estimate associations. LOWESS curve 
fitting was used to explore nonlinear relationships between variables. Kruskal-Wallis independent 
analysis and Spearman’s rho were used to establish associations in non-parametric variables. 
Statistical significance was defined as p <0.05.  Frequency distribution histograms of the data 
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were visually examined and checked for transcriptional and pre/post analytical errors before 
exclusion for statistical analysis. Confidence interval (CI) was established at 95% of the 
population. Circannual rhythm analysis was performed by population-mean cosinor analysis, 
based on cosinor-fitting equation 𝑦 = MESOR + Amplitude × cos(Frequency(𝑥) +
acrophase). Midline estimate statistic of rhythm (MESOR), defined as the rhythm-adjusted mean 
value. Acrophase is the difference (time) between MESOR and peak value in the cosine curve. 
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9.3 Results 
Results from 940 participants were included in the data analysis. Statistical analyses on 25(OH)D 
and 24,25(OH)2D were performed on the respective total (sum of D3 + D2) values, the 
distributions were untrimmed, and no outlier was removed. Summary of the distribution of 
biochemical profile is shown in Table 9.2. 25(OH)D2 was found in 57.8% of the subjects, mean 
(range) of 4.2 nmol/L (0.6-29.1). 24,25(OH)2D2 was found in 0.4% of the subjects, mean (range) 
1.5 nmol/L (1.2-1.8). 
 
Profile mean SD Min 
2.5th  
Percentile 
25th 
Percentile 
Median 
75th 
Percentile 
97.5th 
Percentile 
Max 
25(OH)D, 
nmol/L 
62.4 29.8 6.9 18.1 39.8 59.2 81.0 130.9 222.5 
24,25(OH)2D, 
nmol/L 
5.4 3.3 0.5 1.0 2.9 4.9 7.4 13.0 29.6 
1,25(OH)2D, 
pmol/L 
138.8 39.6 32.3 71.9 111.0 135 161.0 229.7 380.0 
25(OH)D:24,2
5(OH)2D 
VMR 
13 4 2 7 10 12 15 25 39 
1,25(OH)2D:2
4,25(OH)2D 
VMR 
38 33 5 9 18 28 45 132 300 
Intact PTH, 
pmol/L 
3.7 1.2 1.0 1.9 2.9 3.5 4.3 6.8 11.4 
ACa, mmol/L 2.38 0.07 2.00 2.20 2.32 2.40 2.41 2.50 2.60 
 
Table 9.2 Distribution of biochemical measurements performed in the study. 
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9.3.1 24,25(OH)2D and 25(OH)D 
 
The mean concentration of 24,25(OH)2D was on average 9.5-fold lower than 25(OH)D. Linear 
regression analysis (Fig. 9.1a) showed a directly proportional relationship between 24,25(OH)2D 
and 25(OH)D concentrations: [24,25(OH)2D] = 0.0946 × [25(OH)D] − 0.42; 𝑟
2 = 0.7206. 
Using this equation, the derived serum 24,25(OH)2D concentration of ≥4.3 nmol/L is equivalent 
to the IOM vitamin D replete status (i.e. 25(OH)D of 50 nmol/L), and 24,25(OH)2D concentration 
of ≤2.4 nmol/L is equivalent to deficiency status (i.e. 25(OH)D of ≤30 nmol/L). 
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Figure 9.1a-d  Non-parametric correlations of (a) 24,25(OH)2D (b) 1,25(OH)2D (c) 
25(OH)D:24,25(OH)2D VMR and (d) 1,25(OH)2D:24,25(OH)2D VMR, against their respective 
25(OH)D concentration. Solid lines in (a) and (b) represent linear regression line. LOWESS fitted 
curve in (c) and (d) (99% point fit). The mean 24,25(OH)2D and 1,25(OH)2D concentrations, 
25(OH)D:24,25(OH)2D VMR and 1,25(OH)2D:24,25(OH)2D VMR represent 8.7%, 222.4%, 
20.8% and 60.9% of their respective 25(OH)D concentration. Assay lower limit of quantification 
(LLoQ): 25(OH)D and 24,25(OH)2D=0.1 nmol/L, 1,25(OH)2D=12 pmol/L. 
 
9.3.2 1,25(OH)2D and 25(OH)D 
Despite a direct enzymatic conversion of 25(OH)D to 1,25(OH)2D, there was no significant 
correlation in serum concentrations between these two vitamin D metabolites (Fig. 9.1b). This 
finding is consistent with published studies; 1,25(OH)2D can directly inhibit the expression of 1α-
hydroxylase, and indirectly inhibit by suppressing PTH and stimulating FGF23 production170,171. 
This negative feedback system provides an essential safeguard mechanism against 
hypercalcaemia. Hence 1,25(OH)2D concentration is unaffected by the circulatory concentration 
of 25(OH)D. 
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9.3.3 25(OH)D:24,25(OH)2D VMR and vitamin D status 
The 25(OH)D:24,25(OH)2D VMR showed an indirect relationship with 25(OH)D (Fig. 9.1c); 
LOWESS fitting showed a steady increase in 25(OH)D:24,25(OH)2D VMR with the decline in 
25(OH)D concentration. One-way ANOVA showed a significant increase in 
25(OH)D:24,25(OH)2D VMR (p>0.001) at 25(OH)D below 50 nmol/L (Fig. 9.2). The greatest 
increase was observed when 25(OH)D concentration decreased below ≤30 nmol/L.  The decrease 
in relative production of serum 24,25(OH)2D in response to the decline in 25(OH)D suggests 
down-regulation of CYP24A1. 
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Figure 9.2 Distribution of 25(OH)D:24,25(OH)2D VMR by 25(OH)D intervals. Each 
interval contains an equal number of subjects to illustrate the significantly elevated ratio in those 
with serum 25(OH)D ≤50 nmol/L. Box and whiskers represent the median, interquartile range 
and 95% population intervals. 
 
9.3.4 1,25(OH)2D:24,25(OH)2D VMR and vitamin D status 
Vitamin D status, as indicated by 25(OH)D concentrations, revealed an exponential negative 
correlation (r2Exp=0.582) with 1,25(OH)2D:24,25(OH)2D VMR (Fig. 9.1d). Post hoc analysis 
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identified a significant increase in 1,25(OH)2D:24,25(OH)2D VMR at 25(OH)D ≤60 nmol/L (Fig. 
9.3). Using the Jacobson and Truax150,151 method to determine the cut-off value for clinically 
significant change54, 1,25(OH)2D:24,25(OH)2D VMR of ≥35 was estimated to be the predictive 
threshold value for vitamin D insufficiency, and ≥51 to be the predictive threshold for vitamin D 
deficiency. The threshold values were determined from subject samples collected in the winter 
months (January to April) due to the seasonal variation of 25(OH)D. Receiver Operating 
Characteristic (ROC) curves generated from data collected between January to April produced 
area under the curve (AUC) values of 0.88 and 0.86, indicating the VMR cut-offs are excellent at 
discriminating individuals with vitamin D insufficiency and deficiency. The 
1,25(OH)2D:24,25(OH)2D VMR at 35 and 51 achieved true positive rate (sensitivity) at 80% and 
78%, respectively, and false positive rate (specificity) of 82% and 74%, respectively. (Fig. 9.4a 
and b). 
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Figure 9.3 Distribution of 1,25(OH)2D:24,25(OH)2D VMR by 25(OH)D intervals. It 
demonstrates the exponential increase in 1,25(OH)2D:24,25(OH)2D VMR with the decrease in 
serum 25(OH)D. Box and whiskers represent the median, interquartile range and 95% population 
intervals. Each interval contains an equal number of subjects. 
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a)  
b)  
Figure 9.4a-b  Diagnostic performance of 1,25(OH)2D:24,25(OH)2D VMR in the 
assessment of vitamin D status during winter months (Jan-April) (n = 402). Receiver Operating 
Characteristic (ROC) curve depicts diagnostic sensitivity and specificity levels. (O) represents 
decision threshold for (a) vitamin D replete (i.e. 25(OH)D ≥50 nmol/L), 
1,25(OH)2D:24,25(OH)2D VMR threshold value of 35 (sensitivity = 80%, specificity = 78%), (b) 
vitamin D insufficiency (i.e. 25(OH)D ≥30 nmol/L), 1,25(OH)2D:24,25(OH)2D VMR threshold  
value of 51 (sensitivity = 82%, specificity = 74%). The diagonal lines represent the line of no 
discrimination. 
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9.3.5 1,25(OH)2D:24,25(OH)2D VMR and PTH 
Circulating PTH is influenced by 25(OH)D and 1,25(OH)2D, and vice versa. Based on this 
assumption, a hypothesis was made that PTH concentration changes with 
1,25(OH)2D:24,25(OH)2D VMR and 25(OH)D. To test the hypothesis, median PTH 
concentrations were established from grid analysis based on groupings of 
1,25(OH)2D:24,25(OH)2D VMR and 25(OH)D in ascending order (Table 9.3). A decrease in PTH 
concentration was observed from the high 1,25(OH)2D:24,25(OH)2D VMR (100+) and low 
25(OH)D (<30 nmol/L) group, to the low 1,25(OH)2D:24,25(OH)2D VMR (<30) and high 
25(OH)D (100+ nmol/L) group. Using Kruskal-Wallis independent non-parametric analysis to 
test the distribution of PTH across all groups, a highly significant (p>0.001) change in PTH 
concentration was found across the 1,25(OH)2D:24,25(OH)2D VMR and 25(OH)D categories, 
hence the null hypothesis was rejected. Using Spearman's rank correlation coefficient (2-tailed) 
to assess monotonic functions between variables, significant positive correlations were evident 
between VMRs and PTH (1,25(OH)2D:24,25(OH)2D VMR rho = 0.249, p>0.001 and 
25(OH)D:24,25(OH)2D VMR rho = 0.134, p>0.001); whereas vitamin D metabolites showed 
significant negative correlations with PTH (25(OH)D rho = -0.287, p>0.001, 24,25(OH)2D rho = 
-0.282, p>0.001 and 1,25(OH)2D rho = -0.87, p>0.001). The statistical significance remained 
unchanged after adjustment for BMD and BMI as covariates. 
 
Median PTH, pmol/L 
25(OH)D, nmol/L 
<30 30-50 51-100 100+ 
1,25(OH)2D:24,25-
(OH)2D VMR 
100+ 5.7 (0.2)* 5.4 (0.5)* - - 
51-100 4.3 (0.2)* 3.8 (0.2) 3.4 (0.3) - 
30-50 4.0 (0.2)* 3.7 (0.1) 3.5 (0.1) 2.7 (0.2)* 
<30 3.8 (0.3) 3.9 (0.1) 3.3 (0.1)* 3.2 (0.1)* 
*denotes significance at the p<0.05 level. 
 
 
Table 9.3 Median (SEM) PTH concentrations in categories of increasing 
1,25(OH)2D:24,25(OH)2D VMR and 25(OH)D. One-way ANOVA showed PTH concentrations 
decreased significantly (p>0.001) from high 1,25(OH)2D:24,25(OH)2D VMR/low 25(OH)D to 
low 1,25(OH)2D:24,25(OH)2D VMR/high 25(OH)D. 
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9.3.5 Circannual variations in vitamin D metabolites and VMRs 
Cosinor-fit curves (Fig. 9.5a-f) show significant circannual rhythm for 25(OH)D (p<0.001), 
24,25(OH)2D (p<0.01),  25(OH)D:24,25(OH)2D VMR (p<0.001), 1,25(OH)2D:24,25(OH)2D 
VMR (p<0.001) and PTH (p<0.05). No significant rhythm was observed for 1,25(OH)2D 
(p=3.125). The rhythm observed for 25(OH)D is consistent with previous reports172,173. 
24,25(OH)2D showed a similar peak (July-Aug) and nadir (Jan-Mar) pattern as for 25(OH)D. 
25(OH)D:24,25(OH)2D VMR and 1,25(OH)2D:24,25(OH)2D VMR exhibited patterns in the 
opposite direction, with peak (Mar-April) and nadir (Aug-Sept) suggesting that the production of 
24,25(OH)2D is relatively higher during summer/early autumn months. Acrophase, defined as the 
lag time between rhythm-adjusted mean and peak cycle value, was on average (SD) of 8.1(0.3) 
months for all vitamin D metabolites except for 1,25(OH)2D. A low amplitude, circasemiannual 
PTH secretory rhythm was observed, with an acrophase of 3.5 months. 
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Figure 9.5a-f  Cosinor-fit circannual rhythm for a) 25(OH)D, b) 24,25(OH)2D, c) 
1,25(OH)2D, d) 25(OH)D:24,25(OH)2D, e) 1,25(OH)2D:24,25(OH)2D, f) PTH. Error bars 
represent 95% CI. 
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8.4 Discussion and conclusion 
This study is the first to demonstrate a relationship between serum concentrations of 25(OH)D 
and 1,25(OH)2D when expressed as a relative ratio with serum 24,25(OH)2D. The findings 
provide evidence that the conversion of 25(OH)D to 1,25(OH)2D is associated with the catabolism 
of 25(OH)D to 24,25(OH)2D, which can be assessed by the measurement of serum 24,25(OH)2D 
and its derived VMR.  
The inverse exponential correlation between 1,25(OH)2D:24,25(OH)2D VMR and 25(OH)D 
provides insight into the dynamics of vitamin D metabolites in healthy, young adults; when 
vitamin D status is sufficient, serum concentrations of 1,25(OH)2D and 24,25(OH)2D are 
maintained in relative proportion and showed no significant change beyond the sufficient 
threshold. In contrast, when vitamin D status is insufficient, a progressive and highly significant 
increase in 1,25(OH)2D:24,25(OH)2D VMR is evidence that the production of serum 1,25(OH)2D 
is favoured over 24,25(OH)2D as the availability of vitamin D precursors in circulation 
diminishes. The data imply two possible regulatory functions of the 24,25(OH)2D pathway; in 
hypervitaminosis, the pathway is ‘switched on’ to allow excess 25(OH)D to be converted to 
24,25(OH)2D. The 24-hydroxylase pathway results in the formation of calcitroic acid for 
excretion. In hypovitaminosis, the 24,25(OH)2D pathway is partially inactivated to conserve 
25(OH)D and to maintain an adequate supply of substrate for conversion to 1,25(OH)2D. 
Although the biological activity of 24,25(OH)2D is yet to be fully elucidated, its role in vitamin 
D catabolism appears certain. Low serum concentrations of 24,25(OH)2D and elevated 
25(OH)D:24,25(OH)2D VMR is useful in identifying patients with loss-of-function CYP24A1 
mutations42,43,55. Chapter 7 described a case of biallelic CYP24A1 mutation in a patient presenting 
with hypercalcaemia, elevated serum 1,25(OH)2D concentration (293 pmol/L, reference range 43-
144 pmol/L), and elevated 25(OH)D:24,25(OH)2D VMR of 32. On diagnosis, the patient’s 
1,25(OH)2D:24,25(OH)2D VMR was 212 (1.6 times the upper 97.5th percentile of 132), which 
was attributed to supplementation with vitamin D. One month after treatment for hypercalcaemia 
and cessation of vitamin D supplement, serum 1,25(OH)2D was within the reference range, the 
1,25(OH)2D:24,25(OH)2D VMR decreased to 130 (below the 97th percentile), and the 
25(OH)D:24,25(OH)2D VMR remained elevated at 35. 
A major finding of this study was the link between vitamin D metabolites and VMRs with the 
distribution of PTH. To the best of the author’s knowledge, this is the first such report in a human 
population study. It is widely accepted that the PTH concentration is associated with 25(OH)D, 
but not with the active 1,25(OH)2D. This is due to the tight regulatory mechanisms, and the 
regulatory processes that take place via the vitamin D receptor (VDR) to activate intracellular 
transport of calcium and stimulate PTH secretion. Using the 1,25(OH)2D:24,25(OH)2D VMR and 
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25(OH)D model (Fig. 9.1d), it shows that individuals with low 25(OH)D (≤50 nmol/L), normal 
1,25(OH)2D but high 1,25(OH)2D:24,25(OH)2D VMR (≥101) have significantly higher PTH 
concentration than those at the opposite end of the spectrum (Fig. 9.6). An interpretation of the 
finding supports a biological role of 24,25(OH)2D other than as a catabolic metabolite of vitamin 
D. Relative high production of 24,25(OH)2D may reduce the bioactivity of 25(OH)D and 
1,25(OH)2D, particularly extra-renal production of 1,25(OH)2D, to down-regulate the secretion 
of PTH whilst maintaining  1,25(OH)2D concentrations within the strict boundaries required for 
appropriate calcium homeostasis. Relatively low 24,25(OH)2D could enhance the anabolic effects 
of vitamin D metabolism, by stimulating PTH production. The biological action of 24,25(OH)2D 
on the inhibition of PTH secretion was first reported in animal and in vitro models in the late 
seventies174,175. More recently there is increasing evidence supporting physiological functions of 
24,25(OH)2D on bone and cartilage49,176,177 in promoting fracture healing, and protection against 
cartilage damage. The existence of a 24,25(OH)2D-specific nuclear or membrane receptor has 
been reported178, but its function has yet to be elucidated. Given that CYP24A1, the enzyme 
responsible for the production of 24,25(OH)2D, is present in most tissues with VDR, 
understanding the mechanisms controlling the production of 24,25(OH)2D relative to other 
vitamin D metabolites may have significance beyond vitamin D catabolism, potentially shaping 
vitamin D supplementation strategies. 
 
 
Figure 9.6 Figure depicts the distribution of PTH concentration in the 
1,25(OH)2D:24,25(OH)2D VMR/25(OH)D model. 
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Mapping the circannual rhythms of vitamin D metabolites and VMRs is an important component 
of this study. In the literature, reports on longitudinal studies (Macdonald et al.)172,173,179, 
describing the changes in serum 25(OH)D and 24,25(OH)2D throughout a year in vitamin D 
supplemented or non-supplemented subjects. In the VICtORy (Vitamin D and 
CardiOvascularRisk)172 and VICtORy RECALL173 randomised controlled studies performed 
using  a group of postmenopausal women residing in the northeast of UK, the placebo group 
showed a two-fold increase in serum 25(OH)D in peak summer months (July-August), compared 
to the nadir in late winter months (January-March). The younger cohort of healthy individuals in 
this study showed similar trends; 24,25(OH)2D had a propensity to fluctuate with 25(OH)D 
throughout the year, with  changes between summer and winter months, as indicated by a lower 
25(OH)D:24,25(OH)2D VMR during January to March than during July to September. Serum 
1,25(OH)2D displayed no rhythm and was within the reference range throughout the year. The 
circannual variation of 1,25(OH)2D:24,25(OH)2D VMR was dependent on 24,25(OH)2D, with a 
peak-to-nadir difference of 19; such sharp demarcation between seasons would inevitably create 
uncertainty when using 1,25(OH)2D:24,25(OH)2D VMR in diagnostic decision-making. In 
contrast, 25(OH)D:24,25(OH)2D VMR is less susceptible to seasonal fluctuation, allowing the 
use of the VMR with fixed reference intervals irrespective of the time of the year.  
A major strength of the data is the chosen cohort; with participants attending blood sampling visits 
at strictly controlled time intervals and that the vitamin D metabolites were measured using gold-
standard methodologies. The participants are well-defined, largely from a similar social-economic 
background, and exposed to the same level of fitness training, diet, and frequency of outdoor 
activities. The relative homogeneity of the subjects, in combination with the inclusion criteria, 
formed the basis of a reference population of which important changes in analytes can be 
identified. The limitations are that the findings are observational and based on baseline sampling 
at the start of training. Also, the cohort represents young adults of Caucasian extraction (92.9%), 
and cannot be extrapolated to the wider population of mixed ethnicity. The predictive threshold 
values were established based on the equivalent vitamin D status as described by IOM, and not 
based on data generated by the study as it was not randomly controlled. Measurement of vitamin 
D binding protein (VDBP) and free 25(OH)D were not performed due to the ethnic homogeneity 
of the population, factors that may influence VDBP levels (e.g. oral contraceptive use in female 
recruits) were not excluded. 
In conclusion, the present analysis characterises the absolute and relative concentrations of the 
active and catabolic form of vitamin D metabolites in a well-defined young, healthy and 
physically fit population. The use of VMRs provides insight into the metabolic pathway and the 
variations exhibited throughout the year. The proposed a three-dimensional model incorporating 
1,25(OH)2D, 24,25(OH)2D and 25(OH)D measurements demonstrated a strong correlation 
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between the metabolites and PTH. Such modelling could help establish vitamin D-adjusted PTH 
reference intervals, and ultimately contribute to the goal of a “Treat to target” approach to vitamin 
D supplementation. 
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Chapter 10 Immunoaffinity extraction and DAPTAD 
derivatisation for LC-MS/MS quantification of serum 
1,25-dihydroxyvitamin D. 
 
10.1 Background  
1,25-dihydroxyvitamin D (1,25(OH)2D), the most biologically active form of vitamin D, mediates 
its pleiotropic effects through the ubiquitous vitamin D receptor (VDR) that binds to vitamin D 
response elements in target genes to regulate their transcription. 1,25(OH)2D has potent 
antiproliferative and cell differentiation-inducing activities in addition to its classical role in the 
absorption of calcium and phosphate from the intestine, and the retention of calcium from renal 
excretion and bone mineralisation. Deficiency of 1,25(OH)2D occurs in chronic kidney disease–
mineral and bone disorder (CKD-MBD), vitamin D dependent rickets (1α-hydroxylase 
deficiency), X-linked hypophosphataemia and hypoparathyroidism. Excessive production of 
1,25(OH)2D occurs in vitamin D-deficient rickets (end-organ resistance), granulomatosis disease 
(e.g. sarcoidosis), primary hyperthyroidism, ectopic production (malignancy), and genetic defects 
resulting in the inactivation of CYP24A1 gene in children and adults. Serum 1,25(OH)2D can be 
measured to monitor therapy with vitamin D analogues (calcitriol), 1α-hydroxyvitamin D (alpha 
calcidol) and calcimimetics used to treat patients with CKD-MBD and metabolic bone disease180. 
The low concentration of serum 1,25(OH)2D (pmol/L), its lipophilic nature in combination with 
the co-existence of other forms of dihydroxyvitamin D metabolite in circulation pose a difficult 
challenge for separation and quantification. Immunoassays (radioisotopic or enzyme-labelled) are 
commercially available, but concerns over cross-reactivity with other dihydroxyvitamin D 
metabolites have limited their application. Many LC-MS/MS assays have been described in the 
literature (presented in chapter 1.3.3) that combines an immunoaffinity approach using 
1,25(OH)2D antibodies to capture the analyte, followed by derivatisation to enhance the ionisation 
efficiency of the molecule for MS detection. However, such a method still requires a high-end 
sensitive LC-MS/MS instrument that is capable of performing the separation and detection. In 
January 2019, the Bioanalytical Facility at UEA purchased a Waters® Xevo TQ-XS tandem mass 
spectrometer with the Acquity I-class UPLC LC system (Fig. 10.1). It is one of the top-end, class-
leading LC-MS/MS system currently available in the market. The aims of the study were to use 
this system to develop and validate a robust method to measure 1,25(OH)2D3 and 1,25(OH)2D2 
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in serum and plasma, and perform sample comparison with the existing immunoassay method 
that is currently in routine service. 
 
 
Figure 10.1 Waters Xevo TQ-XS tandem mass spectrometer (picture right) with Acquity I-
class UPLC system with integrated sample organiser (left). 
 
10.2 Materials and methods 
 
10.2.1 Serum sample collection 
Serum patient samples (n=69) were collected from residual samples following their course of 
routine care in accordance with generic ethical approval80. The samples were selected at random 
from routine requests for 1,25(OH)2D measurement received by the Department of Laboratory 
Medicine at the Norfolk and Norwich University Hospital.  All samples were anonymised at the 
point of access. Blood samples were collected into serum gel separator tube (BD Vacutainer) and 
centrifuged immediately. After a 10 minute centrifugation at 3,000 x g, serum layer was aliquoted 
into a separate polystyrene tube and stored at -20C until analysis. 
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10.2.2 Reagents, standards and controls 
Certified pure ethanolic standards for 1,25(OH)2D3, 1,25(OH)2D2 (IsoSciences, King of Prussia, 
PA, USA) were spiked into vitamin D depleted serum (BBI Solutions, Cardiff, UK) to create a 
series of calibration standards with concentrations ranged between 30-900 pmol/L. Three pools 
of human sera containing 1,25(OH)2D3 and 1,25(OH)2D2 at 35, 75 and 300 pmol/L were analysed 
with each batch of samples as controls. A carbon-13 labelled 1,25(OH)2D3-25,26,27-13C3 
(Cerilliant, Round Rock, TX, USA) was used as internal standard. Chromasolv™ LC-MS grade 
deionised water and methanol (Honeywell Riedel-de Haen™, Seelze, Germany) were used in the 
mobile phases. Formic acid, ethanol were LCMS grade, ethyl acetate and isopropanol were 
analytical grade (Fisher Scientific, Loughborough, UK). ImmuTube® 1,25(OH)2D LC-MS/MS 
kit (cat# LM1100, ImmunoDiagnostik, Bensheim, Germany) was used for sample 
extraction. Stock derivatisation reagent was synthesised by combining 40 mg of 4-[4-
(Dimethylamino)phenyl]-1,2,4-triazolidine-3,5-dione (DAPTAD) (Santa Cruz Biotechnology, 
Dallas, TX, USA) with 60 mg of Iodobenzene diacetate (Sigma-Aldrich, Dorset, UK) in 40 mL 
of ethyl acetate, the mixture was placed on a magnetic mixer at room temperature for 3 hours until 
the colourless solution turned red (Fig. 10.2).  
 
 
Figure 10.2 Synthesis of DAPTAD. 
 
10.2.3 Sample preparation procedure for LC-MS/MS 
An outline of the sample extraction procedure is shown in figure 10.3. The immunoextraction 
step was performed according to the kit manufacturer’s instruction, 300 µL of samples was used 
instead of the recommended 500 µL. Test samples, calibration standards and quality control 
materials were placed into the respective spin column containing 100 µL of 1,25(OH)2D antibody 
slurry, followed by 200 µL of 1,25(OH)2D3-25,26,27-13C3 in 50:50 isopropanol/water internal 
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standard mixture (100 pmol/L) added into each column. The isopropanol releases the protein-
bound form of 1,25(OH)2D. The columns were capped and placed onto a vertical carousel rotator 
for a 1-hour incubation at room temperature while rotated end-over-end at 15 rpm. After the 
incubation, the columns underwent three repeat cycles of wash through with 500 µL of the kit 
wash solution performed in a centrifuge set at 550 xg for 2 minutes. The outlet of the columns 
was removed to allow the waste to drain into a discard tube while the antibody-bound 1,25(OH)2D 
remained inside the column. After the wash cycles, 250 µL of the kit elution reagent was added 
into each column and centrifuged at 550 xg for 2 minutes. The eluents were collected into a fresh 
set of glass tubes and then dried under nitrogen gas in a sample concentrator heated at 60°C. 
The working DAPTAD solution was made up fresh on the day by diluting the stock 1 in 5 with 
ethyl acetate, 100 µL was used to reconstitute the dried sample tubes. After a 1-hour incubation, 
the dienophilic reaction was terminated by adding 50 µL of ethanol (Fig. 10.4) into each tube. 
The tubes were returned to the sample concentrator for a second dry down under nitrogen gas 
heated at 60°C. The dried tubes were reconstituted with 50 µL of methanol followed by 50 µL of 
water. After a brief vortex, 30 µL of the derivatised extract were injected into the LC-MS/MS. 
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Figure 10.3 Schematic representation of the immunoextraction and sample derivatisation 
procedure. 
 
 
Figure 10.4 The dienophilic reaction of 1,25(OH)2D3 with DAPTAD and formation of the 
derivatised product. 
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10.2.4 Liquid chromatography 
Extracted samples were injected into LC-MS/MS by Waters® Acquity I-class UPLC system 
(Waters Corp., Milford, MA, USA) equipped with a 10-drawer cooler stack regulated at 15˚C. 
Chromatographic separation was achieved using a CORTECS™ core-shell C18 50 × 2.1mm, 2.7 
µm, reversed-phase (Waters Corp., Milford, MA, USA) column heated at 50˚C. Waters VanGuard 
pre-column C18 1.7µm. 5 x 2.1mm was used to protect the column. A gradient elution profile 
was set up to deliver the mobile phase at a flow rate of 0.4 mL/min (Fig. 10.5). At the start of the 
gradient, the mobile phase consisted of 50:50 (v/v) of (A) water containing in 0.1% formic acid 
and (B) methanol in 0.1% formic acid. The gradient was gradually increased to 100% of the 
mobile phase (B) then returned to the starting gradient at 4 minutes. Solvent divert was employed 
to the divert ion suppression region of the separation to waste to minimise contamination to the 
source of the mass spectrometer. 
 
 
Figure 10.5 The percentage composition of mobile phase B (methanol in 0.1% formic acid) 
during a 4-minute gradient run. 1,25(OH)2D3 peak eluted at 1.10 minutes. 
 
10.2.5 Tandem mass spectrophotometry analysis 
LC-MS/MS analysis of vitamin D metabolites was performed using Waters Xevo TQ-XS tandem 
mass spectrometer (Waters Corp., Milford, MA, USA). MassLynx version 4.2 and QuanLynx 
software (Waters Corp., Milford, MA, USA) were used for system control, data acquisition, 
baseline integration and peak quantification. Optimisation of MS/MS parameters was 
accomplished by direct infusion of derivatised standards (Table 10.1). Argon gas was applied to 
the collision cell during the Collision Induced Dissociation (CID) process. The precursor to 
product ion transitions for each compound was ascertained based on the molecular weight of the 
DAPTAD derived products (Fig. 10.6). 
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Parameter Setting 
Ion source Electrospray positive 
Capillary voltage 1.7 kV 
Cone energy 30 V 
Collision energy 27 eV 
Nebuliser gas flow rate 7.0 Bar 
Cone gas flow rate 150 L/hr 
Desolvation gas flow rate 600 L/hr 
Collison gas flow rate 0.18 mL/min 
Source temperature 85C 
Desolvation gas temperature 200C 
m/z transitions (Precusor>Product) 
1,25(OH)2D3 635>357 
1,25(OH)2D2 647>357 
1,25(OH)2D3-[13C3] 638>357 
 
Table 10.1 Mass spectrometer settings and MRM precursor to product ion transitions for 
1,25(OH)2D3/D2. 
 
Figure 10.6 Mass spectrum showing the precursor ion mass of DAPTAD-derivatised 
1,25(OH)2D3 (m/z 635) and fragmentation product ion (m/z 357). 
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10.2.6 Method validation 
Method validation was validated for linearity, lower limits of quantification/detection (LLoQ/D), 
accuracy, precision and recovery following the 2013 U.S Food and Drug Administration (FDA)145 
and the 2012 European Medicines Agency (EMA)146 guidance. NIST traceable standards for 
1,25(OH)2D3, 1,25(OH)2D2 are not available, certified pure standards for 1,25(OH)2D3 and 
1,25(OH)2D2 were spiked gravimetrically into vitamin D depleted human serum to create a six-
point calibration. Three controls were analysed with each batch of sample analysis. The controls 
provide the basis of accepting or rejecting the batch, the assay acceptance criteria require over 
half of the IQC samples analysed in each batch produce results within 15% from their respective 
target value, and 20% at LLoQ146. 
 
10.2.7 Linearity 
Serum standards with known concentrations ranged from 0-900 pmol/L for 1,25(OH)2D3 and 
1,25(OH)2D2 were analysed at the start and end of every batch. A standard curve was generated 
by plotting the ratio of analyte peak area to internal standard peak on the y-axis against the 
weighted (1/x) concentration of their respective standards on the x-axis. The goodness-of-fit of a 
standard curve is justified by linear regression that produced a correlation coefficient (r2) value 
of >0.980. 
 
10.2.8 Accuracy, precision and recovery 
Due to the lack of NIST reference standards, the accuracy of an analytical method was assessed 
by spike and recovery performed at low, medium and high concentrations across the analytical 
range. Method bias was assessed using DEQAS samples and compared against the mean values 
generated by other participating laboratories. A multiple reaction monitoring (MRM) transition 
using the 184 Da product ion was included in the acquisition method to monitor the level of 
phospholipids present in the sample matrix. Imprecision of the assay was assessed by six 
consecutive measurements of the control materials within a single run (intra-assay) and repeatedly 
over one month (inter-assay). Imprecision was expressed as the coefficient of variation (CV), 
acceptance criteria defined the intra-assay CV limit of <10% and cumulative inter-assay CV limit 
<15%. 
 
10.2.9 Lower limit of quantification and detection 
A precision profile was carried out to determine the lower limit of quantification (LLoQ) and 
detection (LLoD) of the assay. Samples containing 1,25(OH)2D3 and 1,25(OH)2D2 at 
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concentrations of 10, 15, 20, 25 and 30 pmol/L were each analysed six times, the CVs of each 
sample were plotted against their respective concentration. The analyte peak must produce a 
signal-to-noise (s/n) ratio of 10:1, the LLoQ was defined as the concentration at which the CV 
15%. 
 
10.2.10 Method comparison 
The 1,25(OH)2D3 values generated by the newly developed method was compared against the 
DiaSorin LIAISON® XL 1,25(OH)2D chemiluminescent immunoassay (Stillwater, MN, USA). 
Serum samples (n=69) that were previously analysed by the immunoassay were retested by the 
new method. Samples from the DEQAS external quality assurance scheme (n=21) were analysed, 
and results compared against the LC/MS method mean. Passing-Bablock regression was used to 
assess the comparability of results between methods; a correlation is deemed satisfactory if the 
linear regression produced a correlation coefficient (r2) value of >0.90. 
 
10.2.11 Statistical data analysis 
Passing-Bablock regression plots and bias plots were constructed and analysed by GraphPad 
Prism 8.2 (GraphPad, San Diego, CA, USA) analysis. Statistical significance was defined as p 
<0.05.  All numerical data were visually examined and checked for transcriptional, pre/post 
analytical errors before statistical analysis. 
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10.3 Results 
Chromatographic peaks for 1,25(OH)2D3 and 1,25(OH)2D2 were eluted at 1.12 and 1.14, minutes, 
respectively (Fig. 10.7). No phospholipids peak was detected during this period. 
 An ion suppression test was conducted by post-column infusion of an aqueous mixture of 
1,25(OH)2D3 with simultaneous injection of an extracted pooled serum or phosphate buffered 
saline blank (Fig 10.8). Moderate reduction of baseline signals was observed during the first 
minute of the chromatographic run before the 1,25(OH)2D3 peak. The period of ion suppression 
was diverted to waste to prevent contamination of the instrument source. Phospholipids in the 
sample matrix monitored by the acquisition of m/z transitions 184>184 did show significant 
presence during the peak elution period. 
 
 
 
Figure 10.7 Chromatogram from a patient serum sample containing 154.5 pmol/L of 
1,25(OH)2D3 and 27.1 pmol/L of 1,25(OH)2D2. 
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Figure 10.8 Ion suppression test. Chromatographic trace recorded during co-injection of (a) 
extracted serum sample, or (b) phosphate buffered saline blank with post-column infusion of 1 
nmol/L of pure 1,25(OH)2D3 (c). Moderate ion suppression occurred within the first minute of 
the run, prior to the elution of 1,25(OH)2D3 peak at 1.13 min. 
 
10.3.1 Assay performance 
Method validation results are summarised in Table 10.2. The assay achieved adequate linearity 
(Fig. 10.9a-b), sensitivity, precision, and demonstrated reproducible recovery to satisfy method 
validation criteria. Carry-over testing confirmed no peaks were present during the analysis of a 
blank sample following an injection of a sample spiked with high concentrations (1 mol/L) of 
1,25(OH)2D3 and 1,25(OH)2D2. No interfering peaks were found between the analyte transitions. 
The LLoQ of the method was established by the analysis of a series of samples that contained a 
decreasing concentration of analytes. Results showed the lowest 1,25(OH)2D3 and 1,25(OH)2D2 
concentrations determined with a CV of 15% were 20 pmol/L (Fig. 10.10a-b). 
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  1,25(OH)2D3 1,25(OH)2D2 
Linearity, pmol/L 
(typical r2) 
0-900 (0.977) 0-900 (0.985) 
LLoQ (LLoD), pmol/L 20 (16) 20 (12) 
Imprecision 
conc. (±SD), 
%CV 
Intra (n=6) 
37.1 (±3.5) 9.4% 
75.6 (±5.6) 7.4% 
305.5 (±6.2) 2.0% 
39.7 (±3.6) 9.0% 
81.5 (±4.9) 6.0% 
434.7 (±11) 2.5% 
Inter (n=6) 
40.3 (±3.6) 9.0% 
75.3 (±5.6) 7.4% 
302.8 (±10.3) 3.4% 
42.4 (±4.2) 9.8% 
89.6 (±4.9) 5.5% 
280.2 (±8.5) 3.0% 
Recovery 
spiked conc. 
pmol/L (mean 
recovery% ±SD) 
Spiked into 
vitamin D 
depleted 
serum 
+50 (109%±2.1) 
+100 (93%±6.5) 
+300 (92%±8.2) 
+50 (115%±6.5) 
+100 (91%±4.6) 
+300 (94%±1.2) 
Spiked 
into pooled 
EDTA 
plasma* 
+50 (103%±2.5) 
+100 (108%±5.6) 
+300 (93%±6.2) 
+50 (97%±3.5) 
+100 (105%±5.6) 
+300 (95%±6.2) 
*Pooled EDTA plasma contained 164.3 pmol/L of 1,25(OH)2D3 and 19.2 nmol/L of 
1,25(OH)2D2  
 
Table 10.2 Performance characteristics of the DAPTAD 1,25(OH)2D LC-MS/MS method. 
Recovery was determined by spiking known amount of 1,25(OH)2D3 and 1,25(OH)2D2  into 
vitamin D depleted serum and a pool of EDTA plasma containing endogenous 1,25(OH)2D. Each 
spiked sample was analysed three times in separate runs. 
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a)  
b)  
Figure 10.9a-b  Typical standard curves for a) 1,25(OH)2D3 and b) 1,25(OH)2D2  
constructed by plotting the response of each standard on the y-axis against their respective 
concentrations (nmol/L) on the x-axis. The response of each compound was determined by the 
ratio of the peak area of the standards to the peak area of the deuterated internal standards. 
Regression analysis showed a typical correlation coefficient r2 >0.99. 
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Figure 10.10a-b Method imprecision profile for a) 1,25(OH)2D3 and b) 1,25(OH)2D2 . 
The reproducibility across the analytical range of the assay is expressed by plotting the coefficient 
of variation (CV) against their respective mean concentration (pmol/L) on the x-axis. Each 
concentration was analysed three times over separate runs. The concentration of which CV=10% 
and 15% are indicated by red and green lines. The LLoQ was determined at the CV of 15%. 
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10.3.2 Method comparisons 
To assess the comparability of the new method, 18 DEQAS samples and 52 serum samples 
previously analysed by the DiaSorin LIAISON XL 1,25(OH)2D chemiluminescent immunoassay 
was tested by the new method. Passing-Bablock regression analysis between the 1,25(OH)2D3 
values produced by the DAPTAD LC-MS/MS method with the DEQAS LC-MS method group 
mean (Fig. 10.11a) showed a highly significant correlation 𝑦 = 1.042𝑥 − 6.177, 𝑟2 = 0.9199, 
p<0.001. Bland-Altman residual plot (Fig. 10.11b) showed a small mean (±SD) bias of -0.4% 
(±8.4). None of the values deviated outside the ±30% from the mean and therefore met the 
DEQAS performance proficiency criteria. 
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Figure 10.11a-b Comparison of 1,25(OH)2D3 between the new method and DEQAS LC-
MS method group mean (n=21). (a) Passing-Bablock regression analysis showed a highly 
significant correlation (r2=0.9199, p<0.001). (b) Bland-Altman residual plot showing the 
percentage deviation of the measurements with DEQAS LC-MS group mean values. The trend 
line is represented in blue; purple dashed lines represent the mean bias. The dotted lines represent 
±20% limits of agreement. The red dashed line in (a) represents the line of identity. 
 
Comparison of with the DiaSorin immunoassay also showed a highly significant correlation y =
0.8812𝑥 − 9.724, 𝑟2 = 0.9416, 𝑝 < 0.001 (Fig 10.12a). Four of the 69 samples tested by the 
immunoassay below the detection limit (<12 pmol/L) were also below the limit for the LC-
MS/MS assay (<16 pmol/L). Bland-Altman residual plot showed a small mean (±SD) bias of -
1% (±12.3) (Fig. 10.12b). In contrast with the DEQAS comparison, greater variability was 
observed between the LC-MS/MS and immunoassay results; the line of best fit in figure 10.12a 
showed a greater negative bias towards values >150 pmol/L produced by the LC-MS/MS. The 
evidence suggests the variance is method specific. 
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Figure 10.12a-b (a) Comparison of results generated by the LC-MS/MS against Diasorin 
immunoassay (n=69). Four samples with 1,25(OH)2D concentration below the detection limits 
assayed both methods were not shown in the plot. The red line in the graph represents the fitted 
regression; red dashed line is the line identity. (b) Bland-Altman plot showing the percentage 
deviation of the LC-MS/MS from immunoassay. The dotted lines represent ±20% limits of 
agreement. The purple dashed line represents the mean bias. 
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10.4 Discussion and conclusion 
This final chapter fulfils the most challenging objective set out in this PhD study, that is to develop 
an LC-MS/MS assay for the measurement of serum 1,25(OH)2D3, and 1,25(OH)2D2. The poor 
ionisation properties of 1,25(OH)2D and its low circulating concentration in serum require 
extensive sample preparation to enrich and extract the compounds from the matrix, followed by 
derivatisation to transform 1,25(OH)2D into a robust complex for ionisation. There were 
compromises; the immunoextraction step is a long (1 hour) process that required a relatively large 
volume (300 µL) of serum/plasma sample, which could be a concern for paediatric patients. The 
procedure involved lengthy manual handling steps that cannot be easily adapted by automated 
platforms. Also, the immunoaffinity spin columns were costly at £20 per test. On the contrary, 
the DAPTAD was synthesised from relatively inexpensive raw materials; the derivatisation 
reagent was <£1 per test. A comparable alternative with AmplifexTM Diene reagent (SCIEX) is 
commercially available at £10 per test. During the initial development period, attempts were made 
to use the SLE sample extraction and PTAD derivatisation as described in chapter 5, but the 
procedure failed to achieve sufficient sensitivity to detect samples with 1,25(OH)2D3 
concentration less than 50 pmol/L, which is necessary for analysis of samples from patients with 
chronic kidney disease and vitamin D-dependent rickets. 
The new Waters Acquity Xevo TQ-XS tandem mass spectrometer system had shown to be 
superior to the Micromass Quattro Ultima Pt system described in the previous chapters. The low 
internal dwell volume in the Acquity LC/autosampler system helped reduce band dispersion and 
peak distortion. Noticeable improvement in the base peak width was observed; peaks were eluted 
within 1/10th of a minute using the Acquity system (Fig. 10.7), whereas the Microssmass system 
operated in the same conditions eluted peaks in ½ of a minute (chapter 7 fig. 7.2). Higher peak 
resolution concentrates the sample in the column, allowing for a sharper, more focused delivery 
to the source of the mass spectrometer, thus enhancing the sensitivity. Derviatisation is a key step; 
the Xevo TQ-XS instrument, similar to other high-end instruments of the latest generation, 
features an off-axis ion source and transfer optics (StepWave™) that actively removes interfering 
compounds in order to increase signal strength. Such design creates a harsh environment that is 
suboptimal for 1,25(OH)2D. Without derivatisation, water loss product ions are formed from the 
fragmentation of the two hydroxyl groups in the 1α and 25 positions. Water loss products are less 
specific and can be prone to interference by other compounds with similar chemical structure. 
Derviatisation also increased the m/z to a higher mass range where it is less prone to interference 
by other small molecules. 
The method was compared against DEQAS and the DiaSorin immunoassay platform. Although 
the sample size for the DEQAS comparison was small (n=21), the target values were based on 
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the mean values generated by LC-MS/MS methods, providing a more method-specific 
comparison. The 1,25(OH)2D3 results produced by the new method showed a strong correlation 
with the DEQAS LC-MS/MS consensus, with 19 out of 21 results (90.5%) showed less than 10% 
deviation. The comparison with the DiaSorin immunoassay using routine patient samples 
provided a different perspective on a larger sample size (n=69). The new method correlated with 
the DiaSorin immunoassay with a negative bias that was more significant in sample concentration 
>150 pmol/L. More considerable variability was observed between the methods, with 42 out of 
69 (60.9%) samples showed less than 10% deviation with the immunoassay. The disparity is 
likely due to the cross-reactivity of the antibodies used in the immunoassay and the difference in 
the serum matrix components (e.g. vitamin D binding protein) associated with the patient’s 
pathophysiological conditions. The samples were collected anonymously; therefore, it was not 
possible to ascertain whether the reasons for the disparity was related to the diagnosis. There are 
reports of assay bias published in the literature; Higgins et al.75 reported high disparity between 
the DiaSorin and LC-MS/MS methods in pooled neonates and infants samples with elevated 
1,25(OH)2D, a positive bias of up to 26.5% was observed in immunoassay results, 3-epi-
1,25(OH)2D was ruled out as a potential source of bias. Ivison et al. reported a negative bias (mean 
-47.8%, range -160 to 15%, n=78) of their LC-MS/MS method with the IDS radioimmunoassay76. 
Spanaus and Von Eckardstein evaluated the Diasorin immunoassay with a LC-MS/MS method 
using 93 patient samples72, and their results showed a mean bias of 2.3% (95%CI: -29.2 to 33.7%), 
which was not dissimilar to results produced by the new method. 
The 1,25(OH)2D2 method was validated alongside 1,25(OH)2D3, but few patient samples with 
endogenous 1,25(OH)2D2 were identified; therefore, it was not possible to carry out a comparison 
study. Future study would be to collect samples with 1,25(OH)2D2 present from routine requests 
and send the samples to another LC-MS/MS laboratory for a blind comparison. Currently, there 
is no routine service for 1,25(OH)2D2 available in the UK. 
In conclusion, this final chapter describes the successful development and validation of an LC-
MS/MS method for the quantification 1,25(OH)2D3 and 1,25(OH)2D2 in serum and plasma. The 
immunoaffinity column extraction combined with DAPTAD sample derivatisation procedure was 
robust and reproducible to provide a low to medium throughput routine analytical service. The 
new method performed well against the Diasorin immunoassay and other LC-MS method users, 
concerns over the disparity of results observed in some patient samples will require further 
investigations to determine the source of bias. 
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Chapter 11 Conclusion and summary of research 
impact 
 
This PhD thesis described a series of successful method developments using LC-MS/MS 
techniques to provide accurate and precise measurements for the major circulating vitamin D 
metabolites, and the applications in research and clinical context. All the methods had satisfied 
the performance validation criterion. The dried blood 25(OH)D method using microsampling 
device described in Chapter 6 extends the application further; allowing self-sampling at home or 
at remote locations where access to phlebotomy service is limited, whilst the low sample volume 
requirement is ideally suited for use in paediatric practice and elderly population. This thesis is 
the first to provide supporting evidence that a relationship exists between 25(OH)D with the active 
(1,25(OH)2D) and the catabolic (24,25(OH)2D) forms of vitamin D (Chapter 9). The finding had 
led to the successful publication in Scientific Reports in early 2019181. The assay for simultaneous 
measurement of 24,25(OH)2D and 25(OH)D (Chapter 7) published in the Journal of Nutritional 
Biochemistry in 201754 have been providing routine service for NHS patients, and have supported 
many collaboration research studies, resulting in important findings and publications that had 
significant impacts in several areas of science. 
 
Underpinning research 
The introduction of a high-throughput extraction technology combined with the excellent 
sensitivity of the LC-MS/MS has allowed large numbers of samples to be analysed for several 
clinical trial studies. The 24,25(OH)2D and 25(OH)D assay, using a biochemical technique to 
remove the built-up of phospholipids in sample matrix (Chapter 5), allowed accurate 
measurement of vitamin D metabolites in long term storage samples. Chapter 8 described three 
vitamin D3 supplementation studies with different dosing modality; the VICtORY study (400 IU 
and 1000 IU/day) was collected over a 2-year period, retrospective sample analysis could not have 
been possible without adequate phospholipids depletion. Results from the study had formed the 
basis for a compare and contrast study with the other two high dose vitamin D supplementation 
studies; where a  single 100,000 IU bolus and weekly (35,000 and 70,000 IU/wk) had shown gross 
elevation of serum 24,25(OH)2D as a result of excessive intake of vitamin D3. The publications 
that followed161,162,173 provided a stark warning to the scientific community, clinicians and sports 
nutritionist that administration of high dose vitamin D supplement may not be beneficial to the 
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individual, but the practice can be detrimental to a person’s health. The importance of the finding 
was such that I was selected to give an oral presentation at the 2016 European Calcified Tissue 
Society Congress (Rome, Italy)169, and poster presentations at the American Society of Bone and 
Mineral Research conference (Atlanta, USA)182 and the British Endocrine Society meeting 
(Brighton, UK)183. In the follow-up publication on the secondary analysis of the VICtORY study, 
the daily low dose of vitamin D3 treatment showed significant improvement in spine and hip 
BMD in postmenopausal women with baseline 25(OH)D ≤30 nmol/L, whereas no treatment effect 
was observed in women with 25(OH)D ≥30 nmol/L179. It was recommended that future vitamin 
D studies on bone health should focus on individuals with 25(OH)D in this concentration range. 
The finding from this research and the recommendation that 25(OH)D should be measured by 
tandem mass spectrometry method to distinguish 25(OH)D3 and D2 were endorsed by the Royal 
National Osteoporosis ‘Vitamin D and Bone Health. A Practical Clinical Guideline For Patient 
Management’10(Specific references to UEA work with Prof. William Fraser are on pages 2, 7). 
The studies performed at UEA to date that involved the use of the vitamin D metabolite assays 
developed in this thesis had contributed to important research in other areas of medicine; 
significant association of vitamin D status with, or effect on, disease, are extensive and include 
respiratory disease184,185, pregnancy186, chronic fatigue syndrome/myalgic encephalomyelitis187, 
renal transplant recipients188, cannabis use189, fetal development (animal model)190. Research 
undertaken at UEA in 2013 had established that vitamin D2 supplementation is not effective as 
vitamin D3 in changing clinical outcomes172. The finding had a significant effect on public health, 
resulting in new approaches to vitamin D supplementation and interpretation of vitamin D 
deficiency. This research has been cited extensively and incorporated into several meta-analyses 
of the role of vitamin D in disease, and in attempts to define the optimal therapeutic thresholds 
for treatment and prevention of disease. 
 
Impact on patient care and the NHS economy 
Before the development of LC-MS/MS methodology, 25(OH)D was measured by a variety of 
immunoassays with poor standardisation that could result in over or underestimation of results 
resulting in erroneous diagnosis and incorrect treatment. All immunoassays have poor antibody 
cross-reactivity with 25(OH)D2 resulting in underestimation of 25(OH)D2 and, depending on 
25(OH)D3 assay standardisation, total 25(OH)D status. The superior specificity and selectivity 
of mass spectrometry detection allowed measurement of vitamin D metabolites with precision, 
accuracy and sensitivity. Co-determination of 24,25(OH)D and 25(OH)D with their respective 
D3 and D2 forms from a single sample analysis enabled the assessment of the individual’s vitamin 
D storage and catabolic status. The use of 25(OH)D:24,25(OH)D vitamin D metabolite ratio can 
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identify patients with potential CYP24A1 mutations and hence the avoidance of unnecessary and 
expensive patient investigation for malignancy as a cause of hypercalcaemia. 
In recent years, hospital laboratories have experienced a marked, year-over-year increase in 
requests for 25(OH)D measurement191,192. The demand on workload while under significant 
financial constraints, plus deskilling of the laboratory workforce and increasing regulatory 
requirements has seen many hospital laboratories returning to immunoassays. LC-MS/MS 
methodology must be rapid and cost-effective. Since 2015, the 24,25(OH)2D and 25(OH)D assay 
has been providing a routine service for patients from the Norfolk and Norwich University NHS 
hospitals, with typical turnaround <3 days. The assay is also offered as part of the Supraregional 
Assay and Advisory service (SAAS) for other NHS and private hospitals in the UK. The cost per 
sample for an LC-MS/MS 25(OH)D analysis is £10.50, which is significantly below the NICE 
estimated national average of £17193. The Bioanalytical Facility at UEA currently processes 
around 10,000 patient samples per annum, representing a yearly cost saving of £65,000 for the 
NHS. 
The assay has consistently met the performance target set by the Vitamin D External Quality 
Assessment Scheme (DEQAS) and achieved proficiency certificates since the method was 
implemented. 
 
Impact on the MOD Army training programme and in sports science 
Based on the underpinning research outlined in the previous section, the vitamin D metabolite 
assays described in this thesis has supported collaborative programmes of work with the Army 
Health and Physical Performance Research (APRC). The British Army recruits up to four 
thousand new soldiers every year, the high physical demands in the initial military training 
combined with periods of energy deficit and sleep deprivation increase the risk of injury and 
illness to recruits resulting in lost training days. Up to 20.4% of Army recruits suffer from 
musculoskeletal injuries and up to 10% suffer skeletal stress fracture194. Previous pilot studies had 
shown a high prevalence of vitamin D insufficiency in the British Army195. The Army Lower 
Limb Injury prevention programme (ALLIPP) was established in 2013 by the UK Ministry of 
Defence (MoD) to study the association of vitamin D status with injury risk, health and physical 
performance in British Army Recruits. A subset of baseline data collected in this large scale 
(n=2292) study was described in Chapter 9. The follow-up data analysis showed 38% of the 
participants identified as vitamin D insufficiency (25(OH)D <50 nmol/L) were associated with 
increased risk (odds ratio) of training-related stress fracture SFx(1.03), medial tibial stress 
syndrome (MTSS) (1.26), upper limb trauma (1.02), respiratory infections (1.13); and upper limb 
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overuse injuries (3.18) and prolonged the length of recovery (3.49) (data not included as part of 
this PhD thesis). I was selected to give an oral presentation at the 2018 British Endocrine Society 
meeting (Brighton, UK)196. The MOD has now recognised that a high percentage of recruits have 
significant vitamin D deficiency, and that female recruits, in particular, have a higher 
predisposition to injury. This has prompted a review of the nutritional recommendations for all 
recruits in training and an alteration in the training programme for servicewomen in ground close 
combat (GCC) roles197. 
In sports science research, LC-MS/MS technology is not available to the majority of researchers 
in this field. The methods described in this thesis have facilitated many research studies in sports 
science; contributing to the discovery of the beneficial effects of vitamin D supplement on 
physical performance in elite professional athletes. Positive associations with skeletal muscle 
regeneration198 but not on muscle function199, improved resistance to infections111, enhanced 
exercise endurance (1.5-mile run time was approximately 0.5 seconds faster for every 1 nmol/L 
increase in 25(OH)D concentration200) have been published. 
 
Conclusion 
This thesis presented the development of methods to measure the major circulating vitamin D 
metabolite 25(OH)D, 1,25(OH)2D and 24,25(OH)2D. Using state of the art LC-MS/MS 
technology and robust sample preparation techniques to enhance sensitivity, accuracy and 
precision, results from the studies have demonstrated the role that each metabolite plays in 
maintaining homeostasis. This study is the first to describe a relationship between the three 
vitamin D metabolites; using serum concentrations and their respective ratio to give a mechanistic 
view of the physiological response during states of deficiency and toxicity. The established 
reference intervals and diagnostic thresholds can be utilised clinically for the assessment of 
vitamin D metabolic status, and in the investigation for the cause of hypercalcaemia. The newly 
developed methods have provided the analytical platform for many large scale studies, results of 
which have, and will continue to help further our understanding and appreciation of the vitamin 
D metabolism as part of the hormonal network; expanding our knowledge base in the field of 
musculoskeletal research and other areas of science. The publications and citations are a testament 
to the far-reaching impact from the product of this programme of research. 
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